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Summary 
Vaccines are invaluable factors in our current health system for preventing pathogenic 
infection. However, traditional vaccines have been unsuccessful in preventing against some 
important infections, such as malaria, HIV and hepatitis C. Although many potential antigens 
have been discovered, the lack of universal protection may be due to the inability of 
conventional delivery methods to elicit the immune responses appropriate for a particular 
infectious agent. Most of the protein subunit vaccines primarily induce antibody-mediated 
humoral responses; therefore, there is an urgent need for a new delivery method that delivers 
antigen to also elicit more potent antigen-specific cellular responses.  
Utilising nanotechnology in the field of medicine has gained pace in recent years. 
Nanoparticles such as silica, liposomes and more recently synthetic polymer particles, have 
been developed as vaccine/drug carriers and many are being studied comprehensively as 
promising candidates. These nanoparticle vehicles have been demonstrated to be efficiently 
taken up by dendritic cells, one of the most important cells which controls the fate of an 
antigen-specific immune response. These particles therefore have the ability to induce strong 
humoral and cellular responses. However, there have been no reports of a vaccine delivery 
system based on the preparation of nanoparticles derived from antigen only using a template, 
which would alleviate some of the disadvantages of existing nanoparticles. Through a 
templating system using silica nano-sized particles, proteins can be immobilised in the 
mesoporous shell by solution adsorption. This simple-step preparation of antigen 
nanoparticles has the potential to develop new generation vaccines against currently 
unpreventable infectious diseases.  
In this study, solid core mesoporous shell (SC/MS) silica nanoparticles averaging 410 
nm in diameter were fabricated as a template for the subsequent synthesis of protein-based 
nanocapsules, employing ovalbumin as a model protein. Firstly, the ovalbumin-based 
nanocapsules of approximately 500 nm were successfully taken up by murine immature 
dendritic cells, and processed peptides were presented on MHC class I molecules, required for 
the activation of cytotoxic T cells. Secondly, a murine malarial protein, the merozoite surface 
protein 4/5 from Plasmodium chabaudi adami was used to synthesise nanocapsules using the 
templating system, and shown to elicit both humoral and cellular responses in immunised 
mice. These results highlight the potential of antigen-based nanocapsules, prepared from the 
nanoparticle templating system, for antigen delivery. 
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1 CHAPTER 1 
 
Literature review 
 
This chapter provides an overview to the current vaccine technologies and explores the 
advances made towards next generation vaccine development, in particular using 
nanotechnology. This chapter also reviews one of the most prevalent  
global diseases - malaria. Finally, the rationale of this project is provided. 
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1.1 Introduction 
The fight to control infectious disease has always been an endless task for humanity. With 
millions of deaths from infectious disease each year, it has an enormous impact and a burden 
on the global economy and health care system. Sanitation and prevention are key to reduce 
the impact of infectious disease (Nichol, 2003), rather than the use of treatments and 
medications. A number of infectious diseases have been prevented since the birth of vaccines 
practiced by Jenner and Pasteur 200 years ago; however there are still no registered or 
effective vaccines for some of the most prevalent diseases in the modern era. These infectious 
and parasitic diseases include acquired immune deficiency syndrome (AIDS), tuberculosis, 
malaria, leishmaniasis and hepatitis C, which causes millions of deaths every year (data 
shown in Table 1.1). Recently, an outbreak of the Ebola virus was observed in the West 
African region (May, 2014). Absolute morbidity and mortality rate is currently low, however, 
the projection is set to increase if no appropriate prevention is applied.  
 
For a vaccine to be successful, it must satisfy a number of important criteria (Table 1.2). 
Firstly, it must be able to elicit an immune response with a minimal number of doses (ideally 
a single dose), and provide long-lasting protection (Atkins et al., 2006; Beverley, 2002). 
Secondly, it must be totally safe and effective in all vaccinated subjects, as the vaccine will be 
distributed across all age groups, including infants and children. 
 
It should also be stable and inexpensive for manufacturing (Beverley, 2002). Further to these 
requirements, an effective antigen delivery system must be able to deliver antigens to specific 
cells that play a crucial role in immune system, and initiate a specific immune response 
accordingly. The efficiency of the delivery system must also not be diminished by 
pre-existing immunity (Moron et al., 2004), or induce immune tolerance. 
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Table 1.1: Number of deaths caused in 2011 by infectious and parasitic diseases for 
which effective vaccines are not yet available.  
Disease Number of deaths 
AIDS (HIV) 1,590,952 
Tuberculosis 975,903 
Malaria 58,218 
Leishmaniasis 53,675 
Hepatitis C 39,520 
Schistosomaiasis 23,313 
Trypanosomasis 19,026 
Ebola virus (2014 outbreak) 4,818 (total number of cases, 13,042) 
 
(Latest data available from World Health Organization (WHO), Global health observatory 
data repository (World Health Organization, 2014), and the Ebola outbreak record was 
obtained on 2nd Nov 2014 WHO Ebola Situation report (World Health Organization, 2014)). 
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Table 1.2: Properties of an ideal vaccine. (Adapted and modified from Beverley, 2002).  
 
Properties  
• Life-long immunity 
• Broadly protective against all variants of an organism 
• Prevent disease transmission, e.g. by preventing shedding 
• Rapidly induce effective immunity  
• Effective in all vaccinated subjects, including infants and the elderly 
• Transmit maternal protection to the fetus 
• Requires few (ideally one) immunisation to induce protection 
• No need to be administered by injection 
• Cheap, stable (no requirement for cold chain), and safe 
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1.2 Types of vaccines 
Since the discovery of first vaccine by Edward Jenner, which focused on using a whole-cell 
vaccine, different approaches of vaccine development have emerged. While they may contain 
killed or attenuated, or parts of pathogen, the term “vaccine” applies when the products are 
formulated to be introduced into the body and elicit a protective immune response, without 
causing disease. This section describes some of the traditional vaccine platforms used for the 
current vaccine scheme worldwide, and some rather newer approaches studied in more recent 
years. These are; inactivated vaccines, attenuated vaccines and partial component vaccines; 
and synthetic peptide vaccines, recombinant vector and DNA vaccines, respectively. Types of 
major vaccines currently distributed in the USA with formulation types are summarised in 
Table 1.3.  
 
1.2.1 Inactivated/killed vaccines 
Vaccines of this type are derived from the bacterium or virus grown in culture media, and 
killed to become non-infective by treatment, typically using heat, chemicals or radiation. This 
was the basis of the vaccine formulation method used in the early vaccine era. The treatments 
destroy the pathogens preventing their ability to replicate, while keeping antigens intact for 
the immune system to recognise. While the pathogen’s inability to replicate provides an 
advantage over attenuated vaccines since there is no risk of reversion to the virulent wild type, 
however, this can reduce the efficacy of the vaccine (Belshe et al., 2007). Although the 
majority of currently licensed vaccines are formulated as inactivated vaccines, their modest 
efficacy results in the need for multiple doses (Zangwill & Belshe, 2004).  
 
1.2.2 Attenuated/live vaccines 
Attenuated vaccines are also derived from organisms grown in laboratory settings. The 
organism is “attenuated” or weakened through a series of passages in altered conditions using 
culture media or typically, chicken embryos. They may be subjected to up to 200 passages in 
non-human cells, after which it loses the ability to replicate to a level that can cause disease in 
a human host. The organisms that became avirulent can still replicate at a minimal level 
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Table 1.3: Major vaccines distributed in the USA and their type of formulation - 2011  
Vaccine Type 
Anthrax Inactivated 
Diphtheria, Tetanus, acellular Pertussis  Inactivated toxin 
Haemophilus influenza type b Inactivated 
Hepatitis A Inactivated 
Hepatitis B Inactivated 
Human papillomavirus (bi, or quadrivalent) Inactivated 
Influenza, trivalent Inactivated 
Influenza Live attenuated 
Japanese encephalitis Inactivated 
Measles, Mumps, Rubella Live attenuated 
Meningococcal  Conjugate, polysaccharide 
Pneumococcal (13, or 23-valent) Conjugate, polysaccharide 
Poliovirus Inactivated 
Rabies Inactivated 
Rotavirus (mono, or pentavalent) Live attenuated 
Typhoid Vi Polysaccharide, inactivated 
Typhoid Live attenuated 
Varicella (chickenpox) Live attenuated 
Yellow fever Live attenuated 
Zoster (Herpes zoster) Live attenuated 
 
(Adopted and modified from Atkinson et al., 2011) 
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within the human host, and since the host immune system cannot distinguish between 
symptomatic and asymptomatic infection, an immune response is provoked. Attenuated 
vaccines have been shown to be much more effective, often requiring only a single dose, with 
protection outlasting that of inactivated vaccines (Fleming et al., 2006; Belshe et al., 2007).  
 
However, several safety concerns are expressed about the use of attenuated vaccines in 
humans. Firstly, any attenuated virus vaccine may undergo spontaneous mutation that may 
cause the loss of attenuation and reversion to the virulent form. Although the occurrence of 
such an incident is quite rare, reversion to virulence has been seen with the oral polio live 
vaccine (OPV). Mutation in OPV resulted in the generation of a vaccine-associated polio 
virus which resulted in rare cases of paralytic poliomyelitis in vaccine recipients, as well as 
disease in unimmunised or non-adequately immunised personnel (World Health Organization, 
2002; 2014).  
 
Secondly, a double-infection of an attenuated virus and a wild strain of a non-human virus in 
humans may pose a serious risk. An example is influenza virus. If the wild virus is of a human 
origin, then it is safe to administer the vaccine at the time of infection (Youngner et al., 1994). 
However, if the infection was caused by a virus of non-human origin, gene reassortment 
between the attenuated virus from vaccine and virus of non-human can lead to the creation of 
a viral strain with pandemic potential. The ability of a non-human virus to infect humans has 
been shown in the case of avian-origin human influenza A-H5N1, in Hong Kong in 1997 
(Claas et al., 2005). Gene reassortment between three host-species (including humans) was 
also evident with the 2009 human influenza A-H1N1, more commonly known as swine flu 
(Trifonov et al., 2009; Fraser et al., 2009).  
 
Thirdly, attenuated vaccines cannot be administered to certain populations with low immunity 
including immunocompromised patients, as well as children and the elderly. Lastly, due to the 
nature of live organisms, most attenuated vaccines require cold-chain storage and transport. 
This may be difficult in developing countries where access to refrigeration is limited.  
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1.2.3 Partial component vaccines  
Unlike the two previously mentioned vaccines where the entire pathogen is used, the partial 
component vaccine is formulated with only specific parts of the organism. It is often 
composed of proteins or capsular polysaccharides, which have been isolated or produced 
recombinantly, and shown to be immunogenic. Use of an antigen that is highly conserved 
may also provide protection across several species or serotypes. An example of such a 
vaccine is the subunit pneumococcal vaccine used in infants to prevent disease caused by 
Streptococcus pneumoniae (Rueckinger et al., 2011).  
 
The major advantage of subunit vaccines is safety. Subunit vaccines can also circumvent 
concerns associated with the administration of attenuated vaccine to immuno-compromised 
patients. However, this can also become a disadvantage, as vaccine efficacy is 
compromised/limited in comparison to an attenuated vaccine. When polysaccharide has been 
used alone, it often fails to elicit T cells for long-lasting memory, and was incapable of 
producing highly effective IgG antibodies. Therefore a process to conjugate the 
polysaccharide with a protein or toxoid carrier was introduced in order to stimulate a better 
response. The most successful conjugate subunit vaccine is the Haemophilus influenzae type 
b (Hib) vaccine to prevent meningitis in infants and children. Since the introduction of routine 
Hib vaccination in the 1990s when disease was endemic, the number of cases of Hib 
meningitis has declined significantly (Peltola et al., 1992; Georges et al., 2013). However, 
subunit vaccines often require the addition of adjuvant in order to be effective (Aguilar & 
Rodriguez, 2007). 
 
1.2.4 Synthetic peptide vaccines 
As an addition to the subunit vaccines with enhanced safety, an alternative approach to the 
attenuated/live vaccines is the peptide vaccine. It is often a section of the whole protein that is 
immunogenic, and that is sufficient to elicit an immune responses. Subunit and peptide 
vaccines can also benefit when there might be a complication in delivering the entire 
organism in killed or attenuated form (e.g. parasites). By using peptides, these epitopes can be 
delivered in a high dose. Synthetic peptide vaccines are also economically attractive and do 
not require a cold-chain to maintain biological effectiveness, as they can be stored 
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lyophilised, and produced easily in large scale with chemically defined quality (Purcell et al., 
2007).  
 
However, similar to the subunit protein, synthetic peptides lack strong immunogenicity and 
require the use of an adjuvant. Peptides are more susceptible to extracellular proteases and 
may therefore be rapidly degraded before they are able to stimulate a T cell response. T cell 
tolerance or anergy may also occur if T cells are stimulated incorrectly with insufficient 
co-stimulatory molecules by non-professional antigen presenting cells (APCs) (Celis, 2002; 
Kyburz et al., 1993). Furthermore, the conformation of the peptide must be greatly considered 
when synthesised. Peptide vaccines usually comprise surface-exposed regions which are 
highly immunogenic. The conformation of these peptides plays a role in their virulence, and 
conformation must be maintained in order to produce antibodies. Therefore, the conformation 
of the peptide must closely resemble the epitope as the production of antibodies relies on the 
discontinuous structure (Serardic, 1993). T cells can recognise sequential or continuous 
epitopes of a linear peptide, however difficulties in delivering peptides to APCs hinders this 
process.  
 
1.2.5 Recombinant vectors and DNA vaccines 
This is a rather newer technique used for vaccines, which has developed over the past twenty 
years. The recombinant vector vaccine uses attenuated virus or bacteria as a vaccine vehicle, 
and is introduced to the host in a contained form as part of plasmid or chromosomal DNA. 
DNA vaccines are similar as they only consist of DNA, but they are delivered without live 
vectors. Recombinant vectors can produce their own heterologous protein once delivered 
inside the host, while DNA vaccine uses the host’s cell machinery to produce the antigen 
encoded in the delivered DNA. The DNA vaccine consists of a sequence encoding the antigen 
cloned into a plasmid, with a few other important elements for the expression of the protein 
within host cells. Upon administration, host cells such as dendritic cells and myocytes 
internalise the plasmid DNA and express the encoded antigen. The antigen is then processed 
and presented as endogenous antigen to induce cellular responses, or it can be secreted from 
cells (i.e. myocytes) as an exogenous antigen. The exogenous antigen can directly interact 
with B cells, which after binding the antigen with the B cell receptor, internalise it and present 
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peptide on MHC class II molecule to T helper (Th) cells. The subsequently activated Th cells 
then provide help to the B cell, enabling it to mature into a plasma cell and secrete antigen 
specific antibody. Lastly, the secreted exogenous antigens can also be taken up by dendritic 
cells and cross-presented to cytotoxic T lymphocytes (CTLs) precursors.  
 
DNA vaccines were first discovered in 1990 by the observation of heterologous protein 
expression in mouse myocytes in vivo, two months after plasmid DNA was given by 
intramuscular injection (Wolff et al., 1990). This key discovery was further demonstrated by 
the induction of an immune response elicited by the marker protein encoded in the plasmid 
DNA (Tang et al., 1992). However, it was in 1993 that Ulmer et al. demonstrated the theory 
of using DNA as a vaccine, by demonstrating that protective immunity was induced in mice. 
Mice were immunised with DNA encoding the influenza virus A nucleoprotein and were 
successfully protected against challenge with homologous and heterologous viral strains, with 
an increased production of CTLs. This study showed that DNA vaccines are capable of 
eliciting potent cellular responses, which are required for many prevalent diseases.  
 
Four DNA vaccines are currently licensed for veterinary use, however despite this success, 
the progress of DNA vaccines for human use has been slow. The ease of manufacture and 
vaccine stability at ambient temperature is a major advantage of DNA vaccines. These 
vaccines are also incapable of causing secondary infection in immunocompromised 
populations, however these advantages of DNA vaccines are often diminished by safety 
concerns over host gene integration and the possible spread of antibiotic resistance to 
pathogens (Faurez et al., 2010). However, most of all, the inability to induce appropriate 
levels of immune response is the major hurdle for DNA vaccines. Several strategies have 
been studied to improve the immunogenicity of DNA vaccines, including co-delivery of 
stimulatory molecules, gene optimisation, delivery in an attenuated viral or bacterial vector, 
and nanoparticles (reviewed in Taki et al., 2011). 
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1.3 Nanoparticles for vaccine delivery platform 
Traditional vaccines using attenuated or killed organisms are the majority of vaccine 
formulations currently used in the market. Although it may be a more efficacious formulation 
because it can elicit sufficient humoral and cellular responses with a single dose, use of live 
organisms however poses many risks associated with reversion to the virulent strain, or an 
emergence to a new pandemic disease. Subunit vaccines offer a safer alternative to attenuated 
vaccines, however immunogenicity is impaired. It is very clear that a new type of vaccine is 
urgently required, or an efficient antigen delivery system to increase the efficacy of subunit 
vaccines.  
 
Over the past decade, nano-sized materials of less than 1 µm, have presented promising 
potential as drug and antigen delivery systems. Nanoparticles and nanocapsules can stabilise 
vaccine antigens and ensure delivery to intracellular compartments to increase the vaccine 
immunogenicity, which subunit vaccines cannot achieve. Delivering antigens in particulate 
form offers several advantages over soluble antigens. Antigens are encapsulated within the 
nanocapsules to provide protection from extracellular protease degradation and prolong their 
circulation in the system. Antigens can also be adsorbed on the surface of nanoparticles, 
sometimes in combination with adjuvants (e.g. pathogen-associated molecular patterns 
(PAMPs)), which allows direct interaction of the antigens with immune cell surface receptors 
(i.e. Toll-like receptors (TLRs)). Particulate form also facilitates more efficient cellular uptake 
by the APCs, therefore capable of inducing potent antigen-specific humoral and more 
importantly, cellular responses by promoting a higher level of cross-presentation.  
 
1.3.1 Materials and preparation choices for nanoparticles 
A variety of materials exist from which nanoparticles can be synthesised. Some inorganic 
materials such as silica and iron oxide nanoparticles have shown potential as a delivery 
system (reviewed in Mody et al., 2013; Tang et al., 2012)(Pusic et al., 2013), however their 
toxicity and clearance from the body raises a few concerns (Kang & Lim, 2012; Vallhov et 
al., 2007; Wang et al., 2007a; Liu et al., 2011). Therefore, more biocompatible and 
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biodegradable materials have gained interest as nanomedicines. Different types of 
nanoparticle using chemically defined materials are studied comprehensively as promising 
candidates.  
 
Examples of such materials are; lipid (viral envelop or phospholipids) (Tyler et al., 2014; 
Slupetzky et al., 2007; Henriksen-Lacey et al., 2011; Heurtault et al., 2010), synthetic 
polymers such as poly(allylamine hydrochlroride) (PAH) (Mauser et al., 2004; Wang et al., 
2008a; 2008b; Tong et al., 2006), poly(acrylic acid) (PAA) and poly(methacrylic acid) 
(PMA) (Mauser et al., 2004; Zelikin et al., 2008), poly(lactide-co-glycolide) (PLGA) (Akagi 
et al., 2007; Yang & Hsu, 2008), and polypeptides such as poly-L-lysine (PLL) (Akiyoshi et 
al., 2000; Zhao & Li, 2008), natural polymer such as chitosan (Chu et al., 2012; Goethals et 
al., 2013; Al-Qadi et al., 2012), and protein such as albumin (Langer et al., 2008; 2003; 
Elzoghby et al., 2012; Altintas et al., 2013). Although the formulation of nanoparticles and 
preparation techniques are the same for antigen and drug delivery systems, a few examples of 
various types of nanoparticles studied for antigen delivery are listed in Table 1.4.  
 
Amongst nanoparticle delivery systems, liposomes were one of the first to be studied. 
Liposomes are self-assembling phospholipid bilayer micelli with an aqueous core. Liposomes 
can be fabricated in a multilayered structure; therefore can allow the encapsulation of both 
hydrophilic and hydrophobic antigens between different layers. There are currently two 
liposome-based vaccines approved for human use, and some others in different phases of 
clinical trials (Watson et al., 2012). Several other liposomes are available for therapeutic drug 
delivery of anti-cancer agents and antimicrobials (Bhujbal et al., 2014). Several polymeric 
nanoparticles are also available for therapeutic use (Wang et al., 2012). PLGA is perhaps the 
most studied polymer material for antigen delivery due to its biodegradability.  
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Table 1.4: Examples of various types of nanoparticles studied for antigen delivery.  
 Nanoparticle material Size Antigen (pathogen) References 
Inorganic  
(Non-degradable) 
Iron 
Silica  
20-300 nm MSP1 (Plasmodium falciparum) 
BSA  
(Pusic et al., 2013) 
(Lim et al., 2012) 
Liposome  
(Non-viral lipids 
particle) 
Cholesterol  
 
Lipid  
Lipid 
200 nm Polysaccharides  
(Streptococcus pneumoniae serotype 14) 
VMP001 (Plasmodium vivax) 
RTS,S/AS01B (Plasmodium falciparum 
CSP + hepatitis B protein hybrid) 
(Deng et al., 2014) 
 
(Moon et al., 2012) 
(Richards et al., 1998) 
Virus-like particle Viral capsid expressed in Bacurlovirus  
Bacteriophage expressed in E. coli C41 
27-60 nm Capsid protein L1+L2 (HPV) 
Capsid protein L2 (HPV) 
(Slupetzky et al., 2007) 
(Tyler et al., 2014) 
Polymeric Chitosan 
PLGA 
PLGA 
PVPONAlk 
γ-PGA 
160-1000 nm Hepatitis B 
Ovalbumin 
Tetanus toxoid 
Ovalbumin 
gp120 (HIV-1) 
(Prego et al., 2010) 
(Shen et al., 2006) 
(Diwan et al., 2002) 
(Mintern et al., 2013) 
(Wang et al., 2007b) 
Chapter 1 
14 
1.3.2 Disadvantages of the preparation methods 
While the approval of some nanoparticles for the commercial vaccines demonstrated that the 
particulate delivery system is biocompatible, effective and marketable, the variability caused 
by the manufacturing methods adds a strict limitation on approval and success (Toh & Chiu, 
2013).  
 
Firstly, this is largely due to the requirements of harsh chemical treatment and physical stress 
used in the preparation process which causes degradation or possible contamination with an 
organic solvent (e.g. chloroform, methanol, dichloromethane) (Tamber et al., 2005). A 
frequently used method for encapsulating antigen is an emulsification technique, which 
requires the use of an organic solvent to create a water-in-oil-in-water (w/o/w) emulsion of 
nanoparticles. This is followed by stabilisation of the nanoparticle-antigen complex with 
either chemical or thermal treatment (Borchert et al., 2006; Yang & Hsu, 2008; Patil, 2003; 
Sundar et al., 2010).  
 
The main issue with this encapsulation technique is the organic solvents used to dissolve 
polymers and lipids, as inadequate removal of surfactant and organic solvents can result in 
toxicity (Langer et al., 2003). The denaturation of antigens has also been observed (Sah, 
1999; Panyam et al., 2003), due to the solvents and sheer stress or high temperature used in 
the process. Furthermore, efficiency of antigen entrapment by the encapsulation method is 
very low, however this method is still widely used for PLGA nanoparticles (Akagi et al., 
2012). 
 
The cationic nature of liposomes (lipid particles) and polysomes (synthetic polymer particles) 
also makes them difficult to use for vaccine delivery, however, there are some benefits. The 
positive surface charge of particles allows adsorption of negatively charged antigens (i.e. 
protein, DNA), and increases electrostatic interactions between the anionic cell membrane to 
facilitate better uptake (Kwon et al., 2005; Nam et al., 2009). However, their cytotoxic effects 
add a limitation to the administration dose (Lv et al., 2006).  
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Nanoparticles exhibiting a strong positive electrostatic charge have greater toxic effects than 
strongly anionic nanoparticles, and can lead to cell death depending on the strength of the 
charge (Yang & Hsu, 2008; Kwon et al., 2005). A decrease in antigen presentation and 
reduction in metabolic activity are also accompanied with the cytotoxicity of strongly cationic 
particles (Kwon et al., 2005; Fischer et al., 1999). The net positive charge of a nanoparticle 
surface can also lead to rapid agglomeration and binding to serum proteins and erythrocytes 
(Khan et al., 2007; Minami et al., 2014). This may cause particle clearance from tissues 
where APCs reside, thus hindering the process of antigen uptake (Verma & Stellacci, 2010). 
Cationic nanoparticles may also cause inflammation mediated by the reactive oxygen species 
generated through the burst (rupture) of liposomes and PLGA particles to release the internal 
contents, or damage to the intracellular microenvironment from the production of acid from 
polymer hydrolysis during degradation, as is the case with PLGA nanoparticles (Dokka et al., 
2000; Schwendeman, 2002). To overcome such issues, the addition of poly(ethylene glycol) 
(PEG), other hydrophilic polymers, Mg(OH)2 or surfactants to coat the surface of cationic 
nanoparticles is utilised (Zhu et al., 2000; Jiang & Schwendeman, 2001). While PEG-coating 
is often used for liposome and polymer nanoparticles currently on the market or in clinical 
trial for both drug and vaccine delivery, this however reduces the efficiency of cellular uptake 
and inhibits endosomal escape into cytosol (Hatakeyama et al., 2013).   
 
Other commonly used techniques to fabricate nanoparticles include; self-assembly (Xu et al., 
2011; Battaglia & Ryan, 2005; Lee et al., 2006), inkjets (Hauschild et al., 2005), desolvation 
(Rahimnejad et al., 2009; Weber et al., 2000; Langer et al., 2003), and nanoparticle 
albumin-bound (nab-)technology for albumin (Desai et al., 1996; Zhang et al., 2013). While 
some of these methods do not require the use of organic solvents nor physical stress, the 
resulting nanoparticles often have high polydispersity in regard to size. 
 
This draws attention to the importance of employing a simpler preparation method, which 
enables the fabrication of nanoparticles with increased homogeneity and stability. In 
particular, methods to utilise fewer materials for preparation with employing less cationic or 
amphiphilic materials to reduce cytotoxicity, is a preferred option to fabricate a safe and 
effective vaccine delivery platform.  
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1.3.3 Nanocapsule assembly using templates 
A templating method has also been employed in the synthesis of polymer nanocapsules 
(Donath et al., 1998; Caruso et al., 1998). This approach uses adsorption of polymer to the 
surface of monodispersed silica nanoparticles by the electrostatic interaction, followed by the 
subsequent removal of the nanoparticles to form a hollow polymer nanocapsule (Yang & Hsu, 
2008; Goethals et al., 2013). The templating method allows the fabrication of nanocapsules to 
overcome some of the issues associated with other preparation techniques.  
 
In the non-templating system, the broad size distribution of synthesised nanocapsules can 
range from nanometres to micrometres. However, the use of a monodispersed, colloidal 
nanoparticle allows the synthesis of nanocapsules in a narrow size distribution (Wang et al., 
2008a). A sacrificial template can also provide greater mechanical stability to the capsule 
formation during the preparation process (Cui et al., 2014). Moreover, this method does not 
rely on the use of organic solvents and surfactants required for the fabrication of liposome or 
polysome nanocapsules, as chemically cross-linking the adsorbed antigens and polymers 
eliminates the need for antigen encapsulation by emulsification. Finally, the properties of 
nanoparticle templates can provide precise control over their size, composition, colloidal 
stability, permeability and surface functionalisation (De Rose et al., 2008). 
 
There are several techniques to synthesise nanocapsules, which utilise the templating method. 
The most commonly used technique is the layer-by-layer (LbL) assembly approach, which 
uses solid spherical nanoparticles as a template (shown in Figure 1.1a). More recently, a 
single step assembly approach employing a solid core mesoporous shell (SC/MS) 
nanoparticle has been demonstrated (shown in Figure 1.1b). Both methods provide the 
properties that are superior to the non-templating methods, however use of SC/MS 
nanoparticles over the LbL assembly approach offers several distinct advantages (Wang et al., 
2008a). Comparison of the two different techniques is summarised below.  
 
1.3.3.1 Layer-by-layer 
In LbL assembly, a solid spherical nanoparticle is used as a sacrificial template to sequentially  
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a)  
 
 
 
 
 
 
b)  
 
Figure 1.1: Schematic representation of a) LbL assembly process, and b) single step 
assembly with SC/MS silica template. (Reproduced from a) De Rose et al., 2008, and b) 
Wang et al., 2008a) 
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deposit multiple layers of polymers and antigen. The layered complex is then chemically 
cross-linked to immobilise the bound material, and then the template is removed (Sexton et 
al., 2009). The polymers and antigens usually consist of opposing charge and are adsorbed by 
their electrostatic force or similar interactions (Decher & Hong, 2011). The multilayer 
structure enables the combination of materials with different properties to be adsorbed in the 
one structure. The LbL approach has a greater advantage over non-templating techniques due 
to its fine control over size and composition of the nanocapsules synthesised. This is 
particularly important in the production of a vaccine as it minimises variability by allowing 
for delivery of an antigen in a measurable dose. 
 
Polymer nanocapsules assembled with this method have shown their potential for antigen 
delivery. It was demonstrated that nanocapsules synthesised with a variety of polymers could 
bind and be internalised by blood APCs in vitro, and HIV peptide-loaded nanocapsules 
efficiently induced MHC class I presentation, and activated CD8+ T cells (De Rose et al., 
2008; Chong et al., 2009). The efficiency of nanocapsules assembled by the LbL approach 
was further assessed in vivo as an antigen delivery system, and showed that ovalbumin-loaded 
thiol-modified PMA (PMASH) nanocapsules could induce high levels of humoral and cellular 
responses than when ovalbumin was administered alone (Sexton et al., 2009). 
 
1.3.3.2 Single step assembly  
Despite the advantages that LbL assembly can offer, sequential adsorption of materials is 
labour intensive and time and material-consuming. The deposition of materials is also driven 
by electrostatic forces or similar interaction of molecules, therefore the overall thickness of a 
single layer is very limited within these transient interactions (Wang et al., 2008a). This 
results in lower antigen loading per nanocapsule, which does not alleviate the problem 
associated with some of the other preparation techniques. Furthermore, this assembly 
approach does not result in a single component of material (i.e. polymer or antigen) in the 
nanocapsule structure. Therefore the control over nanocapsule behaviour in vivo becomes 
more complicated.  
 
To overcome the limitations of LbL assembly, different type of nanoparticles can be 
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employed as a template. A mesoporous sphere is a spherical nanoparticle with a porous 
structure throughout. The adsorption of polymer or antigen is performed in the same principle 
as the LbL method, with molecules adsorbed onto the surface by the electrostatic interaction. 
However, molecule adsorption can be performed in a single step by infiltrating the material 
into the mesoporous matrix. The infiltrated matrix is then chemically cross-linked for 
immobilisation, then the template is removed to form a porous nanoparticle/capsule (Wang & 
Caruso, 2006). As the specific surface area is significantly larger with the intercalating pores, 
this allows a larger capacity of molecules to be loaded per nanoparticle, in a single step. A 
mesoporous sphere can be used to load water-insoluble compounds (Wang et al., 2010), and 
various types of enzymes (Wang & Caruso, 2005; 2006). However, such protein nanoparticles 
cannot be formed without co-loading molecules with polymers to connect the proteins (Wang 
& Caruso, 2006).  
 
Another nanoparticle in this class is the SC/MS nanoparticles. The fabrication method of this 
type of nanoparticle has been defined since the primary method was established by Büchel 
and colleague in 1998. They utilised the highly monodispersed solid silica core as the inner 
base (Stöber et al., 1968), to build a highly robust mesoporous shell surrounding the core 
(Büchel et al., 1998), (Figure 1.2d). Recently, SC/MS nanoparticles were employed as a 
template to synthesise polymer capsules. This approach was demonstrated for the first time 
and produced polymer nanocapsules which were highly stable at physiological pH, yet 
amenable to degradation by intracellular protease (Wang et al., 2008a). In addition, the 
nanocapsules consisted of only a single component with a thick capsule wall resulted in the 
higher loading of materials per nanocapsule (Figure 1.2a). Furthermore, the structure of the 
polymer nanocapsule synthesised using this system were highly homogeneous (Figure 1.2b), 
and deformable (Figure 1.2c). Flexibility in structure is an advantage and it has been shown 
previously that a deformable structure like a liposome can cross the endothelium fenestration, 
while rigid particles of the same diameter could not pass through (Romero et al., 1999). The 
properties of the mesoporous layer in SC/MS nanoparticles is controllable, thus the thickness 
of the capsule wall and porosity can be tailored to fit the infiltrating moiety (Goethals et al., 
2013). Most importantly, the fabrication of mesoporous silica nanoparticles is very simple, 
scalable and cost-effective (Tang et al., 2012). 
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d)  
 
Figure 1.2: Polymer nanocapsules synthesised by a single-step assembly method using a 
silica template. a,b) PLL nanocapsules and c) PAH nanopcapsules synthesised with d) 
SC/MS silica nanoparticle as a template. All images captured by TEM with a scale bar of 500 
nm (a-c) and 100 nm (d). (Reproduced from a) Wang et al., 2008a, and d) Büchel et al., 1998) 
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1.4 Cellular fate of nanoparticles 
The efficacy of a nanoparticle vaccine depends on the interaction of the particles with 
dendritic cells (DCs) as they are the most important cells involved in initiating an immune 
response. DCs are capable of inducing primary responses to infection, and the fate of 
subsequent responses depends on how they respond to that particular pathogen. They are also 
the most potent antigen processing cells which present antigen from pathogens for subsequent 
activation of two major T cell types. The polarity of T cell type therefore determines the 
immunogenicity of the vaccine delivered by nanoparticles. In this section, the basic 
background of DCs is explained whilst the interaction of nanoparticles is also discussed. This 
will be followed by an overview of three different antigen processing and presentation 
pathways by DCs, which nanoparticles undergo as antigen delivery system. Lastly, the 
subsequent T cell activation is reviewed.  
 
1.4.1 Dendritic cells 
APCs are effective at internalising, processing and presenting exogenous antigens acquired 
from infecting pathogens. There are three main types of APCs, dendritic cells, macrophages 
and B cells. Amongst these, DCs are the most potent professional APCs for the initiation of 
immune responses, and their ability to prime naïve T cells has been well studied (Steinman, 
2007b; Villadangos & Schnorrer, 2007). The discovery of DCs by Steinman and Cohn in 
1974 has profoundly changed the science of immunology (Steinman, 1974). It is now widely 
accepted that DCs play the central role in mediating immunity and tolerance, as well as being 
the link between innate and adaptive immune responses against infectious agents. 
 
1.4.1.1 Types of DCs to target 
DC populations reside in secondary lymphoid organs and most peripheral tissues such as skin, 
lung and intestines where they have first interaction with materials from the external 
environment (Banchereau et al., 2000). DCs comprise heterogeneous populations and their 
precursor is derived from bone marrow and their heterogeneity depends on the secondary 
lymphoid organs where DCs reside in a resting immature state. Different DC subsets 
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comprise distinct phenotypes and exhibit a variety of functional properties (Heath & Carbone, 
2013).  
 
Resident DC arise from committed progenitors which migrate from the bone marrow to 
lymphoid organs and finally to the blood where they reside permanently. It is only these types 
of DCs that are found in secondary lymphoid organs (Liu et al., 2009). Migratory DCs 
complete their final differentiation and development in peripheral tissues and then 
continuously migrate into lymph nodes (Randolph & Ochando, 2008), even in the absence of 
stimuli released upon binding of TLR to the pathogen (Wilson et al., 2007). Both types of 
DCs express high levels of cluster-of-differentiation (CD)11c, but resident DCs are 
characterised by the expression of CD8a (thus CD8+ or CD8- DC), while migratory DCs are 
characterised by the expression of CD11b (thus CD11b+ or CD11b- DC), along with 
expression of CD205 (DEC205) in all populations (Segura & Villadangos, 2009; Segura et 
al., 2009). DEC205 expressed on migratory DCs, especially on the dermal DCs, is an 
endocytosis-mediating receptor involved in exogenous antigen uptake, and which targets the 
late endosome or lysosome for MHC class II presentation (Mahnke et al., 2000). It is the 
migratory type of conventional DCs that play an essential role in antigen presentation against 
infections.  
 
1.4.1.2 Immunostimulators and DC maturation 
DCs remain in an immature state in the absence of infection, dedicating their function to 
immune surveillance by constitutively presenting self-antigens. T cell activation by these DCs 
is impaired and low levels of MHC class II molecules and co-stimulatory molecules such as 
CD40, CD80 and CD86 are expressed during this state. However, they are characterised by 
their high endocytic and phagocytic capacity to internalise exogenous antigens (Wilson et al., 
2004). Upon infection, the expression of these molecules is up-regulated by several 
extracellular and intracellular stimuli (Han et al., 2009). These CD molecules can allow more 
intimate interaction with T cells for subsequent antigen presentation. One of the stimuli is 
released from the interaction with the PAMPs of pathogens, which elicit the innate immune 
response.  
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Stimuli are released when TLRs on DCs binds to the surface molecules such as PAMPs of 
invading pathogens, which include lipopolysaccharides (LPS) within the cell wall of gram 
negative bacteria, and bacterial unmethylated CpG oligodeoxynucleotides (Medzhitov, 2001). 
TLRs are an evolutionally conserved family of receptors and are expressed on a variety of 
innate immune cells (Medzhitov, 2001). PAMPs are found on non-mammalian cells, therefore 
TLRs have broad specificity for these conserved patterns (Underhill & Ozinsky, 2002; Kopp 
& Medzhitov, 2003). The ligation of PAMPs to TLRs can also stimulate cells to increase the 
phagocytosis of exogenous antigens (Redlich et al., 2013).  
 
Up-regulation of surface molecule expression on DC is also induced by inflammatory 
cytokines including tumour necrosis factor alpha (TNFα), interleukin (IL)-1β, and IL-6 
(Guermonprez et al., 2002). Using a murine immature DC line, DC2.4, He et al. (2007), 
demonstrated that interferon gamma (IFNγ) was also able to induce DC maturation in vitro 
for more efficient stimulation of CD8+ T cell responses. Upon receiving exogenous stimuli 
produced from PAMPs or cytokines, the intracellular trafficking of MHC molecules and 
antigen processing were also enhanced (Théry & Amigorena, 2001). This direct interaction 
with pathogens therefore induces DC to undergo a development process often referred to as 
maturation. The maturation process activates DCs to become efficient APCs, thus 
transforming them to be potent T cell activators.  
 
1.4.1.3 Adjuvant  
Improving the immunogenicity of a vaccine can be achieved by the co-delivery of stimulating 
molecules. Molecules such as PAMPs can induce more efficient uptake of a vaccine and 
ensure the activation of DCs. Adjuvants are defined compounds that are added to the vaccine 
to enhance antigen-specific immune responses. Adjuvants approved for human used are 
aluminium hydroxide mineral salts (Alum), MF59®, virus-like particles, cholera toxin, and 
MPL® (glycoprotein) (Reed et al., 2009). However, conventional adjuvants such as Alum 
have been historically shown to elicit strong humoral responses with weaker cellular 
responses. More potent adjuvants are available however their use in human is limited due to 
their high toxicity. The optimal balance between the toxicity of adjuvant and combination 
with the vaccine must be carefully considered.  
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An important feature of a particulate vaccine is the ability to directly conjugate an additional 
molecule on the nanoparticle surface. The conjugation of PAMPs with either protein or a 
DNA sequence can be achieved by adsorption by electrostatic interactions and chemical 
cross-linking (Hermanson, 2013; Di Marco et al., 2010). A variety of PAMPs have been 
studied as co-delivery molecules in a particulate delivery system, which specifically target the 
matching TLRs (reviewed in Demento et al., 2011), however the most commonly studied 
element is the unmethylated CpG motif. The CpG motif is rich in cytosine and guanine, is 
recognised by TLR9, which is primarily expressed in the endosome of blood APCs (Hemmi 
et al., 2000). The use of the CpG motif in a particulate delivery system to induce cellular 
responses was demonstrated using PLGA nanoparticles surface-modified with the CpG motif. 
This combination elicited humoral, as well as cellular responses, and provided protection 
against live viral infection (Demento et al., 2010). Interestingly, encapsulation of the CpG 
motif has also been shown to increase the cellular response much higher than the soluble 
antigen formulated with the CpG motif in solution, encapsulated antigen without CpG motif, 
and encapsulated antigen delivered with CpG in solution. The CpG motif co-encapsulated 
with tetanus toxoid in PLGA nanocapsules increased the level of IFNγ, IgG2b and IgG3 by 
Th1-biased immune response, and IgG1 by Th2-biased immune response (Diwan et al., 
2002). This indicates that lower amounts of potentially toxic adjuvant can be used in 
conjunction with nanocapsules to induce more potent humoral and cellular immunity.  
 
Coupling of TLR ligands and PAMPs is not the only option for targeting DCs. The surface of 
nanoparticles can be functionalised with DC-specific antibodies. Mintern and colleagues 
(2013), demonstrated that the CD11c and DEC205 DC subsets can be targeted by 
functionalisation of nanoparticles with monoclonal antibodies.  
 
1.4.1.4 Trafficking of antigen to the lymph nodes 
Once the migratory DC captures the antigen, it will migrate out from the peripheral tissues 
into the draining lymph nodes through afferent lymph vessels (Randolph & Ochando, 2008). 
It will then complete its journey for the interaction and activation of naïve T cells. The 
transformation of migratory DC to the mature state by encountering exogenous antigens and   
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Figure 1.3: Maturation and migration of conventional migratory DC. DC progenitors are 
formed in the bone marrow, and then migrate to various peripheral tissues (e.g. the epidermis, 
intestine, blood vessel wall or atherogenic plaques), and reside as immature DCs. Upon 
interaction with a pathogen, DC undergo maturation and migrate to lymph nodes to present 
the internalised antigen to naïve T cells to initiate their activation. (Reproduced from Szatmari 
& Nagy, 2008) 
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the transport to lymph nodes is presented graphically in Figure 1.3. DC migration is attributed 
to the changes in the expression level of surface adhesion molecules and cytoskeleton 
modification during the maturation process (Banchereau et al., 2000; Lamsoul et al., 2013)  
 
After exposure to stimuli, and following the maturation process, DCs lose the ability to 
further endocytose and process newly countered antigens (Guermonprez et al., 2002). 
Therefore, the activation of T cells is limited by the presentation of specific antigen 
internalised by APC’s prior to maturation. The ability of migratory DC to transfer internalised 
antigens to the lymph node resident DC has also been documented. Allan et al. (2003), found 
that DCs from lymph nodes presented viral peptide after cutaneous injection of mice with 
human herpes simplexvirus. Initially it was thought that the skin DC, i.e. Langerhan cells 
migrated to lymph nodes and initiated T cell activation, however it was found to be a different 
DC subset. It was also shown that blocking the migration of Langerhan cells from the infected 
skin inhibited presentation and subsequent immune response to the viral infection (Allan et 
al., 2006). This finding leads to the discovery of how migratory DC can be an antigen carrier, 
instead of directly presenting antigen themselves and priming T cells in lymph nodes.  
 
However, with the particulate delivery system, the resident DCs can be directly targeted for 
antigen uptake instead of relying on capture by the migratory DCs. Nanoparticle trafficking to 
draining lymph nodes has been observed, and this is thought to depend on particle size (Fifis 
et al., 2004; Reddy et al., 2006; Manolova et al., 2008). Nanoparticles of less than 200 nm in 
diameter can freely drain to the lymph nodes spontaneously by leaving the interstitial space 
and being transported via the interstitial flow (Nishioka & Yoshino, 2001; Reddy et al., 
2006).  
 
Reddy and colleagues (2007), assessed the feasibility of nanoparticle transport to the lymph 
nodes using 25 nm and 100 nm polypropylene sulphide nanoparticles loaded with ovalbumin. 
They found that the 25 nm nanoparticles reached the lymph nodes much more efficiently than 
the 100 nm nanoparticles following intradermal injection. The ovalbumin-specific IgG level 
subsequently induced by the 25 nm nanoparticles was equivalent to that of soluble ovalbumin 
formulated with adjuvant, whereas the level induced by the 100 nm was significantly lower 
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(Reddy et al., 2007). This study was followed by Manolova and colleagues (2008), to 
demonstrate that the nanoparticles injected intracutaneously are trafficked to the draining 
lymph nodes in less than 2 h, while nano- and microparticles of 200 nm to 2 µm, respectively, 
require 8 h to enter the subcapsular sinus (Manolova et al., 2008). These findings show that 
smaller nanoparticles have the potential to directly target lymph nodes, and this 
DC-independent trafficking can decrease the time to antigen presentation (Pack, 2004). 
 
 
1.4.2 Antigen processing and presentation 
Exogenous antigen derived from an infectious pathogen and endogenous antigen derived from 
viral infection or normal cellular metabolism, are all processed within APCs via several 
pathways. These antigens are enzymatically digested within distinct intracellular 
compartments, and the processed peptides are delivered to the surface membrane in context 
with MHC class I and MHC class II molecules. Peptide-MHC molecule is presented to naïve 
CD4+ and CD8+ T cells to initiate immune responses depending on the primed T cell type. 
This process, called antigen presentation, is imperative for T cell activation against infection, 
as well as immune surveillance for tumour detection. Different intracellular processing will 
result in the fragmentation of antigen to be associated with either MHC molecule, thus 
leading to the activation of different T cells. Three pathways are known to this date; the MHC 
class I pathway, MHC class II pathway and the cross-presentation pathway. These pathways 
are presented graphically in Figure 1.4.  
 
1.4.2.1 MHC class I pathway 
Endogenous antigens such as viral proteins, tumour antigens, intracellular pathogens and 
defective cells are processed through the MHC class I pathway, for the activation of CD8+ T 
cells. MHC class I molecules are commonly expressed with fragmented endogenous 
self-antigens on the cell surface of all nucleated cells (Janeway, 2001). However, the 
presentation of peptides from intracellular pathogens and tumours will be recognised as 
non-self-antigens, which will induce CD8+ T cells to kill cells presenting these antigens (Belz 
et al., 2004; Huang et al., 1994).  
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Figure 1.4: The antigen presentation pathway in dendritic cells. On the left, the MHC class II presentation pathway shows where exogenous 
antigen or endogenous antigen secreted from other cells is taken up by endocytosis and loaded onto MHC class II molecules. On the right, the MHC 
class I presentation pathway is shown where endogenous antigen in the cytosol is fragmented by a multisubunit proteasome complex, and then loaded 
onto MHC class I. In the middle is the cross-presentation pathway where antigens are processed through the MHC class II presentation pathway but are 
subsequently loaded onto the MHC class I molecule. (Reproduced from Hubbell et al., 2009)  
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Endogenous proteins are processed in the cytosol through a multicatalytic enzyme complex 
called the proteasome, which consists of 28 subunits. The proteasome is expressed in all 
eukaryotic cells and plays a major role in the regulation of cell-cycle, proliferation, 
differentiation, tumour suppression and apoptosis (Zheng et al., 2004; O'Connor, 2005). 
Deregulation of the proteasome process can lead to malignancies (Adams, 2004). Proteasomal 
proteolysis produces peptides, which still require further fragmentation before loading onto 
MHC class I molecules. Therefore, degraded peptides are transported into the endoplasmic 
reticulum (ER) through a molecule termed transporter associated with antigen processing 
(TAP), where the peptides can be further trimmed by an aminopeptidase called ER 
aminopeptidase associated with antigen processing (ERAAP). TAP is localised on the ER 
membrane on the cytoplasmic side, binds to peptides and actively transports them from the 
cytosol into the lumen of the ER. The function of ERAAP was identified when blocking 
ERAAP expression severely reduced the presentation by MHC class I molecules on the cell 
surface (Serwold et al., 2002). It was further characterised by using the ERAAP-deficient 
mice, which showed how it selectively allows peptides to be trimmed at the N-terminus 
(Hammer et al., 2005). This is due to ERAAPs specific function as a molecular ruler to assess 
and trim peptides depending on their length (Chang et al., 2005). A peptide is loaded onto a 
newly synthesised MHC class I molecule in the lumen of the ER, then transported to the cell 
surface through the Golgi apparatus (Hewitt, 2003). The peptide presented on the MHC class 
I molecule is then recognised by the TCR on CD8+ T cells for subsequent induction of 
cellular responses.  
 
1.4.2.2 MHC class II pathway 
Exogenous antigens including extracellular pathogens and some endogenous antigens 
secreted from other cells are endocytosed and processed through the MHC class II pathway. 
Peptides processed through this pathway are presented with MHC class II molecules for the 
activation of CD4+ T cells. MHC class II molecules are mainly expressed by APCs, including 
DCs, macrophages and B cells (Janeway, 2001; Neefjes et al., 2011). Cellular proteins from 
APCs can also be presented on MHC class II molecules (Sant, 1994). This type of 
endogenous antigen is derived from some components of the endocytic pathway, plasma 
membrane and cytosolic proteins. Some viral proteins are also presented on MHC class II 
molecules (Paludan et al., 2005). Self- and pathogen-derived endogenous antigens are 
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however, processed thorough a separate pathway by autophagy. Autophagy is a pathway 
which separates and surrounds cytoplasmic material into an autophagosome, and delivers it to 
lysosomes for proteolytic degradation where it then meets MHC class II molecule for loading 
(Münz, 2012).   
 
Exogenous antigens are internalised via various endocytic pathways depending on their size. 
Generally, antigens or particles larger than 1 µm, i.e. the size range of a bacterial pathogen, 
are internalised via phagocytosis. Smaller antigens (~1 µm) are internalised via 
macropinocytosis, and even smaller antigens (virus sized) are internalised by 
receptor-mediated clathrin endocytosis (~120 nm) (Daecke et al., 2005), 
clathrin-independednt and caveolin-independent endocytosis (~90 nm) (Petros & DeSimone, 
2010), or caveolae-mediated lipid rafts (Chen & Norkin, 1999) (shown in Figure 1.5).  
 
Antigen internalised by the endocytic pathway is mediated by the plasma membrane. As the 
antigen localised in the endocytic vesicle cannot cross the membrane, it is not degraded by the 
proteasomes in the cytosol. Inactivated proteases are also encapsulated within the vesicle, 
which is now called the early endosome. However, acidification of the endosome increases 
while it egresses to the perinuclear area (late endosome stage), which results in the activation 
of these proteases to degrade the antigen contained within. The late endosome that carries 
fragmented antigen peptide fuses with lysosomes containing MHC class II molecules. The 
loading of peptide onto MHC class II molecules also takes place in the lysosome. MHC class 
II molecules are synthesised in the lumen of the ER and transported to the lysosome through 
the Golgi apparatus instead of binding to peptides in the ER. During the transport of the MHC 
class II molecule to the lysosome, the MHC class II molecule is blocked with a polypeptide 
called the invariant chain to inhibit the binding of other cellular peptides to the molecule 
(Landsverk et al., 2009). Cathepsin S, a lysosomal protease, then digests the invariant chain to 
allow the replacement to antigen peptide onto the MHC class II molecule for the presentation 
(FernandezBorja et al., 1996; Bania et al., 2003). The peptide-MHC class II complex is then 
transported to the cell surface to be recognised by CD4+ T cells. 
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Figure 1.5: Mode of size-dependent cellular uptake. (Adapted from Petros & DeSimone, 
2010) 
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1.4.2.3 Cross-presentation pathway 
Exogenous antigens internalised by APC are normally processed through the MHC class II 
pathway, however they can also be presented onto MHC class I molecules to prime CD8+ T 
cells. Antigens are degraded in endosome/lysosome compartments, and then the peptides 
somehow escape the vesicle, possibly to the cytosol, where they can be loaded onto MHC 
class I molecules. This alternative pathway is called the cross-presentation pathway.  
 
Evidence of cross-presentation was first observed by Bevan in 1976. Bevan reported a 
generation of MHC haplotype-restricted CD8+ T cell responses in mice after the injection of 
unmatched allotype-cells (Bevan, 1976). In his experiment, mice (BALB/b x BALB/c) that 
expressed MHC haplotype (H-2b/d) were immunised with the C57BL/10 (B10) mouse cells 
with H-2b haplotype, and B10.D2 mouse cells with H-2d haplotype. It was initially assumed 
that only H-2b restricted CD8+ T cells would be generated, as it should only recognise H-2b on 
B10 cells, but not H-2d on B10.D2, due to minor histocompatibility differences. However, in 
addition to the H-2b priming in vivo, the H-2b restricted CD8+ T cells not only recognised the 
H-2b B10 cell, but also H-2d B10.D2 in vitro. Since there was no H-2b expression from 
B10.D2 cells, it was concluded that the antigen-specific CD8+ T cell recognition came from a 
cross-priming of B10.D2 cell-associated antigen to the mice APC with H-2b, by a pathway 
now known as cross-presentation. The term “cross-priming” was used to describe the 
activation of T cells, therefore to encompass this phenomenon, the term “cross-presentation” 
is used in contrast to the other know effect “cross-tolerisation” of T cells.  
 
Several mechanisms have been proposed for the cross-presentation process, mainly the 
cytosolic pathway and vacuolar pathway. The cytosolic pathway transfers internalised antigen 
to the cytosol, where it has an access to the proteasome to be degraded. This follows the MHC 
class I pathway, thus the fragmented peptide will then go through TAP to access MHC class I 
in the lumen of the ER (Delamarre et al., 2003; Rodriguez et al., 1999; Lin et al., 2008). The 
alternative pathway, the vacuolar or endosomal pathway is independent of the proteasome and 
TAP for cross-presentation. (Rock & Shen, 2005; Schirmbeck & Reimann, 2002; Lin et al., 
2008). The internalised antigen is degraded by endosomal proteases and loaded onto MHC 
class I molecules. Preliminary studies could not address the process by which ER-derived 
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MHC class I molecules could bind antigen without also binding to the other cellular peptides, 
or recycled MHC class I molecules which have already bound peptide (Motal et al., 1993). 
The role of the lysosomal protease, cathepsin S has been suggested, as the level of 
cross-presentation was abolished in cathepsin S-deficient mice (Shen et al., 2004). The 
endosomal compartment is also highly acidic and internalised antigens are rapidly destroyed. 
This environment in the endosome might not allow sufficient time for the antigen to escape 
into the cytosol for cross-presentation (Segura & Villadangos, 2011). However, encapsulation 
of antigen in a nanocapsule was found to maintain the prolonged release of antigen within the 
endosome, possibly increasing the chance of antigen to escape into the cytosol (Shen et al., 
2006). This indeed resulted in an increase in the cross-presentation of antigen.  
 
More recently, another pathway for cross-presentation was proposed (Houde et al., 2003; 
Ackerman et al., 2003; Guermonprez et al., 2002). It has been suggested that the ER can form 
an endosomal vesicle known as a phagosome, to actively bring MHC class I molecules and 
other antigen-processing machinery from the ER to the antigen-containing endosome. It was 
also suggested that the early endosome or pinosomes are enough to facilitate 
cross-presentation (Ackerman et al., 2003). With the loading machinery transported, the 
antigen can be translocated into the cytosol and access the proteasome for degradation. 
Fragmented peptides will return to the phagosome to be loaded onto MHC class I molecules 
for presentation.  
 
What determines the magnitude of cross-presentation to be induced is not fully understood. 
However, the endocytic pathway in which the exogenous antigen is internalised can greatly 
affect subsequent intracellular processing, and hence the presentation pathway (Landsverk et 
al., 2009). This is due to the type of endocytic vesicles made during internalisation. It was 
demonstrated that the mannose receptor supplied an early endosome committed to the 
cross-presentation on MHC class I molecules, while the scavenger receptor delivered the 
antigen more towards presentation on MHC class II molecules (Burgdorf et al., 2007). It has 
also been suggested that the cytosolic pathway is the primary pathway for efficient 
cross-presentation (Rock, 1996).  
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Certain subsets of DC can cross-present more efficiently than others. CD8+ resident DCs in 
secondary lymphoid organs have the ability to cross-present (Segura et al., 2009), while 
CD103+ migratory DCs are known to cross-present exogenous viral antigens (Waithman et 
al., 2013; GeurtsvanKessel et al., 2008), and apoptotic-cell antigens (Desch et al., 2011), to 
CD8+ T cells. The stimuli released upon capturing the pathogen also has an impact on 
cross-presentation. Wagner et al. (2013) demonstrated that TLR ligands and cytokines such as 
TNF-α had negative effects on cross-presentation. Furthermore, cross-presentation was 
strongly inhibited the most in LPS-matured DC, regardless of whether DC was pretreated 
with LPS or exposed to LPS and antigen simultaneously. However, Pooley et al. (2001) 
reported a controversial effect of LPS, as it increased the ability of CD4+ DC to present 
antigen to CD8+ T cells, when these DC subsets were often found to primarily prime CD4+ T 
cells. The ability of CD8+ T cells was also not altered by the presence of LPS. 
 
Targeting the cross-presentation pathway for the delivery of exogenous antigen is therefore 
the key to develop effective vaccines against tumours, intracellular parasites, intracellular 
bacteria and viruses (Rock et al., 1990; Moron et al., 2004).  
 
 
1.4.3 T cell activation 
Following the uptake of antigen, DCs migrate to lymph nodes where naïve T cells reside. 
Antigen captured by DC is degraded within intracellular compartments, and the fragmented 
antigen is then loaded onto MHC molecules to be presented on the surface of DC by the 
mechanisms explained in the previous section. The antigen-MHC molecule complex is 
detected by the T cell receptor on naïve T cells, which causes an antigen-specific signal for 
the induction of T cell priming.  
 
1.4.3.1 T helper versus cytotoxic 
There are two major groups of T cells which can be activated upon interaction with DCs. 
These are characterised by the expression of either CD4+ or CD8+ markers on the cell surface, 
and referred to as Th cells and CTLs, respectively. The functional properties of CD4+ T cells   
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Figure 1.6: Summary of the fate of CD4+ T helper cells. Their functions, secreted cytokine 
profile and cytokines critical for determining their fate. (Image and legend adapted and 
modified from Zhu & Paul, 2008) 
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are to secrete cytokines to promote T cell proliferation, to enhance macrophage activity, 
recruit monocytes to the site of infection, and also to promote B cell proliferation and 
maturation into a plasma cell to produce antibodies specific to the pathogen. These functions 
are attributed by four different subsets of CD4+ T cells as summarised in Figure 1.6, which 
will be discussed in some depth in the subsequent section. The function of CD8+ T cells is 
primarily to kill cells, including self-tissue in the case of autoimmune disease. Cells which 
have undergone apoptosis or are virally infected are also eliminated from the body by the lytic 
functionality of CD8+ T cells. The control of tumour cells and transplanted organs are also 
targeted by this type of T cell (Zhang & Bevan, 2011).  
 
1.4.3.2 Th subsets  
In 1986, Mosmann and Coffman identified that naïve CD4+ T cells can differentiate into two 
major subsets after the activation (Mosmann et al., 1986). These subsets are named type 1 T 
helper (Th1) cells and type 2 T helper (Th2) cells, and are characterised by their distinct 
cytokine profiles. In particular, Th1 secretes its pro-imflammatory cytokine IFNγ, which 
causes macrophage activation (Paul & Seder, 1994), as well as IL-2 which promotes the 
proliferation of CD8+ T cells and delayed-type hypersensitivity. IL-2 produced during the 
initial priming of CD8+ T cells is also an important stimulating factor for antigen-specific 
memory CD8+ T cell expansion (Williams et al., 2006). Th1 therefore promotes cytotoxic 
properties by mediating the immune response against intracellular infection, such as a virus. 
 
Th2 cell secretes an array of cytokines including IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25. 
Most of these are associated with humoral responses, and predominantly the 
anti-inflammatory response. IL-4 is necessary for the proliferation and expansion of 
IL-4-secreting Th2 cells (Swain et al., 1990), and IL-10 is an anti-inflammatory cytokine 
(Berger, 2000), which inhibits macrophage activation as oppose to the Th1 cytokine. Th2 
cells also mediate immune responses against extracellular parasitic infections (Mosmann & 
Coffman, 1989; Paul & Seder, 1994).  
 
Both types of Th cells promote the proliferation and maturation of B cells and induce class 
switching of antigen-specific antibody. Under the influence of Th1 cytokines, IgM switches to 
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IgG2a in mice to become an opsonising antibody for mediating complement induction and 
cellular uptake of antigen by binding to the surface of APCs (ADCC). Cytokines secreted 
from Th2 cells can switch Ig class to IgG1 to become neutralising antibody against the 
specific antigen (Snapper & Paul, 1987; Sideras & Lindqvist, 1985).  
 
More recently, the role of IL-17 has become clearer and the distinct Th subset that produces 
this cytokine was denoted Th17 cells (Steinman, 2007a). Several types of IL-17 cytokines are 
secreted by Th17, and other pro-inflammatory cytokines indicate that Th17 is involved in 
inflammatory immune responses and autoimmunity (Quesniaux et al., 2009; Steinman, 
2007a), and cancer immunology (Nunez et al., 2013). IL-17a and IL-17f secreted from Th17 
can also mediate immune response against bacterial and fungal infection by activating 
neutrophils (Weaver et al., 2006).  
 
Additionally, another CD4+ T cell subset known as T regulatory cells was identified in the 
1990s (Sakaguchi et al., 1995). Although the idea of T cell populations with a suppressing 
function was gaining focus in the 1970s-80s, it quickly diminished without finding any key 
evidence to support it (Sakaguchi et al., 2007). It is now understood that regulatory T cells are 
able to control the T cell repertoire by suppressing their function, therefore maintaining 
self-tolerance and preventing autoimmune diseases.  
 
1.4.3.3 Nanoparticle induced immunity 
Particulate antigens have been documented to enter the cross-presentation pathway in DCs 
(Shen et al., 1997; Sexton et al., 2009; Kaba et al., 2012; Hirosue et al., 2010; Sneh-Edri et 
al., 2011; Yang & Hsu, 2008; Plebanski et al., 1998; Akagi et al., 2007). Different sizes of 
nanoparticles can be endocytosed by various pathways; therefore it is possible that the entry 
pathway is mediating the intracellular fate of antigen processing.  
 
In one study, all of the nanoparticles were found to localise to the lysosomal compartment 
upon internalisation into APCs, therefore the composition of material and the time it can be 
retained in the lysosomal compartment may influence cytosol escape for the 
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cross-presentation (Shen et al., 2006). 
 
One study demonstrated that particles in the viral range (40-50 nm) are an optimal size to be 
trafficked to the draining lymph nodes, therefore eliciting a higher level of cellular response 
by activating CD8+ T cells (Fifis et al., 2004). Another study showed that nano beads of  
40-49 nm could activate CD4+ T cells and induce Th1 biased cytokine secretion, while nano 
beads of 93-101 nm induced Th2 biased cytokine secretion following immunisation (Mottram 
et al., 2007). This suggested that the smaller nanoparticles can elicit both humoral and cellular 
responses by activating both CD4+ and CD8+ T cells. On the contrary, it was shown that the 
nanoparticles of much larger size (350 nm-1 µm) could also be cross-presented while 
inducing a robust Th1 response with predominant IFNγ production by priming CD4+ T cells 
(Sneh-Edri et al., 2011; Shen et al., 2006). Furthermore, nanoparticles in the larger size range 
could also be presented via the cross-presentation pathway in non-competent APCs (B cells) 
(Shen et al., 2006).  
 
While the size of nanoparticles can induce different modes of cellular uptake, the differences 
in size may not corroborate to the type of immune response induced. Several studies 
demonstrated different outcomes of immune response induced by various sizes of 
nanoparticles.  
 
Differences in the immune responses induced by nanoparticles may not be only limited to 
size, but may also depend on the density of nanoparticles (solid beads or capsules), the 
adjuvant effects of the materials and the administration sites for the vaccination (Yip et al., 
1999). The mechanism of uptake and intracellular processing of nanoparticles may also be 
influenced by the surface charge or overall ζ-potential, sequence or density of 
polymer/antigen matrices, and other formulation properties (Sneh-Edri et al., 2011). One 
study demonstrated that a fusion-activated virosome internalised by the receptor-mediated 
endocytosis, actively fused with acidified endosomal membrane to release the antigen directly 
into the cytosol (Arkema et al., 2000). Similarly, antigen encapsulated in the PLGA 
nanoparticles (compared to soluble antigen) was shown to remain longer in the endosome and 
increased the amount of antigen escape into the cytosol (Shen et al., 2006). The level of 
Chapter 1 
39 
antigen cross-presented and also the duration of presentation were also higher than the soluble 
antigen. Encapsulation of antigen was also shown to be more efficient than the antigen 
delivered on the surface of a solid particle. Encapsulation of soluble antigen can possibly 
protect them from endosomal protease degradation, while assisting the slow release of antigen 
over prolonged time to be processed by the cross-presentation pathway. Antigens remaining 
in the endosome can continue to be processed by the MHC class II pathway. 
 
In conclusion, most of the studies demonstrated that potent cellular and humoral responses 
can be elicited with antigen in a particulate form, significantly higher than soluble antigen, 
with increased production and class switching of IgG1 and IgG2a by Th2 and Th1 cytokine 
secretion, respectively (Uto et al., 2013; 2009; Mohr et al., 2010).  
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1.5 Malaria infection  
Malaria infection is one of the most prevalent diseases caused by members of the Plasmodium 
genus. Malaria causes millions of acute cases globally with more than 50,000 deaths each 
year (World Health Organization). However, currently there is no effective vaccine that 
provides protection in all vaccine recipients. One of the major difficulties in malaria vaccine 
development is that the parasite has the ability to undergo repeated antigenic variation in 
order to evade host defence immunity (Su et al., 1995). Several vaccine candidates has been 
developed, which include the most promising candidate RTS,S vaccine currently in phase III 
clinical trial (Bejon et al., 2013; Regules et al., 2011). The RTS,S vaccine is formulated in 
either water-in-oil emulsion adjuvant or liposome (PATH, 2014), and consists of human 
malaria Plasmodium falciparum circumsporozite protein co-expressed with the hepatitis B 
antigen (Richards et al., 1998).  
 
The malaria parasite has a very complex life cycle. As depicted in Figure 1.7, the life cycle of 
malaria starts from the injection of sporozoites from mosquitoes into the blood stream, and it 
infects liver hepatocytes to proliferate to tens of thousands of haploid form before re-entering 
the bloodstream (Nardin & Nussenzweig, 1993). The parasite in this stage is called 
merozoites and it continues to infect the red blood cells during its asexual replication in the 
bloodstream. The time required for malaria parasites to complete one asexual cycle varies 
between species. P. falciparum completes its replication in 48 h. Within this time frame, 
malaria goes through several stages of life cycle within the host erythrocytes, until the 
reproduced merozoites are released by the rupture of the erythrocytes for further infection and 
replication (Tuteja, 2007). Due to the lack of expression of MHC class I molecules by the 
erythrocytes, the infected cells cannot display the intracellular malarial antigens for T cell 
recognition. It is also difficult for any antibodies to bind to malaria during the blood stage, as 
many of the parasites antigens are expressed only within the infected erythrocytes. The only 
period the parasite is exposed to the APCs in the blood stream is when the merozoite is 
released to infect other erythrocytes, therefore the most effective vaccine components are the 
proteins expressed on the surface of merozoite stage (Kedzierski et al., 2001). 
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Figure 1.7: Plasmodium falciparum life cycle. (Reproduced from Regules et al., 2011) 
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Figure 1. Plasmodium falciparum lifecycle. Parasite lifecycle, spanning both humans and mosquitoes.
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1.5.1 Merozoite surface protein 4/5 
The merozoites possess many novel surface proteins are well characterised for their high 
potential as a vaccine candidate antigens. These proteins include merozoite Surface Protein 
(MSP) 1 (Cheng et al., 2013), MSP 2 (Sumari et al., 2011), MSP 4 (Marshall et al., 1997) 
MSP 5 (Gardner, 1998), and apical membrane antigen 1 (AMA1) (Zhu et al., 2011) from P. 
falciparum. MSPs play an important role in initiating the infection of erythrocytes by 
recognising and binding to the surface.   
 
There are four species of rodent malaria which have been utilised extensively for vaccine 
development; P. yoelii, P. berghei, P. vinkei and P. chabaudi. A murine malaria species does 
not infect humans as malaria has very narrow host specificity, however the study of such 
model is very useful for understanding their immune mechanisms and vaccine potential. 
 
A region of P. falciparum chromosome 2 has been identified which encodes for MSP2, 
MSP5, and MSP4 in tandem (Marshall et al., 1998). MSP4 and MSP5 encode 
glycosylphosphatidylinositol (GPI)-anchored proteins with observed molecular weight of 40 
kDa, and both proteins contain a highly conserved region, which codes for a single epidermal 
growth factor (EGF)-like domain. A gene homologous to MSP4 and MSP5 was also 
identified in the murine malaria parasite Plasmodium chabaudi adami DS (Black et al., 1999), 
and hence coined its name MSP4/5. The gene has an intron-exon structure similar to those of 
MSP4 and MSP5 (Figure 1.8), and the encoded protein has major structural and 
immunochemical properties in common with MSP4 and MSP5. The same homologue was 
later identified in two other murine malaria species, P. yoelii and P. berghei (Kedzierski et al., 
2000a). The recombinant MSP4/5 was demonstrated to elicit very strong humoral responses 
and IgG1 and IgG2a antibody production, as well as providing protection against lethal 
malaria challenge in mice (Kedzierski et al., 2000b; 2001). 
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Figure 1.8: Schematic representation (to scale) of the intron-exon arrangement and 
predicted polypeptide structure of PcMSP4/5 to P. falciparum MSP4 and MSP5. The 
position of the EGF-like domain is indicated by a hatched box. Signals for secretion and GPI 
attachment are represented by solid boxes. (Image and legend adopted from Black et al., 
1999) 
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Heterologous immunisation with recombinant MSP4/5 from different murine malaria species 
can also protect mice from the lethal strain challenge. BALB/c mice immunised with variant 
recombinant MSP4/5 were challenged with P. yoelii yoelii YM-parasitised red blood cells and 
the heterologous protections was observed in mice immunised with recombinant MSP4/5 
from different P. yoelii isolates (P. yoelii killicki 193L, P. yoelii nigeriensis N67) and P. 
berghei ANKA (Goschnick et al., 2004). However, there is a correlation between the protein 
similarity and the level of protection or the serum cross-reactivity. No serum reactivity was 
observed between P. chabaudi adami MSP4/5 to the mouse serum raised against other 
MSP4/5 in the above species, probably due to relatively low animo acid sequence similarities 
to P. berghei (56%) and P. yoelii (51%). Nonetheless, the efficacy of recombinant MSP4/5 in 
animal studies to confer protection is evident. This supports the potential of this protein for 
development of a human malaria vaccine.  
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1.6 Rationale of this project 
Traditional vaccines are often formulated from an attenuated organism for their efficacy to 
elicit sufficient humoral and cellular responses with a single dose. However the use of live 
organisms poses many risks associated with reversion to the virulent strain. A subunit vaccine 
or peptide vaccine is a safer alternative to attenuated vaccines, however its immunogenicity is 
relatively low.  
 
Nanoparticles and nanocapsules can stabilise vaccine antigens and ensure delivery to 
intracellular compartments to increase vaccine immunogenicity, therefore they are a 
promising antigen delivery system to increase the efficacy of subunit vaccines. Delivering 
antigens in particulate form offers several advantages over soluble antigens as they can 
provide protection from extracellular protease degradation and prolong their circulation in the 
system. Antigens can also be co-delivered in combination with adjuvants (i.e. PAMPs), which 
allow direct interaction of the antigens with immune cell surface receptors (i.e. TLRs). This 
facilitates more efficient cellular uptake by APCs, therefore inducing potent antigen-specific 
humoral and more importantly, cellular responses by promoting a higher level of 
cross-presentation (Shen et al., 1997; Sexton et al., 2009; Kaba et al., 2012; Hirosue et al., 
2010; Sneh-Edri et al., 2011; Yang & Hsu, 2008; Plebanski et al., 1998; Akagi et al., 2007). 
This is very important as targeting the cross-presentation pathway is the key to develop 
effective vaccines against tumors, intracellular parasites, intracellular bacteria and viruses 
(Rock et al., 1990; Moron et al., 2004).  
 
A variety of materials exist from which nanoparticles can be synthesised. Much research has 
been focused on the use of liposomes and polysomes which are biodegradable to alleviate the 
concerns of clearance from body. However, the preparation methods for these types of 
nanoparticles often introduce toxicity and causes variability for a large-scale manufacture. 
 
A templating method has also been demonstrated for the synthesis of polymer nanocapsules 
(Wang et al., 2008a), employing a simpler preparation method, which enables the fabrication 
of nanoparticles with increased homogeneity and stability. This approach utilises a highly 
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monodispersed solid silica core as the inner base (Stöber et al., 1968), and builds a highly 
robust mesoporous shell surrounding the core (Büchel et al., 1998). Infiltration of material 
into the mesoporous matrix of the SC/MS silica nanoparticles allows adsorption by 
electrostatic interaction, then chemical cross-linking for immobilisation, followed by the 
subsequent removal of the nanoparticles to form a hollow polymer nanocapsule (Yang & Hsu, 
2008; Goethals et al., 2013). This method produces the nanocapsules consisting of only a 
single component with a thick capsule wall due to the large specific surface area of SC/MS 
nanoparticle. This allows a larger capacity of molecules to be loaded per nanoparticle, in a 
single step. Most importantly, the fabrication of SC/MS nanoparticles is very simple, scalable 
and cost-effective (Tang et al., 2012), in addition, the properties of the MS are tailorable to fit 
the infiltrating molecule moiety (Goethals et al., 2013). The templating method allows the 
fabrication of nanocapsules to overcome some of the issues associated with other preparation 
techniques and therefore is attractive option to fabricate a safe and effective vaccine delivery 
platform.  
 
While the templating method has demonstrated its potential for a more efficient nanocapsule 
preparation method, there have been no reports of nanocapsules synthesised through the 
templating approach without the use of polymers as an antigen delivery system. Most of the 
polymeric materials possess strong positive charges; therefore toxicity is a concern. 
Therefore, it is the focus of this study to synthesise nanocapsules derived from antigen only, 
by employing SC/MS nanoparticles as a template. The feasibility of utilising this templating 
method without the use of polymers, the ability of nanoparticle for efficient cellular uptake, 
particularly by DCs, and the magnitude of cross-presentation will be assessed. Furthermore, a 
murine malaria protein, P. chabaudi adami MSP4/5 will be applied to this templating method, 
to evaluate the efficacy of antigen-based nanocapsules as a new antigen delivery system in a 
mice model. Thus, the proposed novel preparation method could be the new generation of 
vaccine delivery system to provide protection from the global prevalent diseases including 
AIDS, malaria, tuberculosis!and!hepatitis C. 
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2 CHAPTER 2 
 
Materials and suppliers 
 
This chapter lists the general materials and suppliers used throughout this project. 
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2.1  General procedures  
All the materials are listed below, with more specific details outlined in the appropriate 
chapter.  
 
Unless otherwise stated, all solutions were prepared with reverse osmosis double distilled 
water (MQH2O), obtained from the Millipore Milli-Q® water system (Millipore, USA) with 
the exception of media, where distilled water (dH2O) was used.  
 
Chemicals used were analytical or molecular grade and stored at ambient temperature unless 
otherwise stated. 
 
Sterilisation of all media and glassware by autoclaving was undertaken at 121ºC (15 lbf/in2) 
for 20 min. Samples were filter sterilised using the Acrodisc® 0.22 µm filters (Pall, USA). 
 
The Finnpipette® digital pipette range (Thermo Fisher Scientific, USA) and the Eppendorf 
Research® (Eppendorf, Germany) were used to dispense solutions. The range included  
0.5-10 µL, 5-50 µL, 20-200 µL, 100-1000 µL, 1-5 mL, 2-10 mL pipettes and 20-200 µL or 
50-300 µL multi-channel pipettes. Volumes above 10 mL were measured with a measuring 
cylinder. 
 
Volumes less than 1.5 mL underwent centrifugation with the Eppendorf microcentrifuge 
MiniSpin® Plus. Volumes of up to 50 mL requiring less than 5,445 × g underwent 
centrifugation in either the Beckman Allegra 21R centrifuge or the Heraeus Multifuge 1S-R 
centrifuge.  
 
Products less than 2 g were weighed on the Mettler Toledo XS105 Dual Range top loading 
analytical balance. Products greater than 2 g were weighed on an ISSCO model 300 top 
loading balance. 
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2.2 Laboratory instruments and suppliers 
1010 TEM JEOL, Japan 
5022F Fast DLS particle sizing spectrometer ALV, Germany 
A1 confocal laser scanning microscope Nikon, Japan 
AllegraTM 21R centrifuge Beckman Coulter, USA  
ASAP 2000 surface analyser Micromeritics, USA 
Biological safety cabinet class II, BH2000 series  Clyde-Apac, Australia  
BioPhotometer UV-visible spectrophotometer Eppendorf, Germany 
CanoScan LiDE 210 scanner Canon, Japan 
Canto II cytometer BD biosciences, Australia 
CO2 incubator Sanyo, Japan 
Countess® automated cell counter Life Technologies, USA 
Digital sonifier Branson Ultrasonic, USA 
Dry heating block Ratek, Australia 
EPS 3000xi power pack Bio-Rad Laboratories, USA  
GelDoc imaging system Bio-Rad Laboratories, USA 
Heraeus Multifuge 1S-R centrifuge Thermo Electron 
Corporation, USA 
iBlot dry gel transfer device Life Technologies, USA 
iMark microplate absorbance reader  Bio-Rad Laboratories, USA 
ISSCO model 300 bench top balance ISSCO, Australia 
IX51 inverted phase contrast microscope Olympus, Japan 
Milli-Q® water filtration system Millipore, USA 
Mini gel (Mini-sub cell GT cell) DNA electrophoresis unit Bio-Rad Laboratories, USA 
Mini-PROTEAN® tetra cell PAGE unit  Bio-Rad Laboratories, USA 
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MiniSpin® Plus microcentrifuge Eppendorf, Germany 
Nova NanoSEM FEI, USA 
Orbital shaker incubator Bioline, Australia 
pH meter Metrohm AG, Switzerland 
Platform mixer Ratek, Australia 
POLARstar Omega microplate reader BMG labtech, Germany 
PowerPac 300 power pack Bio-Rad Laboratories, USA  
PowerPac Basic power pack Bio-Rad Laboratories, USA  
Pulse controller and Gene Pulser™ apparatus  Bio-Rad Laboratories, USA 
SDS-PAGE Electrophoresis unit Bio-Rad Laboratories, USA 
Sonicator wash Soniclean, Australia 
Suspension mixer Ratek, Australia 
Titertek® ELISA shaker platform Flow Laboratories, USA 
Transilluminator (UV)  Novex, Australia 
Water bath Ratek, Australia 
XS105 Dual Range analytical balance  Mettler Toledo, Australia  
 
 
 
 
 
 
 
 
Chapter 2 
51 
2.3 Consumables and suppliers 
2.3.1 Plastic materials 
Acrodisk® filter, sterile (0.22 and 0.45 µm) Pall, USA 
Cell culture flask, filter cap (25 and 75 cm2) Greiner Bio-One, Germany  
Cell culture plate, sterile (6 well) Nunc, Denmark 
Cell culture plate, sterile (24 and 96 well) Greiner Bio-One, Germany  
Centrifuge tube, sterile (10 and 15 mL) Sarstedt, Germany  
Centrifuge tube, sterile (50 mL) Greiner Bio-One, Germany  
Countess® chamber slide Life Technologies, USA 
Cryovial, sterile (2 mL, star bottom) Iwaki, Japan 
Disposable reagent reservoir, sterile VitaLab, USA 
Flat bottom plate, non-sterile (96 well) Nunc, Denmark 
Microfuge tube, non-sterile (1.5 mL) Sarstedt, Germany  
Petri dishes Technoplast Interpath 
service, Australia 
Polypropylene gravity flow column (1 mL)  QIAGEN, Germany 
Polystyrene round bottom tube, 12 x 75 mm BD biosciences, Australia 
Stopcock, sterile BD biosciences, Australia 
Syringes (1, 3, 5, 10, 20, and 60 mL) Terumo, Japan 
UVette® (10 mm)  Eppendorf, Germany 
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2.3.2 Non-plastic materials 
200-mesh holey support films, copper grid ProSciTech, Australia 
Aluminium SEM stub ProSciTech, Australia 
Cell strainer (100 µm) BD biosciences, Australia 
Difiltration cup Sartorius-Stedim, Germany  
Electroporation cuvettes (0.1 cm)  Molecular Bio Products, 
USA  
Glass coverslip (22 x 22 mm) HD Scientific, Australia 
Glass slides (26 x 76 mm, 1 mm-1.2 mm thick) Sail brand, China 
Glass syringes (3 mL and 5 mL) Alltech, Australia 
iBlot transfer stacks (nitrocellulose) Life Technologies, USA 
Mini-PROTEAN® TGX™ precast gel Bio-Rad Laboratories, USA 
Needles (19 and 25 gauge) Terumo, Australia 
Vivaspin®20 (30,000 DaMWCO) Sartorius-Stedim, Germany  
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2.4 Chemicals, solutions and other products 
2.4.1 Chemicals and solutions 
(3-aminopropyl)triethoxysilane (APTES): >98% (Sigma-Aldrich, Germany). 
 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer: 5 mM (Gibco, 
USA), stored at 4°C. 
4’,6-diamidino-2-phenylindole (DAPI): 5 mg/mL stock (Cell Signaling, USA), stored at  
−20°C. 
Acqua instant stain: (Bulldog Bio Inc., USA), stored at 4°C. 
Agarose: 1% (w/v) agarose, DNA grade (Bioline, England). 
Ammonium fluoride: 8 M (Sigma-Aldrich, Germany). 
Ammonium hydroxide: 32% (Merck, Germany). 
Ampicillin (AMP): 100 mg/mL stock (CSL, Australia) in MQH2O and filter sterilised 
through a 0.22 µm filter. Aliquots stored at −20°C. Final working concentration of 100 µg/mL 
used. 
Bacteriological agar: (Oxoid, England). 
Bovine serum albumin fraction V (BSA): 1 mg/mL stock (Sigma-Aldrich, Germany) in 
MQH2O. Aliquots stored at −20°C.  
Bradford reagent: 100 mg Coomassie Brilliant Blue G-250 (Sigma-Aldrich, Germany) dye 
dissolved in 50 mL 95% (v/v) ethanol (Merck, Germany), then mixed with 100 mL 85% (v/v) 
phosphoric acid (Chem Supply, Australia), and brought up to 1 L with dH2O. Stored at 4°C 
and filtered through a 0.45 µm filter before use. 
Carboxyflurescein diacetate succininmidyl) CFSE: 5µM (Sigma-Aldrich, Germany), 
stored at −20°C. 
Chelating SepharoseTM Fast Flow: (GE Healthcare, Sweden), charged with 0.2 M nickel 
sulphate (NiSO4) (BDH, USA). 
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Chloramphenicol (CM): 34 mg/mL stock (Sigma-Aldrich) in 96% ethanol (Merck, 
Germany) and filter sterilised through a 0.22 µm filter. Aliquots stored at −20°C. Final 
working concentration of 34 µg/mL used. 
ClearPAGE Instant Blue Stain: (C.B.S. Scientific Company, USA), stored at 4°C. 
Complete Freund’s adjuvant: (Sigma-Aldrich, Germany) stored at 4°C. 
Concanavalin A (Con A): 2 µg/mL (Sigma-Aldrich, Germany), stored at −20°C. 
Coomassie Brilliant Blue G-250: (Sigma-Aldrich, Germany). 
DNA loading buffer (11x): 10% (w/v) ficoll®-400 (BDH, USA), 50% (v/v) glycerol (BDH, 
USA), 0.5% (w/v) Orange G (Sigma-Aldrich, Germany), 1% (w/v) SDS (Merck, Germany), 
10 mM EDTA (BDH, USA), 50 mM Tris-HCl (pH 8.0) (Merck, Germany). 
Dulbecco’s phosphate buffered saline (DPBS): (Gibco, USA) stored at 4°C. 
ELISA coating buffer: 4% of 84 g/L NaHCO3 (BDH, Germany) and 8% of 106 g/L Na2CO3 
(BDH, Germany) were mixed immediately before use. Stored at 4°C. 
Ethanol: 96% (v/v), (Merck, Germany). 
Ethidium bromide (EtBr): 6 mg EtBr (Sigma-Aldrich, Germany) in 2 L dH2O.  
Ethylenediamine tetra acetate (EDTA): 0.5 M EDTA (Merck, Germany). 
FACS staining buffer: 3% BSA in sterile PBS, made fresh. 
FACS wash buffer: Sterile PBS, 0.1% sodium azide (Sigma-Aldrich, Germany), with 10% 
FBS added through a 0.2 µm filter, stored at 4°C. 
Fetal bovine serum (FBS): heat-inactiated, Australian-certified (Gibco, USA), stored at  
−20°C. 
Glutaraldehyde (GA): Grade I, 5% (v/v) (Sigma-Aldrich, Germany), stored at 4°C. 
Glycerol: 50% (v/v) (BDH, USA), sterile. 
Histopaque-1077: (Sigma-Aldrich, Germany) stored at 4°C. 
Hydrochloric acid (HCl): 32% (Merck, Germany). 
Hydrofluoric acid (HF): 2M (Sigma-Aldrich, Germany). 
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IMAC binding buffer: 10-50 mM imidazole (Sigma-Aldrich, Germany), 0.5 M NaCl (BDH, 
USA), PBS (Oxoid, England)  
IMAC elution buffer: 100-120 mM imidazole (Sigma-Aldrich, Germany), 0.5 M NaCl 
(BDH, USA), PBS (Oxoid, England)  
IMAC stripping solution: 0.5 M NaCl (BDH, USA), 50 mM EDTA (Merck, Germany). 
IMAC wash buffer: 40-80 mM imidazole (Sigma-Aldrich, Germany), 0.5 M NaCl (BDH, 
USA), PBS (Oxoid, England)  
Imidazole: 2.5 M imidazole stock (Sigma-Aldrich, Germany), filtered through a 0.45 µm 
filter, stored at 4°C in a light-proof container. 
Iminodiacetic acid Sepharose®: (Sigma-Aldrich, Germany), charged with 0.2 M nickel 
sulphate (NiSO4) (BDH, USA). 
Incomplete Freund’s adjuvant: (Sigma-Aldrich, Germany) stored at 4°C. 
Interleukin 2 (IL-2): 20 IU/mL, mouse recombinant (Affymetrix eBioscience, USA), stored 
at -80°C. 
Isopropyl-β-D-thiogalactopyranoside (IPTG): 1 M (Progen, Australia) filtered through a 
0.22 µm filter, aliquots stored at −20°C. 
Lambda (λ) DNA: (Promega, USA), stored at −20°C. 
Molecular grade water (MGH2O): DNAse and RNase free (Gibco, USA). 
n-octadecyltrimethoxysilane (TMS): 91.6% (Sigma-Aldrich, Germany). 
Nickel sulfate (NiSO4): 0.2 M NiSO4 stock (BDH, USA), filtered through a 0.45 µm filter. 
p-Nitrophenyl phosphate (pNPP) substrate: (Sigma-Aldrich, Germany) stored at 4°C. 
Ovalbumin: 100 mg/mL albumin stock from chicken egg white, Grade V (Sigma-Aldrich, 
Germany) in MQH2O and filter sterilised through a 0.22 µm filter. The concentration was 
measured and adjusted using UV-vis spectrophotometer. Solution was either used 
immediately or aliquots were stored at −20°C. 
Paraformaldehyde (PFA): 4% stock (w/v) (Sigma-Aldrich, Germany), dissolved by heating 
at < 60°C in MQH2O. Filter sterilised through a 0.22 µm filter, stored at 4°C. 
PBS/Tween: PBS (Oxoid, England) with 0.05% (v/v) Tween 20® (Sigma-Aldrich, 
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Germany).  
Penicillin/Streptomycin: 100 µg/mL, 100 U/mL (Gibco, USA), stored at −20°C.  
Phosphate buffered saline (PBS): 1 tablet of Dulbecco’s A PBS (Oxoid, England) in 100 
mL MQH2O (sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen 
phosphate 0.115%, potassium dihydrogen phosphate 0.02%). pH 7.4 or adjusted to the desired 
level. 
Phosphoric acid: 85% (Chem-Supply, Australia). 
Phosphotungstic acid: 1% (w/v) (Sigma-Aldrich, Germany).  
Precision Plus ProteinTM Dual Colour standard: 10 µL per well (Bio-Rad Laboratories, 
USA), stored at −20°C. 
Precision Plus Protein™ Unstained standard: 10 µL per well (Bio-Rad Laboratories, 
USA), stored at −20°C. 
PrestoBlue® cell viability reagent: (Gibco, USA), stored at 4°C. 
ProLong® gold antifade reagent: 20 µL per slide for mounting (Life Technologies, USA), 
stored at −20°C. 
RPMI 1640 GlutaMAX™: (Gibco, USA), stored at 4°C. 
SDS loading buffer: (5x): 60 mM Tris-HCl (Merck, Germany), 25% (v/v) glycerol (BDH, 
USA), 2% (w/v) SDS (Merck, Germany), 1.4 mM β-mercaptoethanol (Bio-Rad Laboratories, 
USA), 0.1% (w/v) bromophenol blue (Sigma-Aldrich, Germany), stored at −20°C. 
SDS running buffer (10x): 3% (w/v) Tris-HCl (Merck, Germany), 14.2% (w/v) glycine 
(Amresco, USA), 1% (w/v) SDS (Merck, Germany). 
Skim milk: powder (Diploma, Australia). 
Sodium Chloride (NaCl): 0.15 M-0.5 M NaCl (BDH, USA). 
Sodium dodecyl sulphate (SDS): 10% (w/v) (Merck, Germany) 
Sodium Hydroxide (NaOH): 0.1-3 M NaOH (Merck, Germany). 
Tetraethoxysilane (TEOS): >99% (Sigma-Aldrich, Germany). 
Tetramethylbenzidine (TMB): (Life Technologies, USA), stored at 4°C. 
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Tris Buffered Saline (TBS): 25 mM Tris-HCl (pH 7.4) (Merck, Germany), 0.18 M NaCl 
(BDH, USA).  
Tris-Acetate-EDTA (TAE) electrophoresis buffer (1x): 40 mM Tris-HCl (pH 8.0) (Merck, 
Germany), 20 mM acetic acid (Merck, Germany), 2 mM EDTA (Merck, Germany). 
Triton X-100: 0.1% (v/v) (Sigma-Aldrich), in MQH2O. 
Trypan blue stain: 0.4% (Life Technologies, USA). 
Tryptone: (Oxoid, England). 
Tween 20: polyoxyethylene sorbitan monolaurate (Sigma-Aldrich, Germany). 
Western Blue® stabilized substrate for alkaline phosphatase: (Promega, USA). 
Yeast extract: (Oxoid, England).  
β-mercaptoethanol: electrophoresis purity (Bio-Rad Laboratories, USA).  
 
 
2.4.2 Bacterial culture media  
EnPresso™ Tablet cultivation set: The cultivation set (BioSilta, Finland) included 2 
EnBase® medium tablets (white bag), 1 booster tablet (black bag), EnzI'm (600 U/L) stored at 
4°C, AirOtop seal flask closures (BioSilta, Finland) per 50 mL media. Prepared in MQH2O. 
Luria-Bertani (LB) broth: 1% (w/v) tryptone (Oxoid, England), 0.5% (w/v) yeast extract 
(Oxoid, England), 1% (w/v) NaCl (BDH, USA). Prepared in MQH2O. 
Luria-Bertani (LB) agar: 1% (w/v) tryptone (Oxoid, England), 0.5% (w/v) yeast extract 
(Oxoid, England), 1% (w/v) NaCl (BDH, USA), 1% (w/v) bacteriological agar (Oxoid, 
England). Prepared in MQH2O. 
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2.4.3 Restriction endonucleases 
Restriction enzymes were used in the supplied buffer according to the manufacturer’s 
instructions and stored at −20°C.  
BglII New England Biolabs, USA 
NcoI-HF® New England Biolabs, USA 
PstI Promega, USA 
 
2.4.4 Commercial kits 
Materials included in the kits were stored according to the manufacturer’s guideline.  
Bioline ISOLATE plasmid Mini kit  Bioline, Australia 
Mouse Th1/Th2 ELISA Ready-SET-Go® kit  Affymetrix eBioscience, 
USA 
 
2.4.5 Antibodies 
Mouse anti-mouse OVA258-265 bound to H2Kb25-D1.16 
monoclonal 
Affymetrix eBioscience, 
USA 
DyLight 405-conjugated goat anti-mouse IgG monoclonal Affymetrix eBioscience, 
USA 
Mouse anti-6xHis monoclonal Abcam, England 
Alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG 
polyclonal 
Life Technologies, USA 
Horseradish peroxidase (HRP)-conjugated rat anti-mouse 
IgG1 monoclonal 
Life Technologies, USA 
Horseradish peroxidase (HRP)-conjugated rat anti-mouse 
IgG2a monoclonal 
Life Technologies, USA 
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3 CHAPTER 3 
 
Synthesis and characterisation of 
silica nanoparticle template and 
protein-based nanocapsules 
 
 
This chapter reports the fabrication and characterisation of SC/MS nanoparticle templates and 
the subsequently synthesised protein-based nanocapsules using a model protein.  
. 
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3.1  Introduction  
Dendritic cells (DCs) play a central role in initiating primary immune responses against 
infectious pathogens. They are the most potent antigen presenting cells (APCs) and efficient 
immune stimulators. Activation of CD4+ and CD8+ T cells can be induced by the processing 
and presentation of antigenic peptides by DCs, leading to the potentiation of humoral and 
cellular responses. An effective vaccine therefore must be able to efficiently engage with DCs 
to facilitate the induction of an immune response (Gamvrellis et al., 2004).  
 
Many particulate carrier systems have proven to be an effective antigen delivery vesicle, with 
increased levels of intracellular localisation and antigen presentation. Use of particulates in a 
delivery system can also induce higher immune responses. They are therefore promising 
candidates for a vaccine delivery system, which may be superior to the commonly used 
subunit vaccine technology.  
 
Particulate carrier systems are available in a wide variety of materials including synthetic 
polymers, synthetic polypeptides, polysaccharides, phospholipids and proteins which are 
synthesised through various techniques (reviewed in Chapter 1). The use of colloidal silica 
particles has been employed as a sacrificial template in some nanocapsule preparations. To 
date, there have been no reports on the preparation of nanocapsules derived from antigenic 
protein alone, synthesised through a templating system utilising solid core mesoporous shell 
(SC/MS) silica nanoparticles for vaccine delivery system. Such templates could serve as 
fundamental structures that would be universally applicable to produce vaccines with antigens 
of any proteins and polysaccharides.  
 
The template synthesis of protein-based nanocapsules is achievable in three simple steps; 
infiltration of a protein into the mesoporous shell (MS) of the particles, cross-linking 
infiltrated protein by covalent bonding, and then finally removing the silica nanoparticle 
template by acid treatment. Structures of polymer nanocapsules synthesised through this 
system were deformable, yet maintained high integrity. Flexibility in structure is an 
advantage, as the nanocapsules could possibly cross the endothelium fenestration if given by 
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intravenous injection, while rigid particles of the same diameter cannot (Romero et al., 1999). 
High integrity of the nanocapsule wall may assist in the escape from in vivo protease 
digestion, enabling delivery to APCs in a much higher amount than the soluble form. Another 
advantage of protein-based nanocapsules over polymeric nanoparticles is their susceptibility 
to intracellular degradation by lysosomal enzymes (Altintas et al., 2013).  
 
The templating system using SC/MS silica nanoparticles has been successful for polymer 
nanocapsule synthesis in drug carrier systems (Wang et al., 2008a; Goethals et al., 2013). 
However, there have been no attempts to test this system with proteins for vaccine delivery. 
Determining the suitability of the templating system to produce protein-based nanocapsules, 
and its capability of enhancing immune responses must be understood. Therefore, this chapter 
focuses on defining the structural and cellular characteristics of nanocapsules by using 
ovalbumin as a model protein. SC/MS silica nanoparticles were fabricated by previously 
established methods (Stöber et al., 1968; Büchel et al., 1998), and ovalbumin-based 
nanocapsules were subsequently synthesised using the templating method (Wang et al., 
2008a). The ovalbumin nanocapsules were studied for their structure, and the in vitro 
behaviour using murine immature DCs for their ability to localise intracellularly and induce 
antigen presentation.  
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The aim of the experiments outlined in this chapter were: 
 
• To fabricate the SC/MS silica nanoparticles for the subsequent synthesis of ovalbumin 
nanocapsules. 
• To observe the structural assembly under electron microscopy and by dynamic light 
scattering analysis. 
• To determine the specific properties of the mesoporous shell.  
• To evaluate the cytotoxic effect of ovalbumin nanocapsules. 
• To determine the efficiency of ovalbumin nanocapsules to engage with DCs and induce 
cellular uptake. 
• To determine the ability of ovalbumin nanocapsules to be processed and presented with 
MHC class I molecules on DCs by the cross-presentation pathway.  
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3.2 Materials and Methods 
3.2.1 Nano-material protocols 
This section details the methods used to fabricate the SC/MS templates and subsequent 
synthesis of the protein-based nanocapsules. 
 
3.2.1.1 Fabrication of SC/MS silica templates 
3.2.1.1.1 Preparation of solid silica particle (core) 
Based on a modified version of the Stöber method (Stöber et al., 1968), the solid silica 
spheres were prepared through the hydrolysis and condensation of tetraethoxysilane (TEOS) 
in appropriate amounts of ethanol, MQH2O and ammonia solution. More specifically, 37 mL 
of absolute ethanol, 5 mL of MQH2O and 4.2 mL of 32% ammonium hydroxide (w/w) were 
combined in an Erlenmeyer flask and stirred vigorously using a magnetic bar while heating at 
30°C. After the temperature of the solution stabilised, 2.8 mL of TEOS was added rapidly 
followed by immediate vortex for 5 sec to ensure the homogeneity of nanoparticles. The 
solution was then kept very still at room temperature while the reaction was allowed to 
proceed for 1 h. 
 
3.2.1.1.2 Fabrication of SC/MS silica nanoparticle (mesoporous outer shell) 
The SC/MS silica nanoparticles were prepared as reported by Büchel and co-workers (Büchel 
et al., 1998). These particles were synthesised by sol-gel coating of a MS on a preformed 
solid silica particle from Section 3.2.1.1.1. Solution containing a mixture of 2.35 mL of TEOS 
and 0.5 mL of 91.6% n-octadecyltrimethoxysilane (TMS) was slowly added to the solution 
containing solid silica particles, drop wise over a period of 20 min under stirring conditions. 
The solution was then incubated static for 1 h for the formation of MS, followed by 
centrifugation at 1,650 x g for 5 min to harvest the particles. The particles were washed three 
times with ethanol by centrifugation at 3,000 x g for 5 min. Following the washes, the 
particles were dried on a glass petri dish at 100°C overnight to completely remove ethanol. 
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The removal of the porogen TMS was performed through calcination of particles by heating 
to 550°C for 6 h. Calcinated SC/MS silica nanoparticles were kept dry in a polypropylene 
tube for storage. In this condition, the SC/MS silica nanoparticles could be kept indefinitely. 
 
3.2.1.2 Amine-functionalisation of SC/MS nanoparticle templates 
To allow the infiltration of negatively charged proteins, the surface of partially negatively 
charged SC/MS silica nanoparticles were converted to positive charge by the adsorption of 
amine groups. One hundred milligrams of SC/MS nanoparticles were resuspended in 10 mL 
of absolute ethanol, followed by the addition of 0.5 mL ammonium hydroxide and 2 mL 
(3-aminopropyl)triethoxysilane (APTES), in a 15 mL centrifuge tube. The functionalisation 
was allowed to process overnight at room temperature on a suspension mixer, for 
homogenous formation of amino groups on the particle surface. The amine-functionalised 
particles were harvested by centrifugation at 5,000 x g for 2 min, and washed in 10 mL 
absolute ethanol to remove the unreacted APTES. The nanoparticles were washed three times 
and resuspended in 10 mL absolute ethanol for longer storage. Once functionalised, particles 
could be kept indefinitely in this condition. The SC/MS nanoparticles were washed three 
times with PBS before application as a template for the synthesis of protein nanocapsule. 
 
3.2.1.3 Spectrophotometric quantification of ovalbumin  
The concentration of ovalbumin was determined using the UV-visible (UV-vis) 
spectrophotometer. Absorbance was measured at a wavelength of 280 nm and the 
concentration of the protein sample (mg/mL), was equal to the absorbance at 280 nm (with a 
path length of 1 cm). 
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3.2.1.4 Synthesis of ovalbumin nanocapsules using the SC/MS template 
The nanocapsules were synthesised using the SC/MS template based on the previously 
described method (Wang et al., 2008a), with minor alterations. Ten milligrams of 
PBS-washed SC/MS templates were added to the ovalbumin stock solution of up to 10 
mg/mL in PBS, followed by an overnight incubation on a suspension mixer at 4ºC. Excess 
protein was then removed by three cycles of centrifugation and washing with PBS at 5,000 x 
g for 2 min. To stabilise the infiltrated protein in the MS, particles were incubated in 1 mL of 
5% (w/v) glutaraldehyde (GA) solution or 1% (w/v) paraformaldehyde (PFA) solution for a 
minimum of 2 h at 4ºC on a suspension mixer, to form covalent links. Cross-linking agents 
were chosen depending on the application. GA was used in the characterization study where 
fluorescence emitted from GA cross-linking was required, negating the need of fluorescent 
tags. The SC/MS particles that cross-linked with PFA were protected from the light during the 
incubation. After washing with PBS three times, the SC/MS templates were removed by    
500 µL of 2 M hydrofluoric acid (HF) treatment in an 8 M ammonium fluoride buffer, pH 5 
to obtain the protein-based nanocapsules (Yu et al., 2005). Each infiltration reaction was 
performed in 1 mL to ensure the proper removal of silica by HF. HF treatment required 5 min 
incubation with occasional inversion of tube at room temperature, followed by three washes 
with sterilised PBS and centrifugation at 6,500 x g for 5 min. The synthesised nanocapsules 
were resuspended in 100 µL of sterilised PBS, followed by five cycles of 1 min sonication to 
separate aggregated nanocapsules. 
 
All washes were kept at 4°C and the concentration of excess ovalbumin was determined by 
UV-vis spectrophotometry (Section 3.2.1.3). The protein solution was briefly centrifuged to 
precipitate any remaining SC/MS nanoparticle templates for the concentration determination 
as silica could interfere with UV absorbance measurement.  
 
**HF is highly corrosive and toxic. The above work was performed only under the 
supervision of trained personnel in a HF filter fitted fume hood, with an adequate supply of 
calcium gluconate gel. 
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3.2.1.5 Optimisation of protein infiltration into SC/MS template 
To measure the amount of ovalbumin load within the MS of the SC/MS template, the 
concentration of ovalbumin was measured before and after the infiltration process. This was 
used to determine the percentage loading efficiency and capacity per gram of nanoparticles. 
Influence of the protein:template concentration ratio of 1:1, 1:2 and 1:10, and the solvent pH 
ranging 5.5, 7.4 and 8.5, were tested. In a single infiltration reaction, ovalbumin and the 
SC/MS templates were incubated overnight, in a total volume of 1 mL. The ovalbumin-loaded 
templates were washed three times with PBS, and then the concentration of ovalbumin in 
each wash was measured using the UV-vis spectrophotometer (Section 3.2.1.3). 
 
The percentage of protein infiltration loading efficiency (LE), and loading capacity (LC) per 
gram of nanoparticles was calculated using the equation below (Al-Qadi et al., 2012). 
Infiltration %LE was determine to measure the efficiency of protein loading in the MS of 
SC/MS template, while LC expressed the amount of protein loaded per gram of template. 
 
 
%LE =  (Total amount of protein) - (Free amount of protein)   X   100% 
                 (Total amount of protein) 
 
 
LC (mg of protein/g of template) = (Total amount of protein) - (Free amount of protein)    
                                    (Weight of nanoparticle) 
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3.2.1.6 Quantification of synthesised nanocapsules 
Concentration of synthesised nanocapsules was determined by the UV-vis spectrophotometry 
(Section 3.2.1.3). The concentration of PFA cross-linked ovalbumin nanocapsules was also 
estimated using SDS-PAGE.  
 
3.2.1.6.1 SDS-PAGE 
One-dimensional SDS-PAGE was performed using a discontinuous buffer system (Lane, 
1991). PFA cross-linked nanocapsules were mixed with SDS loading buffer and heated to 
100ºC in a dry heating block for 30 min. The proteins were separated using a Bio-Rad 
electrophoresis unit containing SDS running buffer, by electrophoresis at 150 V for 50 min or 
until the dye front reached the bottom of the gel. Mini-PROTEAN® TGX™ precast 4-15% 
gradient gels were used. The Precision Plus Protein™ Unstained standard was used for the 
determination of relative protein mass (Appendix 2). 
 
3.2.1.6.2 Instant stain  
Instant stain was used in place of Coomassie staining. ClearPAGE Instant Blue stain was used 
for staining the SDS-PAGE gel after electrophoresis. The SDS-PAGE gel was immersed in 
instant stain for up to 1 h until bands were appropriately resolved. Gels were rinsed in dH2O 
until the background cleared.  
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3.2.2 Protocols for structural characterisation of nano-materials 
This section details the methods used to characterise the physical properties of SC/MS 
templates and synthesised ovalbumin nanocapsules. 
 
3.2.2.1 Surface characterisation of SC/MS template by nitrogen adsorption 
measurement  
The specific surface area, pore diameter and pore volume of the SC/MS templates were 
measured using the Brunauer–Emmett–Teller (BET) method (Brunauer et al., 1938), on the 
Micromeritics ASAP 2000 surface analyser. Nitrogen gas was used for the adsorption step.  
 
3.2.2.2 Scanning Electron Microscopy (SEM) imaging of SC/MS 
nanoparticle templates 
The homogeneity and the diameter of dispersed SC/MS templates were examined by SEM. 
Approximately 50 µL of SC/MS templates suspended in 96% ethanol were placed directly 
onto an aluminium SEM stub and allowed to air-dry. The dried SEM stub was observed under 
the FEI Nova NanoSEM, operating at an accelerating voltage of 10-15 kV, with a spot size of 
3.5 nm and a working distance of 5-8.2 mm. The diameter of 100 nanoparticles was measured 
to determine the average size of particles from the representative electron micrograph images. 
The relative standard deviation was calculated using Microsoft Office Excel. 
 
3.2.2.3 Transmission Electron Microscopy (TEM) of SC/MS template and 
synthesised protein nanocapsules 
The thickness of the MS on SC/MS template and the size of synthesised protein nanocapsules 
were determined from TEM images. For TEM measurements, approximately 10 µL of 
nanoparticles were placed on top of a 200-mesh holey support film copper grid and allowed to 
air-dry. The excess moisture was removed by placing the copper grid on a tissue. The copper 
grid loaded with the protein nanocapsules was negatively stained with 1% phosphotungstic 
acid and air-dried before imaging. The dried copper grid was observed under the JEOL1010 
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TEM at an accelerating voltage of 100 kV. 
 
3.2.2.4 Particle size distribution of SC/MS template by Dynamic Light 
Scattering (DLS) 
To determine the size distribution of fabricated SC/MS template, a batch-mode DLS 
measurement was conducted in the ALV 5022F Fast DLS particle sizing spectrometer, at 
22ºC with a fixed angle of 90º on highly aqueous solutions. SC/MS templates were suspended 
in 96% ethanol.  
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3.2.3 Cellular and immunoassay protocols 
This section details the methods used to characterise the in vitro effects of synthesised 
ovalbumin nanocapsules. 
 
3.2.3.1 Cell line 
Murine immature DCs, DC2.4 were used for all in vitro assays and immunoassays. This cell 
line was kindly donated by Dr Dodie Pouniotis from the School of Medical Sciences, RMIT 
University, Australia.  
 
3.2.3.2 Culture condition 
DC2.4 cells were cultured in RPMI 1640 GlutaMAX™ media supplemented with 
GlutaMAX™ and 5 mM HEPES buffer with 10% heat inactivated foetal bovine serum added 
through a 0.22 µm filter. To avoid bacterial contamination, 100 U/mL of penicillin and    
100 µg/mL streptomycin were added to the media for the cellular assays; however the cell 
passage was maintained with no antibiotics. Cells were maintained at 37°C in a 5% CO2 
humidified atmosphere. Cells were passaged every 3 to 4 days and used for experimentation 
at 70-90% confluence.  
 
3.2.3.3 Peptide 
Synthesised ovalbumin-derived peptide OVA258-265 (or SIINFEKL) was purchased from 
Auspep, Australia. The lyophilised peptide was reconstituted in PBS and stored in aliquots at 
−80°C.  
 
3.2.3.4 Cell counting  
The number of cells were counted using a Countess® Automated Cell Counter. Ten 
microlitres of either neat or diluted cell sample was mixed with 10 µL of 0.4% Trypan Blue 
Dye in a sterile tube, and then 10 µL of mixture was transferred into a Countess® chamber 
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slide. All samples were processed and read within 2 min. The actual volume counted was  
0.4 µL, the same as counting four (1 mm x 1 mm) squares in a standard haemocytometer.  
 
3.2.3.5 Evaluation of the cytotoxicity of ovalbumin nanocapsules 
The cytotoxicity of GA cross-linked ovalbumin nanocapsules was analysed at different 
concentrations using PrestoBlue® Cell Viability reagent. DC2.4 cells were seeded in a 96 
well tissue culture plate at a density of 5 x 104 cells per well, in RPMI 1640 GlutaMAX™ 
medium supplemented with 10% heat inactivated FBS and incubated at 37°C in a 5% CO2 
humidified atmosphere, overnight. Following incubation, ovalbumin nanocapsules suspended 
in 20 µL of sterile PBS were added to a final concentrations of 3.125, 6.25, 12.5, 25 and    
50 µg/mL in 120 µL per well. Replicate plates for different time points were made and were 
further incubated for up to 72 h with the nanocapsules in the same condition. At each time 
point, 12 µL of PrestoBlue® Cell Viability reagent was added to each well and the 
absorbance read at 570 nm with 600 nm reference wavelength for normalisation after 60 min 
incubation at 37°C in the dark. Absorbance readings were measured using the POLARstar 
Omega microplate reader. 
 
Culture media and 0.1% Triton X-100 served as an internal negative and positive control, 
respectively. Percentage cell viability was calculated by setting the negative control to 100% 
after non-live cell dependent colour conversion (background and positive control), was 
eliminated from all treatment groups.  
 
Statistical variables (mean, standard deviation, and standard error), were calculated for all 
data and presented graphically. Comparisons between groups were accessed by two-way 
ANOVA followed by a Dunnett’s multiple comparison test to determined significant 
differences in cell viabilities against the negative control (media alone) group. GraphPad 
Prism 6 software was used to perform the statistical analysis.  
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3.2.3.6 Cellular uptake of ovalbumin nanocapsules by DCs 
To determine the cellular uptake of synthesised nanocapsules over time, DC2.4 cells were 
seeded onto 25 mm glass coverslips placed in a 6 well tissue culture plate at a density of 2 x 
105 cells per well, and incubated at 37°C in a 5% CO2 humidified atmosphere for 24 h. 
Approximately 30-50 µg of GA cross-linked ovalbumin nanocapsules were added to each 
well, suspended in RPMI 1640 GlutaMAX™ medium with 10% heat inactivated FBS and 
incubated at 37°C for up to 90 min to allow cellular uptake of the nanocapsules. A replicate 
plate was made and incubated at 4°C to serve as a negative control with no cellular uptake, 
but inducing only cell surface attachment. Following incubation, the unbound nanocapsules 
from both plates were removed by gentle washing with cold PBS three times. Cells were then 
fixed onto the coverslips by adding 4% PFA for 15-20 min at room temperature followed   
by three washes with PBS. The cellular nucleus was counter-stained with 
4',6-diamidino-2-phenylindole (DAPI) (1:2000), at room temperature for 5 min, followed by 
three washes with PBS. The coverslips were carefully mounted and sealed onto a glass slide 
with gold antifade reagent. The ovalbumin nanocapsules were highly autofluorescent due to 
GA cross-linking, thus no fluorescent labelling was required. The confocal microscopic 
images of the cells were obtained using a Nikon A1 confocal laser scanning microscope 
(CLSM).  
 
3.2.3.7 Antigen presentation assay  
Presentation of ovalbumin-derived peptide OVA(258-265) (or commonly known as SIINFEKL) 
by MHC class I molecule (Kb), by APCs was measured by an immunoassay. 
 
DC2.4 cells were seeded in a 24 well tissue culture plate at a density of 1 x 106 cells per well, 
in RPMI 1640 GlutaMAX™ medium supplemented with 10% heat inactivated FBS and 
incubated at 37°C in a 5% CO2 humidified atmosphere overnight. Following incubation, 
either PFA cross-linked ovalbumin nanocapsules or soluble ovalbumin suspended in media, 
was added to the test wells to a final concentration of approximately 50 µg/mL in 1 mL per 
well. Internal controls were set up as listed in Table 3.1. Cells treated as the SIINFEKL 
control were pulsed with 40 µM SIINFEKL peptide for 2 h. All other cells were incubated for 
6 h with soluble or capsulated ovalbumin, to allow the uptake and presentation of the proteins. 
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Table 3.1: List of conditions and internal control settings.  
 
Condition Primary 
antibody 
staining 
Secondary 
antibody 
staining 
Description 
Unstained  ✗ ✗ No antibody labelling 
Unstimulated ✓ ✓ Unstimulated control 
SIINFEKL positive control ✓ ✓ Positive control 
SIINFEKL negative control ✗ ✓ Secondary antibody control  
Ovalbumin ✓ ✓ Ovalbumin test 
Ovalbumin nanocapsule ✓ ✓ Nanocapsule test 
Ovalbumin nanocapsule control ✗ ✗ Autofluorescence control 
*✓ = YES,  ✗ = NO.  
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Following incubation, cells were harvested and excess protein was removed by washing three 
times with ice-chilled FACS wash buffer, with centrifugation at 400 x g for 5 min at 4°C. The 
cells were then resuspended in 100 µL FACS staining buffer for surface immunostaining. 
First, SIINFEKL in context with the MHC class I was detected with the 25-D1.16 monoclonal 
antibody (mouse anti-mouse OVA(258-265) bound to H2Kb) (1:200), followed by 1 h incubation 
at 4°C. After the incubation, stained cells were washed three times with chilled FACS wash 
buffer, and labelled with DyLight 405-conjugated goat anti-mouse IgG (1:200), in 100 µL 
FACS staining buffer for 1 h at 4°C in the dark. Following incubation, cells were washed 
three times with chilled FACS wash buffer and fixed in 1% PFA until analysis by a FACS 
Canto II cytometer. 
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3.3 Results 
3.3.1 Structural characterisation of fabricated SC/MS silica 
nanoparticle templates 
3.3.1.1 Surface characterisation of SC/MS template by nitrogen adsorption 
measurement  
SC silica nanoparticles were prepared through the hydrolysis and condensation of TEOS in a 
mixture of ethanol, ammonia and water. Subsequently, a mesoporous silica shell was built 
upon the SC by sol-gel coating of TEOS and TMS. Three batches of fabricated SC/MS 
nanoparticles were analysed for their specific surface area, pore size and pore volume in their 
MS.  
 
Nitrogen adsorption analysis indicated that the SC/MS nanoparticles had a average surface 
area of 209.5 m2/g and an average pore size of 3.22 nm in diameter, with an average pore 
volume of 0.17 mL/g. The nanoparticles with the largest surface area of 219.7 m2/g, and a 
pore size and volume of 3.07 nm and 0.17 mL/g, respectively, were chosen for the subsequent 
ovalbumin-based (Section 3.2.1.4), and malarial protein-based (Section 4.2.2.3) nanocapsule 
synthesis.  
 
3.3.1.2 Determination of particle size and distribution by SEM and DLS  
SEM was used to observe the morphology and measure the size of the fabricated SC/MS 
nanoparticle template. Fifty microlitres of the nanoparticles were placed on an aluminium 
SEM stub and air-dried. Aggregates of dried nanoparticles were observed under low 
magnification (3147 x), as shown in Figure 3.1A. This was possibly due to the electro-static 
interactions occurring between the silica particles, as this was also seen when dried on a glass 
petri dish during the fabrication process. However, it was not clearly determined under SEM 
observations whether these particles were in fact aggregated or fused together.  
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Figure 3.1: Observation of the SC/MS silica nanoparticles under SEM.  
Magnification of A) 3147 x, B) 42,216 x, and C) 103,685 x with the scale bars shown at the 
bottom at the length of 50, 3 and 1 µm, respectively. The red arrow indicates the diameter 
(di). 
 
di#
A#
B#
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At higher magnification, it was revealed that the fabricated SC/MS nanoparticles were 
spherical and homogeneous in structure (Figure 3.1B and C), with an average diameter of 516 
± 20 nm. The diameter of 100 nanoparticles was measured from the representative electron 
micrograph in the SEM imaging program (Figure 3.1C), however, it was difficult to observe 
the edge of MS, therefore more precise measurements were performed. 
 
DLS was used to measure the size and distribution of nanoparticles for better precision. DLS 
measurement determined the size of particles by detecting the random changes in the intensity 
of light scattered by the particles in a solution. The even peaks shown in Figure 3.2A indicate 
that the SC/MS nanoparticles were fabricated with no aggregation, and an average diameter of 
410 nm (shown in radius in Figure 3.2B). Although some particles of larger size were 
detected, they were found to be relatively low in polydispersity.  
 
3.3.1.3 Observation of MS by TEM  
The detail of the MS was observed under TEM. As the transmitted electrons allowed the 
visualisation of the MS, it was able to distinguish it from the solid silica core (SC). The SC 
appeared to be a round object of high density, surrounded by an even coating of porous 
formations. The overlap of nanoparticles indicated that the aggregation observed in SEM 
analysis was in fact due to the electro-static interaction caused by the dried particles, rather 
than agglomeration of fused particles (Figure 3.3A). The thickness of the MS was recorded by 
measuring the distance from the edge to the SC of the particle (as indicated in Figure 3.3B). 
The average thickness was determined to be 62.5 nm.  
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A)  
 
B)  
 
 
Figure 3.2: Particle size and distribution measurement by DLS. A) The graph indicates 
minimal aggregation of SC/MS silica nanoparticles, and in B) the size distribution.  
 
 
  
Chapter 3 
79 
 
 
 
 
 
Figure 3.3: Observation of the SC/MS silica nanoparticles under TEM. A magnification 
of A) 12,000 x, and, B) 75,000 x, with the scale bars shown at the bottom of lengths of 500 
nm and 100 nm, respectively. The red arrow indicates the regions measured to determine the 
thickness of MS.  
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A#
100#nm#
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3.3.2 Synthesis of ovalbumin nanocapsules using the SC/MS 
template 
3.3.2.1 Optimisation of protein infiltration into the SC/MS template 
The SC/MS silica nanoparticle underwent functionalisation of the particle surface with amine 
groups, in order to gain the positive charge to allow the negatively charged protein to 
infiltrate. Albumin from chicken egg white (ovalbumin), was employed as the model protein 
to synthesise the protein-based nanocapsules. The infiltration load of protein in the MS was 
optimised by measuring the effect of different conditions such as the protein:template ratio 
and pH of the solvent where the infiltration reaction occur.   
 
In the first optimisation experiment, the influence of the protein:template concentration ratio 
was tested. In a single infiltration reaction, 10 mg of the SC/MS nanoparticles were used as a 
template. An ovalbumin concentration of 10 mg, 5 mg and 1 mg were incubated with 
nanoparticles to give a protein:template concentration ratio of 1:1, 1:2 and 1:10, respectively. 
This was performed to determine the optimal concentration of ovalbumin required for 
subsequent nanocapsule synthesis, with minimal adverse effects, which may be caused by the 
saturation of protein. The efficiency of protein loading was found to be the highest when the 
amount of template was double that of the protein (1:2). This method achieved a loading 
efficiency of 6.23%, while 1:1 and 1:10 ratios had an efficiency of 3-4%. While the 
differences in the loading efficiency between the 1:1 and 1:10 ratio was much lower, there 
was a 10-fold increase in the amount of protein loaded per gram of template in the 1:1 ratio, 
compared to the ratio of 1:10 (Table 3.2). This showed that the loading efficiency may not 
necessary translate to the actual amount of ovalbumin loaded into the template. The loading 
capacity was proportional to the amount of ovalbumin used for infiltrating reaction; therefore 
an increase in the amount of synthesised nanocapsule was also expected at higher 
concentration of protein. The results also suggested the there was no adverse effects in the 
rate of infiltration by applying high concentrations of protein to the SC/MS template.  
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Table 3.2: The influence of protein:template ratio on the infiltration %LE and LC. 
 
Protein (mg):Template (mg) %LE LC (mg of protein/g of template) 
10 : 10 (1:1 ratio) 3.99 38.7 
5 : 10 (1:2 ratio) 6.23 15.05 
1 : 10 (1:10 ratio) 3 0.36 
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In the second optimisation experiment, the influence of solvent pH was studied. The optimal 
pH was determined at which the greatest electro-static attractions could form between the 
negatively charged ovalbumin, to the positively charged SC/MS templates. This attraction 
could improve when the isoelectric point (pI) of the infiltrating protein was lower than the pH 
of the buffer used for the reaction. The PBS used to prepare the ovalbumin stock, and in all 
wash steps was originally adjusted to pH 7.4. This was the pH commonly used to maintain 
proteins, however, PBS of pH 5.5 and 8.5 was also introduced to determine the effect on 
ovalbumin infiltration load at different pH. In a single infiltration reaction, 10 mg of the 
SC/MS nanoparticles were used as templates. The ovalbumin concentration of 10 mg was 
chosen for this optimisation study, as this concentration was determined to have the best 
infiltration loading capacity (described in Table 3.2). The effect of pH was quite clear. At pH 
5.5, ovalbumin did not show any capacity to infiltrate the template, while both the loading 
efficiency and capacity significantly increased as the pH increased (Table 3.3). An increase 
was also seen from pH 7.4 to 8.5. As the theoretical pI of ovalbumin was 4.6, this result 
confirmed that the higher pH could promote the infiltration of protein with a low pI. By 
observing the results from these optimisation studies, it was decided that subsequent synthesis 
of ovalbumin nanocapsules were to be carried out with 10 mg of ovalbumin to infiltrate  
10 mg of template, in PBS at pH 8.5.  
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Table 3.3: The influence of solvent pH on the infiltration %LE and LC. 
 
pH %LE LC (mg of protein/g of template) 
5.5 0 0 
7.4 4.28 42.8 
8.5 6.52 65.2 
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3.3.2.2 Quantification of synthesised nanocapsules 
Ovalbumin nanocapsules were synthesised by cross-linking the infiltrated ovalbumin with 
either 5% (w/w) GA, or 1% (w/v) PFA. The cross-linking agent was chosen based on their 
application in the subsequent in vitro analysis. The GA cross-linked nanocapsules possessed 
autofluorescence due the formation of Schiff bases between aldehyde groups from the 
cross-linking reaction (Collins & Goldsmith, 1981; Lee et al., 2013). This autofluorescence 
caused by GA cross-linking was known to excite maximally at 540 nm, giving highest 
emission peak at 560 nm (Collins & Goldsmith, 1981). Therefore, GA cross-linking was used 
in instances where the autofluorescence could aid in microscopic visualisation, negating the 
need to add a fluorescent tag to the nanocapsules. The PFA cross-linked nanocapsules also 
emitted fluorescence, but at much lower level. The PFA cross-linked nanocapsules were used 
for the in vitro study where fluorescent tags were used for minimal interference.  
 
The synthesised nanocapsules were initially quantified by the UV-vis spectrophotometry, 
however it was difficult to obtain an accurate concentration for GA cross-linked nanocapsules 
due to the autofluorescence. The concentration could not be estimated based on the infiltration 
load, despite extensive washes given after HF treatment. Loss of some synthesised 
nanocapsules was observed during this process. Finally, attempts were made to quantify the 
concentration of the GA cross-linked nanocapsules, based on the concentration obtained for 
the PFA cross-linked nanocapsules.  
 
A single reaction using the same amount of ovalbumin, was used to synthesise both types of 
nanocapsules, therefore the final nanocapsule concentration was predicted to be very similar 
for both methods. The concentration of the PFA cross-linked nanocapsules was first measured 
by the UV-vis spectrophotometer, and 1 µg of nanocapsule was subjected to SDS-PAGE for 
concentration estimation. Formalin cross-links made by PFA was reversible by a previously 
reported method (Klockenbusch & Kast, 2010), with modification to boiling the nanocapsules 
at 99°C for 30 min in SDS-PAGE sample buffer and successfully entered the SDS-PAGE gel 
(Figure 3.4, lane 4). However, the GA cross-linked nanocapsules did not enter the gel (Figure 
3.4, lane 3). Smearing was seen in the lane where the PFA cross-linked nanocapsules had 
migrated. This was probably due to some residual cross-linking remaining after the treatment. 
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Figure 3.4: Protein estimation of the cross-linked ovalbumin nanocapsules, visualised on 
an instant stained SDS-PAGE gel. Lane 1: protein molecular marker, Lane 2: soluble 
ovalbumin, Lane 3: GA cross-linked ovalbumin capsule, and Lane 4: PFA cross-linked 
ovalbumin nanocapsules. An estimate of 1 µg was run in lane 2-4.  
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One microgram of soluble ovalbumin was also run to make a comparison (Figure 3.4, lane 2).  
 
Both soluble ovalbumin and the PFA cross-linked nanocapsules appeared to be present in the 
same amount, therefore the concentration determined by the UV-vis spectrophotometry for 
the PFA cross-linked nanocapsules was applied to the GA cross-linked nanocapsules.  
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3.3.2.3 Observation of synthesised protein-based nanocapsules by TEM 
Successfully synthesised ovalbumin nanocapsules were observed under TEM for their 
morphology. TEM analysis revealed that the individual nanocapsules were approximately  
500 nm in diameter (Figure 3.5A). Part of the nanocapsules was creased and slight 
invaginations were visible (Figure 3.5B and C). Aggregation was also observed (Figure 3.5B), 
probably due to the drying process. It was difficult to measure the thickness of the 
nanocapsule wall, but it appeared that it had some level of rigidity in the structure.  
 
When nanocapsules were synthesised using protein of a different molecular weight, the 
structural morphology changed from that of the ovalbumin nanocapsules. A 14 kDa 
recombinant viral protein, C27, was expressed in pET45b vector with 6xHis tag in E. coli 
BL21(DE3)pLysS in a separate study (Van, T., Personal communication, 2010), and was used 
to synthesise nanocapsules using the SC/MS templates. C27 forms a hinge region of the 
haemagglutinin protein from influenza virus H1N1 (A/PC/8/34). Purified C27 maintained in 
PBS was applied to SC/MS template at pH 7.4 for the infiltration study. A C27-based 
nanocapsule exhibited a distinctively thicker wall, which may provide higher integrity to the 
structure (Figure 3.6B), as compared to the collapsed ovalbumin nanocapsule (Figure 3.6A). 
A greater amount of protein was required to synthesise and produce the same amount of 
nanocapsules, yet much lower infiltration efficiency was recorded (data not shown). The 
theoretical pI of C27 is 6.81, therefore the infiltration of C27 performed in PBS at pH 7.4 was 
probably deterred by having a low electro-static attraction to the SC/MS templates.  
  
 
  
Chapter 3 
88 
 
 
 
 
 
 
 
 
Figure 3.5: Observation of negatively stained ovalbumin nanocapsules under TEM.  
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Figure 3.6: Observation of negatively stained A) ovalbumin-based, and B) C27-based 
nanocapsules under TEM.  
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3.3.3 In vitro characterisation of synthesised ovalbumin 
nanocapsules 
3.3.3.1 Cytotoxicity of ovalbumin nanocapsules  
The cytotoxic effect of the ovalbumin nanocapsules was evaluated using DC2.4 cells. 
Different concentrations of ovalbumin nanocapsules were applied to 5 x 104 cells and exposed 
for up to 72 h. Cell viability of 100% was represented by cells which were incubated with 
culture medium alone, and complete cell death was achieved by 0.1% Triton X-100. The 
relationship between the nanocapsule concentration (µg/mL) and cell viability (% of control) 
of up to 72 h of exposure time is presented in Figure 3.7A. The same conditions were applied 
to cells incubated with the soluble ovalbumin solution which was the precursor ovalbumin 
solution of synthesise nanocapsules, and the results are shown in Figure 3.7B. Each 
experimental curve represents the mean of three experiments.  
 
The cell viability of cells treated with soluble ovalbumin was maintained above 100% for up 
to 72 h, and the differences in ovalbumin concentration did not change the level of viability. 
The cells treated with ovalbumin nanocapsule, however, showed a decrease in cell viability at 
all times points as nanocapsule concentration increased. The effect of the nanocapsules on cell 
viability became apparent at 25 µg/mL, with viability reduced to 73% when treated with      
50 µg/mL nanocapsules for 24 h. A discrepancy in cell viability was observed as the cells 
treated with 25 µg/mL of ovalbumin nanocapsules for 48 h displayed higher toxicity than the 
cells treated for 72 h. When cells were treated with 50 µg/mL, cell viability was significantly 
lowered to 55% at both 24 h and 72 h time points (p≤0.05) (Figure 3.8), indicating that the 
toxicity of the ovalbumin nanocapsule was dose dependent.  
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A)  
 
 
   B)  
 
Figure 3.7: Cell viability curve of DC2.4 cells against protein concentration of A) 
ovalbumin nanocapsules, and B) soluble ovalbumin over 72 h.  
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Figure 3.8: Cell viability of DC2.4 cells over different time points against different 
concentration of ovalbumin materials. (Statistical significance against 100% viable control 
group is represented in asterisk. ✻ is p≤0.05) 
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3.3.3.2 In vitro uptake of ovalbumin nanocapsules by DCs 
GA was used to cross-link ovalbumin in this study in order to utilise the autofluorescence in 
the cellular imaging using CLSM, without the need to label the nanocapsules with a 
fluorescent tag. DC2.4 murine DCs were incubated with the GA cross-linked nanocapsules 
for up to 90 min, at 4°C or 37°C.  
 
The in vitro uptake of ovalbumin nanocapsules was observed at various time points, and the 
images were taken at three different wavelengths. The fluorescence of the GA cross-linked 
nanocapsules enabled observation in red at 561 nm, while the nuclei were counterstained with 
DAPI and seen in blue at 405 nm. Transmitted light channel (TD) was recorded to capture the 
entire cell morphology merged with the fluorescent signals.  
 
The in vitro uptake of ovalbumin nanocapsules was successfully demonstrated, as shown in 
Figure 3.9. There was no indication of immediate nanocapsule uptake at 0 min and 5 min, 
however it became apparent after 15 min of incubation. The level of internalised ovalbumin 
nanocapsules significantly increased at 30 min, and was maintained for up to 90 min. Most of 
the cells exhibited a large number of internalised ovalbumin nanocapsules by 60 min, 
indicated by the red fluorescence displayed adjacent to the blue-stained nuclei.  
 
A negative control was set up to confirm the internalisation of the ovalbumin nanocapsules, as 
the 2D images could not differentiate from the membrane-adhered nanocapsules, which may 
be viewed as overlaid in the image. As expected, incubation at 4°C did not promote the 
uptake of nanocapsules, but allowed surface attachment of the ovalbumin nanocapsules 
(Figure 3.10). This was clearly indicated by the differences seen in the location of the 
ovalbumin nanocapsules at 90 min (Figure 3.11). When incubated at 37°C, ovalbumin 
nanocapsules localised adjacent to the nucleus, while those incubated at 4°C were located 
nonadjacent/away from to the nucleus and outside the cell surface. The fluorescent images 
captured could only show the distance of the ovalbumin nanocapsules from the nucleus, 
however, the merged TD images showed that these nanocapsules were in fact adhered to the 
membrane, and not internalised.  
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Figure 3.9: Cellular uptake of ovalbumin nanocapsules (red) in DCs over 90 min incubation at 37°C. The top row represents the TD image 
merged with fluorescent signals, the second row indicates the DAPI-stained nucleus in blue, the third row indicates the fluorescing ovalbumin 
nanocapsules in red, and the bottom row represents the merged fluorescent images of nucleus and ovalbumin nanocapsules 
Chapter 3 
95 
TD#
DAPI'nucleus#
OVA'NC#
Merge#
4°C$
0# 5# 15# 60#30# 90#
(min)#
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
Figure 3.10: Surface attachment of ovalbumin nanocapsules (red) in DCs over 90 min incubation at 4°C. The top row represents the TD image 
merged with fluorescent signals, the second row indicates the DAPI-stained nucleus in blue, the third row indicates the fluorescing ovalbumin 
nanocapsules in red, and the bottom row represents the merged fluorescent images of nucleus and ovalbumin nanocapsules. 
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A)          B)  
Figure 3.11: Ovalbumin nanocapsule (red) uptake at 37°C, and surface attachment at 4°C. Ovalbumin nanocapsules are located adjacent to the 
nucleus (blue) at 37°C indicating internalisation, while bound to the cell surface at 4°C. Images showing A) multiple cells, and B) single cells at higher 
magnification.  
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These observations confirmed that the ovalbumin nanocapsules of 500 nm, synthesised by the 
templating system could be endocytosed by APCs, such as the DCs used in this study. 
 
Single cell imaging indicated a more precise localisation of internalised ovalbumin 
nanocapsules (Figure 3.12). The ovalbumin nanocapsules were transported and located 
adjacent to the nucleus in the cytoplasm, however the exact pathway of how the nanocapsules 
were internalised and transported to this location could not be determined from this image. An 
attempt was made to label the lysosomal compartment, as it was the presumed intracellular 
destination of the nanocapsules. However, a large amount of autofluorescence was emitted 
from the GA cross-linked ovalbumin nanocapsule at the same wavelength where the lysosome 
staining was visualised. As the fluorescent signal from ovalbumin nanocapsules was detected 
over a wide range of wavelengths, this limited the number of fluorescent labels that could be 
used for staining the lysosomal compartment. For this reason, determining the co-localisation 
of ovalbumin nanocapsules within the intracellular compartment was not possible in this 
study.  
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Figure 3.12: Single cell image of a DC with ovalbumin nanocapsules. The internalised 
ovalbumin nanocapsules are visualized in red. 
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3.3.3.3 Ovalbumin processing and presentation by DCs  
To test for antigen presentation, DC2.4 cells were incubated with the ovalbumin nanocapsules 
for 6 h for cellular uptake and antigen processing. Ovalbumin nanocapsules were used at a 
concentration of 50 µg/mL, to achieve a measurable presentation level from DC2.4 cells with 
minimal toxicity (as determined in Section 3.3.3.1).  
 
The level of cross-presentation of ovalbumin was measured by detecting the amount of 
presented ovalbumin-derived peptide. An ovalbumin-derived peptide OVA(258-265), commonly 
known as SIINFEKL, in association with an MHC class I molecule (Kb) produced by DC2.4 
was detected with the 25-D1.16 monoclonal antibody (Porgador et al., 1997). Several internal 
controls were deployed, to eliminate the influence of non-specific binding of detection 
antibodies, along with the autofluorescence of nanocapsules.  
 
Firstly, a population of DC2.4 with forward scatter ranging from 50,000 to 250,000 was gated 
(Figure 3.13A). Secondly, cells pulsed with SIINFEKL peptides, but not labelled with the 
25-D1.16 antibody, were used as the baseline to compare the levels from test groups. A shift 
in the fluorescence intensity of samples incubated with soluble and nanocapsule ovalbumin 
was used to evaluate the relative percentage of cross-presented peptide.  
 
The cells treated with the positive control SIINFEKL peptide displayed the highest levels 
SIINFEKL/Kb complex at 94.11%, as the peptides were directly bound to the Kb molecule 
expressed on the surface of DC2.4 (Figure 3.13D). SIINFEKL from soluble ovalbumin could 
be presented at low levels by cross-presentation (3.23%, Figure 3.13C), however the level 
significantly increased for ovalbumin nanocapsules (15.61%, Figure 3.13B) (p≤0.0001%). 
Two small populations of DC2.4 presenting SIINFEKL from ovalbumin nanocapsules were 
also found, as indicated by their stronger fluorescence intensity. This indicated that these cells 
were expressing higher levels of MHC class I molecules with SIINFEKL presentation. The 
increased level of cross-presentation in these populations may be due to the inconsistent 
loading of ovalbumin per cell. This may have happened by internalising different numbers of 
nanocapsules, or internalising larger nanocapsules thus higher amount of infiltrated 
ovalbumin in such capsules, resulting in the higher ovalbumin load.   
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Figure 3.13: Cross-presentation by DC2.4 cells. A) DC2.4 population was gated as shown.  
The level of SIINFEKL in context with Kb molecule was measured from the cells incubated 
with B) ovalbumin nanocapsules, C) soluble ovalbumin, and D) SIINFEKL. The negative 
control is represented by the red open histogram, while the blue shaded histogram represents 
the samples. The Y-axis indicates 100% of the total cell number within each group, achieved 
by normalising to the peak height at the mode of distribution. The X-axis is the level of 
relative fluorescence intensity.  
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3.4 Discussion 
3.4.1 Structural characterisation  
3.4.1.1 Examination of SC/MS silica nanoparticle template 
The SC/MS silica nanoparticles were fabricated and SEM analysis revealed that they were 
homogeneous and spherical in structure. These particles had a MS thickness of 62.5 nm, and 
the detail of the porous structure was evident from TEM images. The average diameter was 
measured by counting 100 particles from the representative SEM micrograph, and was found 
to be 516 ± 20 nm. A more accurate measurement using DLS revealed a diameter of 410 nm. 
The use of DLS has been widely employed for measuring the size of colloidal silica 
nanoparticles (Feifel & Lisdat, 2011; Karpo et al., 2009), and mesoporous silica nanoparticles 
(Tang et al., 2012; Chen et al., 2009).  
 
DLS analysis provides a more precise measurement by calculating the hydrodynamic radius 
on an ensemble average of the particles with the same diffusion coefficient, in a solution with 
specific viscosity (Berne & Pecora, 2000). Although the image magnification may be directly 
proportional to the scanning length in SEM, DLS analysis measures on a statistically larger 
number of particles, thus providing better accuracy. A diameter of 420 nm was actually 
observed when the SC/MS silica nanoparticles were fabricated using the same method with a 
similar MS thickness of 60-75 nm (Wang et al., 2008a; Büchel et al., 1998). Therefore, the 
size measurement obtained by DLS analysis was probably more true to the actual size, despite 
the difference between two measurements being larger than 100 nm. 
 
Nitrogen adsorption data indicated that the SC/MS nanoparticles used for the subsequent 
synthesis of protein-based nanocapsules had a surface area of 219.7 m2/g, and a pore diameter 
and volume of 3.07 nm and 0.17 mL/g, respectively. These nanoparticles allowed infiltration 
of up to 65.2 mg of ovalbumin/g of nanoparticle template. A previous study where the SC/MS 
silica nanoparticles were fabricated with a similar diameter and MS wall thickness, reported 
65 mg/g and 35 mg/g loading of 15 kDa and 70 kDa poly(allylamine hydrochloride) (PAH), 
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respectively (Wang et al., 2008a). It was also reported that the use of smaller PAH of 5 kDa 
resulted in an increase in polymer loading (110 mg/g). The nanoparticles used in the study by 
Wang and colleagues (2008) possessed a larger surface area (390 m2/g), porosity (4.5 nm) and 
volume (0.28 mL/g) of MS. In consideration with the molecular weight of ovalbumin being 
44 kDa, the loading capacity was therefore relatively high for the nanoparticles fabricated in 
this study.  
 
The influence of the wall thickness and the porosity of MS on chitosan loading was 
investigated by Goethals and colleagues (2013), and it was demonstrated that the infiltration 
load increased proportionally to the porosity, pore volume and thickness of the MS, as well as 
an increase in the amount of drug load which was encapsulated within the chitosan 
nanocapsule. The effect of pore size on protein or polymer immobilisation is due to molecule 
adsorption being restricted to the nanoparticle surface, including the MS (Wang & Caruso, 
2005). The method to control the properties of the MS is well established (Büchel et al., 1998; 
Goethals et al., 2013; Chiang et al., 2011), therefore the amount of protein loading can be 
tailored to the optimal level required for specific applications. For advanced specifications, 
the orientation and the shape of pores in the MS can be also modified (Yoon et al., 2007). In 
the same study, use of templates with various properties influenced the degree of integrity in 
the resulting nanocapsules. This indicated the possibility of controlling the degradability of 
the protein-based nanocapsules to target intracellular localisation in different stages of acidic 
endosomes, as well as prolong the presentation period. This may allow the induction of an 
antigen presentation pathway appropriate for a specific pathogen (Sieling et al., 2007).  
 
3.4.1.2 Influence of the physicochemical property of protein on infiltration 
The loading capacity of SC/MS templates can change based on the physicochemical 
properties of the infiltrating molecules. The influence of molecular weight was evident in 
several previous studies where higher loading of smaller molecular weight molecules was 
observed (Wang et al., 2008a; Wang & Caruso, 2005). Accordingly, a decrease in the surface 
area for pristine nanoparticles was reported, indicating that more dense structure was formed 
in the MS. In the present study, C27, a recombinant H1N1 viral protein was used for 
nanocapsule synthesis using this templating system, and it was found that the capsule 
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structure was different to that of the synthesised ovalbumin nanocapsule. From the TEM 
micrograph observation, a C27-based nanocapsule showed a much thicker capsule wall 
structure compared to that of the ovalbumin nanocapsule, and a higher protein density, as 
indicated by the negative staining from the TEM micrograph. The protein-based nanocapsules 
exhibited a folded shape when observed under TEM due to the drying process during the 
sample preparation. Creasing in the ovalbumin nanocapsule was much more obvious than that 
present in the C27 nanocapsules. The structural rigidity of nanocapsules synthesised with a 
higher amount of protein was in line with the capsules synthesised using the template with a 
larger pore volume, which allowed larger numbers of molecules to infiltrate (Goethals et al., 
2013).  
 
The pI of an infiltrating molecule is also an important factor for determining infiltration load. 
Protein immobilisation increases when the pI of the infiltrating protein is lower than the 
physiological pH of buffer in which the reaction takes place. At several pH units away, the 
electrostatic attraction between the positively charged silica template and the protein 
increases, thereby forcing protein to immobilise at a higher rate. An increase in the ovalbumin 
infiltration load was evident from the optimisation study when the pH of PBS increased from 
5.5 to 8.5. This was due to the ovalbumin possessing a stronger negative charge at pH 8.5 as 
the ovalbumin pI is 4.6. In contrast, C27 has a pI of 6.81, which resulted in much lower 
infiltration efficiency in PBS at pH 7.4 than ovalbumin for nanocapsule synthesis (data not 
shown). This may be due to the weaker electrostatic interaction induced by having two 
similarly charged materials. This highlights that the conditions for protein infiltration need to 
be altered according to the molecule applied for the synthesis. 
 
3.4.1.3 Quantification of synthesised ovalbumin nanocapsules 
The amount of immobilised protein was quantified by measuring the protein concentration in 
the washes produced from the infiltration and cross-linking procedure. However, this may not 
accurately translate to the amount of protein in the synthesised nanocapsules, as none of the 
washes after HF treatment were assessed for ovalbumin quantification due to safety reasons. 
Therefore, the protein estimation was made by subjecting nanocapsules to SDS-PAGE 
analysis. PFA cross-linked ovalbumin nanocapsules were able to enter the SDS-PAGE gel as 
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the formalin-induced cross-link was reversed by boiling the nanocapsules. However, 
cross-links induced by GA seemed irreversible after boiling. The aldehyde group from GA 
and PFA react with nitrogen in protein (mainly with the ε-amino group of lysine), and form 
methylene bridge (-CH2-) by reacting between two proteins. GA therefore formed stronger 
cross-linking due to the presence of two aldehyde groups per molecule.  
 
For protein-based nanocapsules to be used in a vaccine delivery system, it is crucial that the 
cross-linked proteins can be degraded by the intracellular enzyme for the presentation of 
peptides. It has previously been reported that the degradation of human serum albumin (HSA) 
nanoparticles, cross-linked by GA is achievable by enzymatic digestion. HSA nanoparticles 
were shown to be degraded in situ by cathepsin B (Langer et al., 2008), which often localised 
in the lysosomes (Tanaka et al., 2000; Mukherjee et al., 1997). In vitro lysosomal digestion of 
GA cross-linked HSA nanoparticles was also demonstrated using a head and neck squamous 
cell carcinoma cell line (Altintas et al., 2013). These findings suggested that the other GA 
cross-linked protein-based nanocapsules, including ovalbumin capsules, would most likely be 
degraded by intracellular proteases. 
 
While the protein-based nanocapsules must be easily degraded by intracellular proteases, it is 
equally important that the nanocapsules can maintain integrity prior to vaccination. An ideal 
vaccine should be very stable, preferably with no requirement for a cold chain, to be able to 
be distributed to countries and rural regions that may require a longer transportation period. 
Therefore, the stability of protein-based nanocapsules at different temperatures (i.e. 4°C, and 
room temperature) needs to be evaluated for different periods of time (i.e. hours to days) in 
future work. 
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3.4.2 In vitro characterisation  
3.4.2.1 Cytotoxicity of ovalbumin nanocapsules 
The use of DC2.4 has been reported in numerous publications (Sneh-Edri et al., 2011; Carney 
et al., 2012; Okada et al., 2001; Shen et al., 1997). DC2.4 cells are immature DCs therefore 
they are suitable for the uptake and presentation studies using extracellular antigens, as the 
uptake efficiency can be reduced in matured DCs (reviewed in Chapter 1).  
 
The ovalbumin nanocapsules were tested for their cytotoxicity by measuring the level of 
DC2.4 cell viability after 24, 48 and 72 h exposure. No significant reduction in cell viability 
was observed until 48 h by cells treated with 50 µg/mL of ovalbumin nanocapsules. The same 
concentration of ovalbumin nanocapsules showed a similar cytotoxic effect after 72 h; 
however the cell viability was well maintained at other concentrations, even after 72 h of 
exposure.  
 
Commercially available ovalbumin that was purchased from Sigma-Aldrich (details in 
Section 2.4.1) in this study is known to contain on average of 40 ng endotoxin/µg of 
ovalbumin (Mac Sharry et al., 2014). Endotoxins often include bacterial LPS, and are 
stimulating molecules (reviewed in Chapter 1). It could be possible that the results observed 
for the ovalbumin nanocapsules were influenced by the non-specific stimulation caused by the 
endotoxin in ovalbumin. However, it is highly unlikely that it had a major cytotoxic effect on 
cells as the cells incubated with soluble ovalbumin were able to maintain a high cell viability 
over 72 h. 
 
One main advantage of the templating system for vaccine delivery is that the resulting 
nanocapsules only consists of negatively charged proteins. Many polymeric nanoparticles and 
liposome are increasingly being used in delivery systems, however these polymers and lipids 
often bear a positive charge and possess cytotoxic effects due to their nature (Lv et al., 2006). 
The cytotoxicity of cationic nanoparticles can be much higher with increasing charge, in 
comparison to anionic nanoparticles with an opposite, but similarly strong charge (Yang & 
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Hsu, 2008). These cationic nanoparticles have also shown to decrease subsequent antigen 
presentation by DCs (Kwon et al., 2005). Several polycationic polymers have even 
significantly higher cytotoxicity (Fischer et al., 2003). Due to these cytotoxic effects, the 
amount of cationic nanoparticles used for vaccine administration may have to be kept to a 
minimal amounts, therefore protein-based nanocapsules (anionic) may be probably more 
suitable for antigen delivery.  
 
3.4.2.2 Cellular uptake of ovalbumin nanocapsules by DCs 
A qualitative study using the CLSM analysis was performed to determine the efficiency of 
uptake of ovalbumin nanocapsules by DC2.4 cells. The result revealed a high level of 
internalisation of ovalbumin nanocapsules in less than 30 min by DC2.4 cells. By 60 min, 
most of the cells had successfully internalised ovalbumin nanocapsules of approximately   
500 nm in size. The cellular uptake of nanoparticles synthesised with various materials has 
been well documented. Nanoparticles consisting of polystyrene beads (Mottram et al., 2007; 
Foged et al., 2005), human serum albumin (Altintas et al., 2013; Langer et al., 2003), PLGA 
(Shen et al., 2006; Lutsiak et al., 2002), PPS (Hirosue et al., 2010), chitosan (Namazi & 
Phillips, 2010; Goethals et al., 2013), lecithin (Sloat et al., 2010), and silica (Huang et al., 
2010), are just some examples of a wide range of materials tested as nano-carrier systems. 
However, regardless of the nanoparticle materials used and the method of either encapsulation 
or adsorption techniques to create the carrier system, many reported on the increased load of 
drug and antigen delivered to intracellular components when delivered in a particulate form.  
 
To confirm the ovalbumin nanocapsules were in fact internalised, a control was set up at 4°C. 
At low temperature, where energy-dependent cellular uptake was blocked, the ovalbumin 
nanocapsules were only able to bind to the membrane surface (Mintern et al., 2013). After  
90 min, a predominant population of cells indicated ovalbumin nanocapsule internalisation, 
while cells incubated at 4°C showed no indication of internalisation.  
 
The uptake mechanism of nanoparticles may vary depending on the particle properties, 
however larger particles (>200 nm), in the size range of a bacterial pathogen, often enter DCs 
via phagocytosis, while smaller particles (<200 nm), exhibit virus-size enter via 
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receptor-mediated clathrin-coated pits (Daecke et al., 2005), or caveolae lipid rafts (Chen & 
Norkin, 1999). In the present study, the pathway which ovalbumin nanocapsules took to enter 
DC2.4 was not investigated. This was largely due to the excessive amount of fluorescence 
from the GA cross-linking interfering with other fluorescence detection at various 
wavelengths. This hindered the fluorescent staining of different cell organelles to determine 
exactly where the ovalbumin nanocapsules co-localised. Such a study could possibly indicate 
the endocytic pathway the 500 nm sized-ovalbumin nanoparticle had taken, hence possibly 
obtaining clues to the fate of antigen processing and presentation by the two MHC pathways.  
 
Investigation of the endocytosis pathway using chemical inhibitors is not uncommon in 
studies of a particulate delivery system. Wortmannin is an inhibitor of phosphatidylinositol-3 
kinase, an extracellular signal-regulated kinase, and therefore blocks Fc receptor-mediated 
phagocytosis (Garcia-Garcia et al., 2002; Wymann et al., 1996; Manna & Aggarwal, 2000). 
Cytochalasin B blocks actin polymerisation, and therefore inhibits actin-mediated membrane 
rearrangement for phagocytosis (Torii et al., 2001). Amiloride directly affects 
clathrin-independent pinocytosis by blocking the Na+-H+ exchange within cells (Tujulin et al., 
1998; Bakker-Grunwald et al., 1986). Investigation using these inhibitors determined that the 
PLGA nano- and microparticles ranging from 500 nm to 4 µm in diameter were internalised 
via phagocytosis by DCs and macrophages (Lutsiak et al., 2002; Yang & Hsu, 2008). 
However, a combination of inhibitors such as chlorpromazine and filipin III, which inhibits 
clathrin-mediated endocytosis and caveolae formation, respectively, indicated that more than 
one pathways were involved in the uptake of 350 nm chitosan nanoparticles (Nam et al., 
2009). It is commonly known that smaller particles than this are preferred for non-phagocytic 
pathways, however chitosan nanoparticles possessed a positive charge, which may influence 
the unusual uptake pathways for a particle this size. Anionic ovalbumin nanoparticles of 
approximately 500 nm, developed in this study, might therefore be endocytosed by the 
phagocytic pathway. 
 
While polystyrene microparticles of up to 15 µm in diameter can be taken up by DCs (Foged 
et al., 2005), smaller size particles of <500 nm are more efficiently taken up. It was also 
reported that nanoparticles in the viral range (40-50 nm), can induce higher localisation in 
DCs within draining lymph nodes, and subsequently elicit a higher immune response (Fifis et 
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al., 2004). A number of studies have demonstrated the correlation between particle uptake 
with a range of sizes using near monodispersed spherical particles, however the shape of the 
particle may result in different uptake efficiency by nonspecific cellular uptake. Huang et al., 
(2010), investigated the effect of the shape of nanoparticles on cellular uptake and found that 
450 nm long rod-shaped nanoparticles were internalised at a much faster rate than 100 nm 
spherical nanoparticles (Huang et al., 2010). It was suggested that the differences in contact 
area of particles with the cell membrane attachment might have assisted in the uptake 
efficiency, as the longitudinal axis of rod shaped-particles was much larger in surface area. 
Whether the rod shaped-particle can mimic bacilli bacteria for more efficient uptake is not 
known, however these particles had increased cytotoxic effects. These investigations were 
performed using dense core beads or mesoporous silica particles, therefore the size- and 
shape-dependent uptake efficiency may not apply to hollow core nanocapsules. Nanocapsules 
used in the present study should exhibit flexibility, therefore size reduction by folding or 
creating different shape by flattening may be possible.  
 
Surface charge of nanoparticles may possibly a key factor for the uptake efficiency. Alteration 
of surface charge to synthesise cationic nanoparticle can increase the electrostatic interactions 
between the anionic cell membrane to facilitate better uptake (Kwon et al., 2005; Nam et al., 
2009). This is especially important for larger particles of 1 µm size, in order to reach a similar 
degree of cellular association as 100 nm nanoparticles could provide (Foged et al., 2005). A 
higher surface charge can bind strongly to the cell surface, however this results in 
non-specific interaction with many types of cells. In order to increase the antigen loading to 
APCs, the use of smaller sized negatively charged nanoparticles might therefore be more 
superior to the cationic particles in a vaccine delivery system.  
 
3.4.2.3 Antigen presentation of ovalbumin nanocapsule peptides 
Effective activation of DCs is important for a vaccine delivery system, as they are the most 
potent APCs capable of inducing primary immune responses, and thus activation of naïve T 
cells (Marland et al., 1996). The ability of a vaccine delivery system to appropriately induce 
the cross-presentation pathway is often studied using ovalbumin (Mottram et al., 2007; Kwon 
et al., 2005; Hirosue et al., 2010; Segura et al., 2009; Shen et al., 1997; 2006). This system is 
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widely employed because of the well characterised ovalbumin-derived peptide (OVA258-265), 
SIINFEKL is known to be a MHC class I molecule-restricted peptide, and the amount of 
SIINFEKL presented on MHC class I molecules (Kb) translates to the level of 
cross-presentation (Shastri & Gonzalez, 1993). DC2.4 cells are immature DCs with a low 
amount of CD80 and no MHC class II and CD40 expressed, while the expression of MHC 
class I molecules (Kb) is present. These have been shown to successfully induce 
OVA-specific CD8+ T cell responses (He et al., 2007). 
 
The level of cross-presented ovalbumin delivered by either soluble or particulate form was 
detected as a shift in the fluorescence intensity from the level induced by the SIINFEKL 
peptide with incomplete staining. Flow cytometry analysis showed that the cross-presentation 
of soluble ovalbumin was significantly less efficient than particulate form. The results also 
indicated that the level of cross-presentation was increased at a higher level in two separate 
DC2.4 populations. Due to the nature of SC/MS templates being slightly polydispersed, 
different sizes of ovalbumin nanocapsules were most likely synthesised. Therefore, larger 
ovalbumin nanocapsules might have delivered an increased amount of ovalbumin, possibly 
resulting in a higher level of presentation. However, it is understood that smaller 
nanoparticles can be taken up more efficiently, as discussed in the previous section. 
Therefore, it is possible that smaller ovalbumin nanocapsules synthesised due to 
polydispersity of the template, which might have been internalised at a better rate/more 
efficiently and caused increased nanocapsule localisation per cell, thus possibly increasing the 
level of presentation. The ovalbumin nanocapsules were often seen aggregated after the 
template removal by HF treatment. Prior to applying the ovalbumin nanocapsules to cells, 
they were sonicated to dissociate the aggregation. However, it is possible that some 
aggregations were still present and internalised by the cells. Mant et al. (2012) have 
investigated the effect of nanoparticle aggregation on cross-presentation in DC2.4 cells. It was 
observed that the aggregated ovalbumin-bound nanoparticles without the sonication treatment 
produced a different magnitude of cross-presentation in DC2.4 cells. The nanoparticles with 
sonication treatment also produced various level of cross-presentation, but with much less 
variability. This indicates that various levels of cross-presentation seen in DC2.4 cells might 
be due to the uptake of aggregated ovalbumin nanocapsules. 
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Nevertheless, the increased level of cross-presentation induced by the nanocapsules was in 
line with other studies. Delivery of an exogenous antigen in PLGA nanoparticles was shown 
to be much more effective at inducing cross-presentation (Shen et al., 2006). In their study, 
the presentation level of SIINFEKL induced by ovalbumin-encapsulating PLGA 
nanoparticles was significantly higher than the soluble ovalbumin alone, it would require a 
1000-fold higher concentration of soluble ovalbumin to induce the same level of presentation. 
The subsequent activation of CD8+ T cells by the PLGA nanoparticle was much higher than 
soluble ovalbumin, demonstrating that nanoparticles were much more effective than soluble 
antigen for eliciting immune responses also. Interestingly, these nanoparticles were also 
capable of inducing cross-presentation in B cells, which are naturally not very competent 
cross-presenting cells. Soluble ovalbumin and ovalbumin-coated latex beads were used as 
comparisons, however neither resulted in presentation, as expected. This is a great indication 
that delivery of antigen in a particulate system is sufficient to elicit an immune response at a 
much lower dose of administration.  
 
The fate of exogenous antigens can often be indicated by the intracellular location for the 
processing and presentation. Exogenous antigens internalised by phagocytosis are often 
trafficked to acidic early endosomes, then eventually to late endosomes or lysosomes where 
the antigens are degraded by proteases. This is where the peptides meet MHC class II 
molecules. In contrast, endogenous antigen or viral proteins are processed by the proteasome 
within the cytosol and bind to MHC class I molecules in the endoplasmic reticulum 
(Villadangos & Schnorrer, 2007). The link between the two pathways for the exogenous 
antigens to be cross-presented is escape into the cytosol from the lysosomal compartment. In 
a study where biodegradable PPS nanoparticles were subjected to mouse bone 
marrow-derived DCs; while the majority of nanoparticles co-localised with LAMP-1 
(lysosomal associated membrane protein-1), and other intracellular MHC class II 
compartments after 90 min, a small number of particles were also found to co-localise with 
calreticulin, a protein found in the endoplasmic reticulum for MHC class I molecule loading 
(Hirosue et al., 2010). This finding indicated the nanoparticles could lead the loaded antigens 
to escape from the endosome. Encapsulation of ovalbumin in PLGA nanoparticles could also 
increase escape into the cytosol by 30-fold more than the soluble ovalbumin (Shen et al., 
2006). Efficient cytosol escape might be attributed to the prolonged release of antigen within 
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endosomes and lysosomes, as these PLGA nanoparticles maintained the sustained level of 
antigen beyond the period which soluble antigen could remain. Supported by these findings, a 
particulate antigen delivery system is most likely more superior to a subunit vaccine due to 
prolonged antigen presentation that in turn can induce higher immune responses.  
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3.5 Conclusion 
Ovalbumin nanocapsules were synthesised by employing the SC/MS silica nanoparticles as a 
template. The properties of resulting nanocapsules can easily be modified by alteration of the 
silica template moiety, providing great flexibility in antigen loading and for in vivo processing 
and presentation. Ovalbumin nanocapsules were synthesised using minimal steps, with final 
particles consisting of only the cross-linked protein. Negatively charged ovalbumin 
nanocapsules produced minimal toxicity to cells, alleviating the cytotoxic effect that cationic 
polymer particles might possess. These ovalbumin nanocapsules were efficiently internalised 
by immature DCs in less than 30 min, and induced a significantly higher level of ovalbumin 
peptide to be processed via the cross-presentation pathway than soluble ovalbumin. Increased 
levels of peptide presentation with MHC class I molecules will lead to the efficient induction 
of a cellular response by activating CD8+ T cells.  
 
In conclusion, SC/MS nanoparticles are suitable for synthesising protein-based nanocapsules, 
which could be tailored for different pathogenic antigens. Protein-based nanocapsules can be 
efficiently taken up by APCs, and increase the level of antigen presentation greater than that 
of soluble protein. The use of such a templating system is therefore suitable for an antigen 
delivery system.  
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4 CHAPTER 4 
 
Malarial protein expression and 
purification for antigen-based 
nanocapsule synthesis 
 
 
This chapter reports the expression and purification of an antigenic malarial protein and the 
subsequent synthesise of the protein-based nanocapsules for in vivo study. 
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4.1  Introduction  
In order to investigate the potential of protein-based nanocapsules as a new vaccine delivery 
system, it is best to compare the immunogenicity with differently formulated vaccines in an 
animal model. To achieve comparable results between a free sub-unit and a nanocapsule 
vaccine and elucidate their efficacy, an immunogenic antigen is the preferred choice to 
formulate the nanocapsules. The use of an immunogenic antigen, which has been shown to 
elicit an immune response in an animal model, will ensure that a measurable immune 
response will be elicited. The antigen of choice must also have suitable physiochemical 
properties for the nanocapsule synthesis, that is, a low pI and a moderately large molecular 
weight. For those reasons, a murine malarial protein, the merozoite surface protein 4/5 
(MSP4/5) was chosen for this study as it is a very efficacious vaccine antigen candidate, 
which also possesses very similar properties to that of ovalbumin described in the previous 
chapter. 
 
In 1999, Black et al. (Black et al., 1999) identified a gene in murine malaria Plasmodium 
chabaudi adami homologous to the MSP2, MSP4 and MSP5 genes found in P. falciparum. 
Despite having low sequence similarity, the gene is structurally similar in that it has an intron, 
and the encoded protein also has common properties to MSP4 and MSP5 in P. falciparum, 
with a well-conserved region of epidermal growth factor (EGF)-like domain and 
glucosylphosphatidylinositol (GPI) anchor. Homologues were also identified in two other 
murine malaria species, P. berghei and P. yoelii in 2000 (Kedzierski et al., 2000a), and the 
recombinant MSP4/5 was shown to provide protection against lethal malaria challenges in 
mice (Kedzierski et al., 2000b; 2001).  
 
The complete sequence of the P. chabaudi adami MSP4/5 (PcMSP4/5) gene is available from 
GenBank (accession number: AF080446) (Black et al., 1999) and in silico protein 
characterisation revealed that its predicted pI is 4.19. The expressed recombinant protein and 
the synthesised nanocapsule will be used in an animal model, therefore all solvents have to be 
at a physiological pH of 7.4. As described in Chapter 3, lower protein pI can promote a higher 
infiltration load of protein into a mesoporous layer of positively charged SC/MS templates in 
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PBS at pH 7.4. Having a similar pI to ovalbumin (pI = 4.6), PcMSP4/5 is an ideal protein 
model for nanocapsule vaccine study. 
 
To fully understand the efficacy of nanocapsules as a delivery system, the recombinant 
protein for both nanocapsule and the free sub-unit vaccine must be produced in the same 
expression system. Escherichia coli is a widely used expression host and all recombinant 
MSP4/5 from previous studies have been expressed in this system. The expression vector was 
obtained from the group who identified the PcMSP4/5 gene. This plasmid was used to express 
the recombinant PcMSP4/5 in this part of the study. 
 
The cloning strategy used to construct this plasmid in the previous study (Black et al., 1999) 
was very extensive. This chapter explains the cloning process used to build this construct, and 
subsequently DNA analysis to confirm the gene orientation and absence of mutation. 
Recombinant PcMSP4/5 was expressed in E. coli and purified by immobilised metal affinity 
chromatography (IMAC). Purified protein was then subjected to nanocapsule synthesis 
reactions and in vitro cytotoxic effects were assessed in murine dendritic cells (DCs) before 
application as a vaccine in the animal model.  
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The aim of the experiments outlined in this chapter were: 
 
• To understand the cloning strategy for building a pTrcHis-A vector construct with 
PcMSP4/5 gene from the previous study (Black et al., 1999). This plasmid was named 
pT.MSP4/5 in this study. 
• To confirm the integrity of the PcMSP4/5 gene, pT.MSP4/5 vector was subjected to the 
restriction endonuclease analysis and nucleotide sequencing.  
• To express PcMSP4/5 as a recombinant 6xHis-tagged protein in E. coli 
BL21(DE3)pLysS.  
• To assess the suitability of PcMSP4/5 for nanocapsules made with the SC/MS 
nanoparticle templating system, and determine any in vitro cytotoxic effects.   
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4.2 Materials and Methods 
4.2.1 General protocols 
This section details the general materials, methods and techniques applied in the experimental 
methods.  
 
4.2.1.1 Bacterial strain 
Plasmid clones were introduced into E. coli strain DH5α and BL21(DE3)pLysS and were 
used for storage and recombinant protein expression, respectively. The description of all the 
bacterial strains used throughout this study is listed in Table 4.1.  
 
4.2.1.2 Plasmid 
A previously constructed pT.MSP4/5 clone was used in this study (Black et al., 1999). The 
plasmid vector pTrcHis-A ligated with the P. chabaudi adami MSP4/5 gene, lacking the 
predicted hydrophobic signal and GPI anchor sequences, was kindly provided by Dr Casilda 
Black from Monash University, Clayton, Australia. pTrcHis-A utilised in constructing 
pT.MSP4/5 was obtained from Invitrogen, USA. 
 
4.2.1.3 Storage condition  
Both transformed E. coli DH5α and BL21(DE3)pLysS strains with pT.MSP4/5 were stored at 
−80°C in 50% glycerol LB broth in 2 mL cryovials.  
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Table 4.1: Bacterial strains used in this study. 
Bacterial strain Genotype/Description Source 
DH5α F- endA1 glnV44 thi-1 recA1 relA1 
gyrA96 deoR nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK- mK+), 
λ– 
 
(Hanahan et al., 1983) 
BL21(DE3)pLysS F-ompT hsdSB(rB- mB-) gal dcm (DE3) 
pLysS (CamR) 
Invitrogen Corporation, 
USA 
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4.2.1.4 Culture condition 
All E. coli strains, grown in broth or on solid microbiological media were incubated under 
aerobic conditions at 37°C for 16-20 h. Escherichia coli DH5α containing pT.MSP4/5 
plasmid was grown in media with 100 µg/mL AMP and E. coli BL21(DE3)pLysS containing 
pT.MSP4/5 was grown in 100 µg/mL AMP and 34 µg/mL CM, while not containing plasmid 
was grown with 34 µg/mL CM for the maintenance of pLysS plasmid. Broths were shaken at 
approximately 200 rpm on a Bioline shaking incubator unless otherwise specified. 
 
4.2.1.5 Preparation of electrocompetent cells 
All steps were performed aseptically. Bacterial cells were grown in 10 mL LB broth on a 
shaker at 37°C overnight. Two millilitres of this culture was used to inoculate 200 mL of LB 
broth in a 1 L Erlenmeyer flask and shaken vigorously at 37°C until an optical density at 600 
nm of 0.4 (early to mid-log phase), was obtained. The culture was then placed on ice to chill 
for 30 min, followed by centrifugation at 4,000 x g for 15 min at 4°C to harvest the cells. The 
supernatant was completely removed and the cells were resuspended and washed in 200 mL 
of sterile ice-cold MQH2O. The centrifugation process was repeated twice, with the cells 
firstly resuspended in 100 mL of sterile ice-cold MQH2O, then 10 mL of sterile ice-cold 10% 
glycerol. The cells were resuspended in a final volume of 400 µL of sterile ice-cold 10% 
glycerol and aliquots of 40 µL were stored at −80°C immediately.  
 
4.2.1.6 Transformation of electrocompetent cells 
The method of electro-transformation was designed according to the Gene Pulser apparatus 
user manual with minor alterations. Frozen electrocompetent cells were thawed on ice for      
5 min and mixed with 1 µL of 100 ng/µL pT.MSP4/5. After sitting on ice for another 1 min, 
the mixture was transferred into a chilled electroporation cuvette with a 0.1 cm gap. The cells 
were pulsed with settings of 2.2 kV, 25 µF and 200 Ω. After the pulse, cells were gently 
resuspended in 1 mL of LB broth and incubated at 37°C for 1 h in a fresh microfuge tube. 
Fifty microlitres of transformed cells were then plated onto LB agar containing the 
appropriate antibiotics and grown overnight at 37°C.  
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4.2.1.7 Plasmid extraction (miniprep) 
pT.MSP4/5 was purified using the Bioline ISOLATE Plasmid Mini kit as per the 
manufacturer’s instructions. Five millilitres of E. coli BL21(DE3)pLysS transformed with 
pT.MSP4/5 were grown overnight in LB broth supplemented with AMP and CM was used for 
the isolation of plasmid.  
 
4.2.1.8 Restriction endonuclease digestion of DNA 
Restriction enzyme used in this study was purchased from Promega USA. Restriction enzyme 
reaction condition was as specified by the manufacturer. Up to 150 ng of DNA was digested 
with 10 U of enzyme, in 1× buffer in a total volume of 20 µL at 37°C for 3 h. Acetylated BSA 
was added to a concentration of 100 µg/mL in every reaction. Enzymes used in the previous 
and present studies are listed in Table 4.2. 
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Table 4.2: List of restriction endonuclease used in this study. 
Restriction endonuclease Recognition sequence 
 
BglII 
 
A⎖GATCT 
 
BspHI 
 
C⎖CATGG 
 
NcoI 
 
C⎖CATGG 
 
PstI 
 
CTGCA⎖G 
 
Where ⎖ represents the point of cleavage. 
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4.2.1.9 Quantification of DNA 
Two methods were used in the quantification of nucleic acids. For the exact quantification of 
well-purified DNA, a UV-vis spectrophotometer was used, and for approximate quantification 
of DNA, DNA was separated on an agarose gel and compared to known standards of λ-PstI 
DNA ladder. 
 
4.2.1.9.1 Spectrophotometric quantification of DNA 
The concentration of DNA and purity were determined using a BioPhotometer UV-vis 
spectrophotometer.  The absorbance was determined at wavelengths of 260 and 280 nm. The 
concentration was calculated from the absorbance at 260 nm while the purity was checked 
using the absorbance ratio from 260/280 nm. One absorbance unit at 260 nm was considered 
equal to 50 µg of double-stranded DNA. A ratio between 1.7-2.0 was considered acceptable 
for DNA and RNA purity (Sambrook & Russell, 2001). The purity of the DNA was also 
checked visually by electrophoresis on an agarose gel. 
 
4.2.1.9.2 Agarose gel DNA electrophoresis 
4.2.1.9.2.1 Preparation of λ-DNA marker 
A solution of 0.1 µg/µL digested λ-DNA was prepared by incubating 20 µg λ-DNA with 10 U 
PstI in 1× Buffer H and MQH2O made up to 120 µL, at 37°C overnight. Twenty microlitres 
of 11× DNA loading buffer was then added to stop the digest, and MQH2O was added to 
make the total volume 200 µL. The marker was stored at −20°C, with 10 µL used on a DNA 
agarose gel. A diagram of PstI digested λ-DNA ladder is located in Appendix 1. 
 
4.2.1.9.2.2 DNA electrophoresis 
One percent agarose gels were used to separate and view DNA fragments. DNA samples were 
mixed with 11x loading buffer and underwent electrophoresis against an appropriate DNA 
marker in an adjacent lane. Gels were run in 1x TAE electrophoresis buffer at 100 V. Gels 
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were stained with ethidium bromide (3 µg/ml) before destaining in running tap water. The 
DNA products were visualised with an UV illuminator and photographed using a Biorad 
Geldoc imaging system running Quantity One software.  
 
4.2.1.9.2.3 DNA electrophoresis quantification 
λ-DNA previously digested with PstI was separated on an agarose gel along with sample 
DNA fragments. The quantity of DNA within each digested fragment of λ-DNA (Appendix 1) 
was compared with intensities of unknown DNA samples. 
 
4.2.1.10 Protein determination 
4.2.1.10.1 Bradford assay 
Protein content determination in samples containing no traces of detergent was performed 
using the Bradford method (Bradford, 1976; Lane, 1991). One millilitre of Bradford reagent 
was added to 100 µL of protein, or standard, mixed by inversion and left to stand for 2 min. 
When required, protein and standards were diluted in 0.15 M NaCl. Bovine serum albumin 
fraction V (BSA) was used as the standard protein solution. Two hundred microlitres of 
processed protein was added to the wells of a 96-well microtiter plate. The absorbance was 
measured using the iMark™ Microplate absorbance reader at 595 nm, and a standard curve 
constructed by plotting the concentrations of the BSA standards (µg) versus absorbance, was 
used to determine the protein content of samples. 
 
4.2.1.10.2 Spectrophotometric quantification of protein  
The concentration of protein was determined using a UV-vis spectrophotometer. The 
absorbance was measured at a wavelength of 280 nm. The concentration of the protein sample 
(mg/mL) was equal to the absorbance at 280 nm (with a path length of 1 cm). 
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4.2.1.11 Protein visualisation  
4.2.1.11.1 SDS-PAGE 
One-dimensional SDS-PAGE was performed using a discontinuous buffer system (Lane, 
1991). Proteins were mixed with SDS loading buffer and heated to 100ºC in a dry heating 
block for 10 min. The proteins were separated in the BioRad electrophoresis unit containing 
SDS running buffer, by electrophoresis at 150 V for 50 min or until the dye front reached the 
bottom of the gel.  
 
Gels where then transferred onto nitrocellulose membranes for immunoblotting, or were 
stained using instant stains. Mini-PROTEAN® TGX™ precast AnykD™ or 4-15% gradient 
gels were used. The Precision Plus Protein™ Unstained standard or Precision Plus Protein™ 
Dual color was used for the determination of relative protein mass (Appendix 2). 
 
4.2.1.11.2 Instant stain  
Instant stain was used in place of Coomassie staining. ClearPAGE Instant Blue Stain, or 
Acqua Stain was used for staining SDS-PAGE gels after electrophoresis. SDS-PAGE gels 
were immersed in instant stain for up to 1 h until bands were appropriately resolved. Gels 
were rinsed in dH2O until the background cleared.  
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4.2.1.12 Immunoblotting 
4.2.1.12.1 Transfer of protein to nitrocellulose membrane 
Proteins resolved by SDS-PAGE were transferred by Western blotting onto a nitrocellulose 
membrane using an iBlot® Gel transfer device as per the manufacturer’s instructions.  
 
4.2.1.12.2 Development of nitrocellulose membrane 
Immunoblot was performed using based on the method of Sambrook and Russell (Sambrook 
& Russell, 2001), with all incubations and washes performed on a orbital shaker. After 
immunotransfer, the nitrocellulose membrane was placed in TBS/skim milk (5% w/v) for 1 h 
at room temperature. The membrane was washed twice in TBS for 5 min, then incubated 
overnight at 4°C in mouse anti-6xHis antibody diluted (1:5000) in TBS/Skim milk (1% w/v). 
The membrane was washed three times in TBS for 5 min, and then incubated with an alkaline 
phosphatase (AP)-conjugated rabbit anti-mouse IgG antibody diluted (1:5000) in TBS/Skim 
milk (1% w/v) for 2 h at room temperature. The membrane was washed three times for 5 min 
in TBS/Tween and the developed in darkness using the Western Blue® Stabilized Substrate 
for alkaline phosphatase for up to 30 min. The reaction was stopped by washing in dH2O and 
the membrane was then air dried. 
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4.2.2 Experimental protocols 
4.2.2.1 pT.MSP4/5 construct 
This section describes the cloning strategy used in constructing the pT.MSP4/5 plasmid 
vector in the previous study (Black et al., 1999), the subsequent gene analysis by 
endonuclease digestion, and nucleotide sequencing to confirm the orientation of gene and to 
determine any mutations which may have occurred during amplification. This work was 
included to ensure that the recombinant PcMSP4/5 could be successfully expressed in E. coli 
BL21(DE3)pLysS. In silico characterisation of PcMSP4/5 was performed to evaluate the 
suitability of the protein for subsequent nanocapsule synthesis.  
 
4.2.2.1.1 Background on the construct (pT.MSP4/5) development 
Early study on the design and development of the P. chabaudi adami DS MSP4/5 construct 
was carried out at Monash University, Clayton, Australia. They identified a region of the P. 
chabaudi adami genome in chromosome 2 as the MSP4/5 gene, a homologue to P. falciparum 
MSP4 and MSP5 (Black et al., 1999). The MSP homologue was identified by detecting a 
highly conserved adenylosuccinate lyase (ASL) gene that was closely located to the region 
which contained MSP4 and MSP5 genes. A chromosome walking analysis using various 
primers were performed, and the resulting sequence was published (GenBank AF080446) and 
was identified to be 713 bp in length with a 83 bp intron (Figure 4.1, top sequence). 
 
A pUC18 cDNA construct (pMC346) was derived from a total RNA isolated from P. 
chabaudi adami DS ring-stage parasites using primers corresponding to the predicted 5’ and 
3’ ends of the PcMSP4/5 gene from the sequenced identified. A plasmid construct with a 
spliced version of PcMSP4/5 gene lacking the 83 bp intron was made to express the 
recombinant PcMSP4/5 protein in an E. coli system. A region containing the PcMSP4/5 gene 
with no predicted hydrophobic signal or GPI anchor sequence was amplified from pMC346. 
A forward primer added a BspHI restriction site and an ATG translation initiation codon, and 
a reverse primer added a BglII site, a termination codon and a C-terminal 6xHis-tag on both 
ends of gene. A C-terminal 6xHis-tag was introduced downstream of the gene (Figure 4.1, 
bottom sequence).  
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Figure 4.1: A schematic diagram of P. chabaudi adami MSP4/5 gene modified for 
protein expression in E. coli system. Top sequence indicates the genomic sequence 
(published sequence) including the 5’ end signal sequence, an 83 bp intron and 3’ end GPI 
anchor sequence. cDNA was derived from the total RNA with the same sequence as this top 
sequence of the figure to amplify the bottom sequence. Bottom sequence indicates the 
amplified sequence used for PcMSP4/5 expression with the addition of an ATG translation 
initiation codon, a termination codon and 6xHis sequence for purification, with two restriction 
endonuclease sites flanking the sequence to allow the ligation into the plasmid vector. 
(Numbers indicate the base pair positions in the genomic sequence) 
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The amplified PCR product was sub-cloned into the plasmid vector pTrcHis-A (Invitrogen, 
USA), of which the original N-terminal 6xHis tag, ATG translation codon, Xpress™ epitope 
and enterokinase cleavage site were removed by restriction endonuclease digestion with NcoI 
and BglII (Figure 4.2). Although the restriction endonuclease used to design one of the 
primers was different to those from the spliced sub-cloning vector, both endonucleases 
(BspHI on PCR products and NcoI on spliced sub-cloning vector) produced the compatible 
ends, enabling the ligation of PCR products into the sub-cloning vector (detailed in Table 
4.3). The original N-terminal 6xHis-tag from the vector was removed as a C-terminal 
6xHis-tag was found to favour purification of full-length product of P. falciparum MSP4 with 
the same vector (Wang et al., 1999).  
 
The resulting construct, pT.MSP4/5 (Figure 4.3) was used for the expression of P. chabaudi 
adami MSP4/5. 
 
4.2.2.1.2 Storage of plasmid construct  
Upon receiving the construct, 1 µL of pT.MSP4/5 was used to electro-transform 40 µL of the 
prepared electro-competent E. coli DH5α for the long term storage (Section 4.2.1.6). Clones 
that grew on LB agar with AMP were selected and used to grown an overnight culture of       
5 mL of LB broth with AMP. An overnight culture was stored at −80°C in 50% glycerol LB 
broth in 2 mL cryovials (Section 4.2.1.3).  
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Figure 4.2: Diagrammatic representation of the introduction of manipulated PcMSP4/5 
gene into pTrcHis-A plasmid vector. Adopted from pTrcHis vector manual (Invitrogen, 
U.S.A) 
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Table 4.3: Ligation strategy for pT.MSP4/5 construct. 
Restriction endonuclease Recognized sequence 
 
BspHI 
 
T⎖CATGA 
GGTAC⎖C 
 
NcoI 
 
C⎖CATGG 
AGTAG⎖T 
 
(Ligated product) 
 
CCATGA 
GGTACT 
 
 
Where ⎖ represents the point of cleave; and black are recognized sequences in PCR product, 
and red are recognized sequences in the sub-cloning vector pTrcHis-A. 
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Figure 4.3: Vector map of pTrcHis-A plasmid construct with PcMSP4/5 gene. 
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4.2.2.1.3 Screening of the PcMSP4/5 gene in the donated plasmid 
A step to transforming E. coli BL21(DE3)pLysS with the donated plasmid was included in 
order to obtain a fresh stock of plasmid for further DNA analysis. Upon receiving the plasmid 
construct, 1 µL of pT.MSP4/5 was used to electro-transform 40 µL of electrocompetent        
E. coli BL21(DE3)pLysS (Section 4.2.1.6). Clones that grew on LB agar with AMP and CM 
were chosen for screening of the PcMSP4/5 gene.  
 
A broth culture of transformed E. coli BL21(DE3)pLysS was grown overnight from a selected 
colony on LB agar and plasmids were isolated using the Bioline miniprep kit as per 
manufacture’s instruction (Section 4.2.1.7). Freshly isolated plasmids were visualised on a 
1% agarose gel by DNA electrophoresis (Section 4.2.1.9.2) and the concentration was 
determined using a UV-vis spectrophotometer (Section 4.2.1.9.1). The isolated plasmids were 
subjected to an endonuclease digestion to confirm the presence of the PcMSP4/5 gene. A 
single digestion using either PstI was performed instead to measure the size of linearised 
plasmid. In a reaction, 120 ng of DNA was digested over 3 h in the presence of 10 U of PstI 
in restriction enzyme buffer H (Promega) (Section 4.2.1.8) with a negative control sample 
excluding the endonuclease. Twenty microlitres of each reaction was visualised on a 1% 
agarose gel (Section 4.2.1.9.2), and a single band indicating for the linearised plasmid vector 
with insert was determined. Once the presence of the insert was indicated by DNA 
electrophoresis, 1000 ng of isolated plasmid was sent for DNA sequencing.  
 
4.2.2.1.4 Nucleotide sequencing analysis 
4.2.2.1.4.1 Primer design 
Primers were designed with the aid of Primer Designer 5, version 5.11 within the Sci Ed 
Central Program. When possible, primers were designed to have guanine/cytosine (GC) 
content between 40-60% and a melting temperature (TmºC) greater than 50°C. Primers were 
obtained as lyophilised samples from Geneworks. List of primers are shown in Table 4.5. 
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4.2.2.1.4.2 Sequencing 
One thousand nanograms of purified plasmid DNA was combined with 9.6 pmol of primers 
(0.8 pmol/µL) in a single microfuge tube according to the sequencing facility’s protocol. 
DNA was sequenced using the Life Technologies AB3730xl 96-capillary sequencer at the 
Australian Genome Research Facility Ltd, Victoria, Australia.  
 
4.2.2.1.5 In silico protein characterisation 
To analyse sequencing data, nucleotide sequence alignments were performed using the 
program SE Central. Basic Local Alignment Search Tool (BLAST®)  
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was also used to confirm identity to the registered P. 
chabaudi adami DS MSP4/5 sequence on GenBank (accession number: AF080446.1) (Black 
et al., 1999).  
 
The nucleotide sequence was translated into a protein sequence using Translate 
(http://web.expasy.org/translate/) in the Expasy suite of programs 
(http://au.expasy.org/tools/). The most suitable open reading frame was selected for the 
prediction of the protein sequence.  
 
The program Compute pI/MW (Bjellqvist et al., 1993; Bjellqvist et al., 1994; Gasteiger et al., 
2005) (http://web.expasy.org/compute_pi/) was used to compute the theoretical molecular 
weight and the isoelectric point of PcMSP4/5. The web-based program ProtParam (Gasteiger 
et al., 2005) (http://web.expasy.org/protparam/) was also used to calculate the theoretical 
molecular weight and isoelectric point of PcMSP4/5, and other theoretical and chemical 
properties including the instability index (Guruprasad et al., 1990) and the charges of amino 
acids in the protein sequence.  
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Table 4.4: Primers used for the sequencing analysis. 
 
*Calculated by Geneworks. 
 
 
Name Sequence (5’ ➤  3’) Description Tm°C* 
MSP45-Fwd GCGCCGATTAAATAAGGAGG Forward primer with 
GC extension, 
position 389 
 
52 
MSP45-Rev ACAGCCAAGCTTCGAATTCC Reverse primer,  
position 990 
52 
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4.2.2.2 Protein expression and IMAC purification  
This section describes the methods to obtain E. coli-expressed recombinant PcMSP4/5. 
Recombinant PcMSP4/5 was expressed in E. coli BL21(DE3)pLysS grown in EnPresso™ 
cultivation system and purified by IMAC.  
 
4.2.2.2.1 Preparation of expression culture 
To ensure the proper expression of PcMSP4/5, as well as avoiding mutations in the plasmid 
sequence, E. coli BL21(DE3)pLysS were electotransformed for each protein expression. One 
microlitre of 100 ng/µL pT.MSP4/5 was used to electro-transform 40 µL of E. coli 
BL21(DE3)pLysS (Section 4.2.1.6) and LB agar with AMP and CM was used for colony 
selection to ensure only recombinant clones were present. A single colony was selected to 
inoculate 1 mL LB broth with AMP and CM and incubated at 37°C for 6 h on a shaking 
incubator at 200 rpm.  
 
4.2.2.2.2 Protein expression 
All protein expression was performed using EnPresso™ Tablet Cultivation Set. EnBase® 
Medium tablets were dissolved in 50 mL of sterile MQH2O in a sterile 500 mL Erlenmeyer 
flask, and inoculated with 500 µL of previously prepared recombinant E. coli culture after the 
addition of AMP, CM and 50 µL of EnZI’m. The inoculated culture was sealed with AirOtop 
seal and incubated at 30ºC on a shaking incubator at 200 rpm overnight. Culture was 
supplemented with a Booster tablet after an overnight incubation and protein expression was 
induced with 1 mM IPTG via the trc (trp-lac) promoter (Amann et al., 1983). Protein 
expression was to proceed for 8 h in the same culture conditions, and the cells were then 
harvested. 
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4.2.2.2.3 Protein purification by Immobilised metal affinity chromatography (IMAC) 
4.2.2.2.3.1 Cell lysis  
Cells were harvested by centrifugation at 4,000 x g for 15 min at 4°C and resuspended in 
chilled IMAC lysis buffer with 10-50 mM imizadole added to the final volume of 10-20 mL. 
The cell suspension was submitted to sonication in an ice bath for 6 pulse cycles of 15 sec and 
intercalated by 30 sec without sonication, at amplitude of 27% using a Branson Ultrasonic 
Digital sonifier. The lysate was clarified by centrifugation at 5,000 x g for 20 min to remove 
cellular debris and the supernatant was aspirated for purification.  
 
4.2.2.2.3.2 IMAC column preparation 
Chelating sepharose fast flow or Iminodiacetic acid Sepharose® (depending on the 
availability), was prepared in 1 mL gravity-flow column. Once packed and washed with 
MQH2O, the resin was charged using half the column volume (CV) of 0.45 µm filtered 0.2 M 
nickel sulphate (NiSO4) solution. The column was washed with at least 10 CV of MQH2O and 
equilibrated with 5 CV of IMAC binding buffer. 
 
4.2.2.2.3.3 Purification optimisation by imidazole gradient  
Cells were lysed in IMAC lysis buffer with 10-50 mM imidazole and clarified by 
centrifugation (Section 4.2.2.2.3.1). Increasing concentrations of imidazole were used in 
IMAC wash buffer to obtain the optimal concentration required to purify the PcMSP4/5 with 
minimal contamination by non-PcMSP4/5 proteins. An increment of 20 mM in imidazole 
concentration ranging from 20 mM to 240 mM was applied to the column to determine the 
elution profile of the proteins. Clarified sample was passed through a 0.22 µm filter to remove 
any particles capable of blocking the IMAC column. Five millilitres of sample was applied to 
the charged nickel column which was equilibrated with 10 mM imidazole. Ten millilitres of 
IMAC wash buffer with 10 mM imidazole was first applied to the column, then subsequently 
1 mL of IMAC wash buffers with increasing imidazole concentration were added. One 
millilitre fractions from each concentrations were collected and visualised by SDS-PAGE 
(Section 4.2.1.11) and western immunoblotting. The nitrocellulose membrane was probed 
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with mouse anti-6xHis antibodies and secondary antibodies (Section 4.2.1.12). 
 
4.2.2.2.3.4 IMAC purification 
Clarified sample was passed through a 0.22 µm filter to remove any particles capable of 
blocking the IMAC column. Up to 10 mL of sample was applied to the column followed by   
1 h incubation on a rotary shaker at low speed for binding at 4°C. The column was washed 
with series of 10 CV of IMAC wash buffers at different imidazole concentrations, then the 
protein eluted with 10 CV of IMAC elution buffer. All washes were collected and 10 µL of 
each was visualised by SDS-PAGE (Section 4.2.1.2.4). Samples containing the recombinant 
PcMSP4/5 were pooled, concentrated and buffer exchanged before storing at −20°C (Section 
4.2.2.2.4). 
 
4.2.2.2.3.5 IMAC column cleaning and regeneration 
Gravity flow columns were stripped and cleaned between each use to remove contaminants 
and were recycled up to 3 times. The Ni2+ was stripped with 2 CV of 50 mM EDTA, 0.5 M 
NaCl, pH 7.0. Cleaning involved the addition of 10 CV of 2 M NaCl, followed by 10 CV of   
1 M NaOH, and finally 10 CV of 70% ethanol (v/v). Columns were washed with MQH2O 
between each solution then finally stored in 20% ethanol solution at 4°C. 
 
4.2.2.2.4 Buffer exchange and concentration 
After purification, appropriate protein fractions containing the recombinant PcMSP4/5 were 
pooled then concentrated using a Vivaspin®20 centrifugal concentrator with a 30 kDa cut-off 
membrane, according to the manufacturer’s instructions. Vivaspin®20 devices were 
centrifuged at 5,000 x g at 4ºC in a swing bucket rotor. Once the protein samples were 
concentrated to 1 mL, buffer exchange to PBS was performed in the same device. Any 
remaining salts and metals were removed by continual dilution of the sample using the 
Sartorius™ Diafiltration Cups by applying a total of 20 mL PBS. The protein concentration of 
final product was quantified by Bradford assay and protein was stored at −20ºC. One 
microgram of protein was visualised using SDS-PAGE (Section 4.2.1.2.4).  
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4.2.2.3 Synthesis of PcMSP4/5 nanocapsules  
This section describes the process taken to synthesise the PcMSP4/5 nanocapsules using 
SC/MS templates fabricated in Chapter 3. Successfully expressed and purified recombinant 
PcMSP4/5 from the previous section was utilised. To determine its safety for the use as a 
vaccine in the later in vivo study, the cytotoxicity of the synthesised PcMSP4/5 nanocapsule 
was tested using DC2.4 cell, a murine dendritic cell.  
 
4.2.2.3.1 Synthesis of PcMSP4/5 nanocapsules using SC/MS nanoparticle templates 
The nanocapsule synthesis using the SC/MS template was based on the method of (Wang et 
al., 2008a) with minor alterations. Ten milligrams of PBS-washed amine functionalised 
SC/MS templates were added to the processed PcMSP4/5 (up to 1 mg/mL in PBS), followed 
by an overnight incubation on a suspension mixer at 4ºC. Excess protein was then removed by 
one cycle of centrifugation at 5,000 x g for 2 min, and kept for the loading efficiency analysis. 
To stabilise the infiltrated protein in the mesoporous shell, particles were incubated in 1 mL 
of 5% (w/w) glutaraldehyde (GA) solution or 1% (w/v) paraformaldehyde (PFA) solution for 
minimum of 2 h at 4ºC on a suspension mixer, to form covalent link. After washing with PBS 
three times, the SC/MS templates were removed by 500 µL of 2 M hydrofluoric acid (HF) 
treatment in an 8 M ammonium fluoride buffer at pH 5 to obtain the PcMSP4/5 nanocapsules 
(Shimizu et al., 1998). HF treatment required 5 min incubation with occasional inversion of 
the tube at room temperature, followed by three washes by centrifugation with sterilised PBS 
at 6,500 x g for 5 min. Each infiltration reaction was performed in 1 mL to ensure the proper 
removal of silica by HF. The synthesised nanocapsules were resuspended in 100 µL of 
sterilised PBS, followed by five cycles of 1 min sonication to separate aggregated 
nanocapsules before combining several batches together.  
 
All the washes were kept at 4°C and the concentration of PcMSP4/5 in each solution was 
determined by both UV-vis spectrophotometry and Bradford assay (Section 4.2.1.10.1). 
Before each assay, the protein solution was briefly centrifuged to precipitate any remaining 
SC/MS nanoparticle templates for the concentration determination as silica could interfere 
with UV absorbance measurement.  
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**HF is highly corrosive and toxic. The above work was performed only under the 
supervision of trained personnel in a HF filter fitted fume hood, with an adequate supply of 
calcium gluconate gel. 
 
4.2.2.3.2 Quantification of synthesised PcMSP4/5 nanocapsules 
Quantification was first attempted by UV-vis spectrophotometry (Section 4.2.1.10.2), 
Bradford assay (Section 4.2.1.10.1), and by SDS-PAGE (Section 4.2.1.11). Finally, the 
concentrations of synthesised nanocapsules were determined by a simplified dot-blot method. 
Two microlitres of PcMSP4/5 nanocapsule in various dilutions (1/100, 1/10, 1/2, neat and 
supernatant) were spotted onto a nitrocellulose membrane with known concentrations of 
serially diluted BSA ranging from 0.078 mg/mL to 10 mg/mL. The spotted nitrocellulose 
membrane was stained with instant stain (Section 4.2.1.11.2) until spots developed and then 
rinsed with tap water. The concentration was estimated by comparison of size and colour 
intensity to the BSA standards. As a recombinant protein standard, 0.45 mg/mL of 
recombinant PcMSP4/5 was also spotted.  
 
4.2.2.3.3 Stability check for the recycled PcMSP4/5 
In order to maximise the use of processed PcMSP4/5, first washes from the post-infiltration 
centrifugation were recycled in the repeated nanocapsule synthesis. All washes were stored at 
4°C immediately after washing, and the integrity of PcMSP4/5 was determined using 
SDS-PAGE to ensure its usability for the repeated synthesis. Five microlitres of each wash 
was measured by SDS-PAGE under reducing conditions as described in Section 4.2.1.11.  
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4.2.2.3.4 The dose-dependent cytotoxicity of PcMSP4/5 nanocapsules  
The cytotoxicity of nanocapsules was analysed at different concentrations using PrestoBlue® 
Cell Viability reagent. DC2.4 cells were seeded in a 96 well tissue culture plate at a density of 
5 x 104 cells per well, in RPMI GlutaMAX™ 1640 medium supplemented with 10% heat 
inactivated FBS and incubated at 37°C in a 5% CO2 humidified atmosphere overnight. 
Following the incubation, PcMSP4/5 nanocapsules suspended in 20 µL of sterile PBS were 
added to give a concentration of 3.125, 6.25, 12.5, 25 and 50 µg/mL in a final volume of  
120 µL per well. Replica plates for different time points were made and were further 
incubated for up to 96 h with the nanocapsules in the same conditions. At each time point,  
12 µL of PrestoBlue® Cell Viability reagent was added to wells and the absorbance read at 
570 nm with 600 nm reference wavelength for normalisation after 60 min incubation at 37°C 
in the dark. Absorbance readings were measured using the POLARstar Omega microplate 
reader. 
 
Culture media and 0.1% triton X-100 served as an internal negative and positive control, 
respectively. Percentage cell viability was calculated by setting the negative control to 100% 
after non-live cell dependent colour conversion (background and positive control) was 
eliminated from all the treatment groups.  
 
Statistical variables (mean, standard deviation, and standard error) were calculated for all data 
and presented graphically. Comparisons between groups were accessed by two-way ANOVA 
followed by a Dunnett’s multiple comparison test to determine significant differences in cell 
viabilities against the negative control (media alone) group. GraphPad Prism 6 software was 
used to perform the statistical analysis. 
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4.3 Results 
4.3.1 Endonuclease digestion and sequencing analysis  
4.3.1.1 Transformation of E. coli BL21(DE3)pLysS and plasmid isolation 
The donated stock of pT.MSP4/5 plasmid was successfully introduced into the E. coli 
BL21(DE3)pLysS which allowed the isolation of new plasmid stocks from an overnight 
grown culture. This freshly isolated plasmid was used for restriction endonuclease digestion 
and sequence analysis.  
 
4.3.1.2 Restriction endonuclease digestion analysis 
A single endonuclease digestion was performed using PstI, to determine the presence of the 
PcMSP4/5 gene by measuring the size of linearised plasmid with inserted gene. The enzyme 
was chosen based on the computer analysis that recognise only one site in pT.MSP4/5. PstI 
successfully linearised plasmid and the DNA fragment was visualised on 1% agarose gel. 
This was the expected size of approximately 4834 bp indicated that the PcMSP4/5 gene was 
indeed present in the vector (Figure 4.4). pT.MSP4/5 incubated without enzyme in the same 
conditions was included as an internal negative control. It was further confirmed by 
nucleotide sequencing to ensure that there were no mutations in the target gene. 
 
4.3.1.3 Nucleotide sequencing analysis 
Nucleotide sequencing of pT.MSP4/5 was performed and produced a sequence. This was 
aligned with the PcMSP4/5 gene sequence used to build a vector map. This sequence was 
predicted based on GenBank data, with no intron, signal or GPI anchor sequences, with added 
6xHis tag. Sequence alignment revealed no mutations in the gene as shown in Figure 4.5 and 
further analysis showed that the PcMSP4/5 gene was placed in the correct orientation, in 
frame with the start codon and encoded a 159 amino acid product. The C-terminal 6xHis-tag 
sequence required for downstream processing was also present directly upstream of the stop 
codon. The identity of the sequence to the published PcMSP4/5 was confirmed by BLAST®. 
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Figure 4.4: PstI digestion of pT.MSP4/5 on 1% agarose gel. Lane 1: λ-PstI ladder, Lane 2: 
undigested negative control, and Lane 3: complete digestion of pT.MSP4/5. The red arrow 
indicates the predicted base pair size of linearised plasmid.  
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pT.MSP4/5       446                         tacaaacaaatgtgcgcataatatggtggg 
MSP45F_C08.s     31                         .............................. 
 
pT.MSP4/5       476 taataacagaattttaggaaatatcccctctgataatacagaagatagtt 
MSP45F_C08.s     61 .................................................. 
 
pT.MSP4/5       526 cgaatcaagttgaaggtaatgctgattcaaacgaagttactagcgaagaa 
MSP45F_C08.s    111 .................................................. 
 
pT.MSP4/5       576 gctaaaaacacatcaaatcaggcaaatggcgaaactgcaaatcaagctgg 
MSP45F_C08.s    161 .................................................. 
 
pT.MSP4/5       626 aactccagctgaacccgctaaagctgacgctactcaaaattcaccagcac 
MSP45F_C08.s    211 .................................................. 
 
pT.MSP4/5       676 agccagataacacaaatggtactgaaagtaaaactacaggcgaaaaagct 
MSP45F_C08.s    261 .................................................. 
 
pT.MSP4/5       726 acccttctttctagtgaagaagacgacgaagaagaagatgatgatgacga 
MSP45F_C08.s    311 .................................................. 
 
pT.MSP4/5       776 acttgaagacggcgattgttcagtggataatggaggatgtggagaaaatc 
MSP45F_C08.s    361 .................................................. 
 
pT.MSP4/5       826 taatatgtgaaaaaatggaaaatggtagaataaaatgctcatgcccatct 
MSP45F_C08.s    411 .................................................. 
 
pT.MSP4/5       876 ggatataaattacatggtactgattgtatcgcattgctcagtgcagattc 
MSP45F_C08.s    461 .................................................. 
 
pT.MSP4/5       926 acatcatcatcatcatcattaaagatctgcagctggtaccatatgggaat 
MSP45F_C08.s    511 .................................................. 
 
 
 
Figure 4.5: Sequence alignment with the predicted PcMSP4/5 gene. Top sequence is the 
predicted sequence from the vector map, while the bottom sequence is from nucleotide 
sequening. ATG start codon is highlighted in yellow, 6xHis tag is in magenta, and termination 
codon is highlighted in cyan blue. This shows 100% match of two sequences within the 
PcMSP4/5 gene. Dots indicates the matching nucleotides. 
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4.3.2 Recombinant PcMSP4/5 protein purification  
4.3.2.1 Expression of recombinant PcMSP4/5 in E. coli BL2(DE3)pLysS 
Recombinant PcMSP4/5 was successfully expressed as a soluble protein in E. coli with the 
EnPresso™ system by induction with 1 mM IPTG. The EnPresso™ cultivation condition was 
already optimised for the controlled growth and metabolism for protein expression for 
between 6-24 h (BioSilta, Finland). Recombinant PcMSP4/5 was produced for 8 h.  
 
4.3.2.2 Optimisation of imidazole concentration and purification of 
PcMSP4/5  
Recombinant PcMSP4/5 was isolated by utilising a C-terminal 6xHis-tag, allowing 
purification by affinity binding using an IMAC column charged with nickel ions. Following 
the protein expression, the clarified E. coli lysate was applied to an IMAC column and 
washed with series of wash buffers containing an increasing concentration of imidazole to 
purify PcMPS4/5 from E. coli proteins. Eluates from each wash were subjected to 
SDS-PAGE. The concentration of imidazole that eliminated most of the E. coli proteins with 
minimal loss of PcMSP4/5 was selected for repeat purifications. 
  
A protein of approximately 37 kDa and two smaller proteins of 20 and 23 kDa were separated 
on a SDS-PAGE gel from elutions with a higher imidazole concentration (Figure 4.6A, Lane 
4-6). One of these proteins was suspected as a 6xHis tag recombinant protein. Interestingly, 
the theoretical molecular weight of a recombinant PcMSP4/5 was predicted to be         
16.7995 kDa, which is much lower than any of these proteins detected using SDS-PAGE. To 
confirm that one of these observed protein was the recombinant PcMSP4/5, Western blotting 
was performed. A nitrocellulose membrane was probed with anti-6xHis antibodies and it 
showed strong reactivity to the protein size of 37 kDa (Figure 4.6B). This observation 
revealed that the recombinant PcMSP4/5 has extremely slow mobility on SDS-PAGE under 
reducing condition. 
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A)  
 
B)  
 
Figure 4.6: Purification optimisation by imidazole washes visualised on A) an instant 
stained SDS-PAGE gel, and B) a nitrocellulose membrane probed with anti-6xHis 
antibody. Concentrations of imidazole increasing by 20 mM increment. Lane 1-2: From        
80 mM to 100 mM, Lane 3: Molecular weight marker, and Lane 4-7: From 120 mM to 180 
mM. Samples loaded on lane 1 in both figures were run on a separate gel/membrane, and 
merged as one image by aligning the molecular weight marker.
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Optimisation of wash buffer with an imidazole gradient ranging from 20 to 240 mM showed 
that the recombinant PcMSP4/5 was eluted from the nickel charged column at 100 mM 
imidazole. Wash buffers of up to 80 mM imidazole removed most of the contaminants, 
however some proteins at several different molecular weights were co-eluting and 
contaminating the PcMSP4/5 fractions in 100 mM and above. Proteins of around 23 and      
27 kDa were also present in the 80 mM wash, suggesting that more stringent washes were 
required for higher PcMSP4/5 purity.  
 
From optimisation of imidazole, 5 CV of 80 mM imidazole wash was initially chosen to 
purify PcMSP4/5 from E. coli proteins. It was observed that the proteins with molecular 
weights of 23 and 27 kDa were still contaminating PcMSP4/5 (Figure 4.7, left), showing 
strong binding capacity much the same as the recombinant protein. Although most of the 
contaminating proteins were removed with 5 CV of 80 mM imidazole wash, PcMSP4/5 was 
also partially eluted from the column as indicated on an immunoblot probed with anti-6xHis 
antibody with a single band at 37 kDa (Figure 4.7, right). More pure PcMSP4/5 was obtained 
from 120 mM imidazole buffer, however the loss of product had to be avoided due to a low 
expression level found, albeit with the use of EnPresso™ system. Protein expression in LB 
broth showed almost no protein yield (data not shown).  
 
Clarified E. coli lysate was bound to the IMAC column with 10 mM imidazole buffer, but this 
was changed to 50 mM to increase the PcMSP4/5 competition against the initial binding of 
the 23 and 27 kDa contaminants to the column. However, no obvious changes were observed 
in the final elution product (data not shown). Finally the concentration of imidazole in the 
binding buffer was adjusted to 20 mM and wash buffers were decreased to 60 mM with the 
addition of 40 mM wash prior to avoid protein loss (Figure 4.8). Contaminants at 23 and 27 
kDa were still present after this purification method, as confirmed by both SDS-PAGE and 
Western blot analysis, however this method gave the highest PcMSP4/5 yield of up to 0.5 mg 
(with >70% purity), per 50 mL EnPresso™ culture. In some experiments, an extra protein 
approximately 70 kDa was observed. This was most likely a dimer complex of recombinant 
proteins as it reacted with anti-6xHis antibodies (Figure 4.9).  
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Figure 4.7: Purification of recombinant PcMSP4/5 with 80 mM imidazole wash 
visualised on (left) an instant stained SDS-PAGE gel, and (right) a nitrocellulose 
membrane probed with anti-6xHis antibody. Lane 1: Molecular weight marker, Lane 2: 80 
mM wash, second CV, Lane 3: 80 mM wash, last CV, and Lane 4: 120 mM final elution. The 
red arrow indicates recombinant PcMSP4/5. 
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Figure 4.8: Purification of recombinant PcMSP4/5 with 40 and 60 mM imidazole wash 
visualised on an instant stained SDS-PAGE gel. Lane 1: protein molecular marker, Lane 2: 
100 mM final elution concentrated and buffer exchanged, estimated 1 µg. The red arrow 
indicates recombinant PcMSP4/5. 
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Figure 4.9: Purification of recombinant PcMSP4/5 with dimer complexes visualised on 
(left) an instant stained SDS-PAGE gel, and (right) a nitrocellulose membrane probed 
with anti-6xHis antibody. Lane 1: protein molecular marker, Lane 2: concentrated and 
buffer exchanged PcMSP4/5, estimated 1 µg. The red arrows indicate monomer and dimmer 
recombinant PcMSP4/5.  
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4.3.2.3 Protein processing and storage 
Concentration of the final elution containing PcMSP4/5 and the buffer exchange was carried 
out in a Vivaspin®20 filtration device with 30 kDa cut-off membrane. Despite the size of the 
filter membrane being bigger than the 23 and 27 kDa, these contaminants were still in the 
filtered PcMSP4/5 solution. Flow-through collected from the filtration was also subjected to 
SDS-PAGE but showed neither of contaminants was filtered through (Figure 4.10).  
 
These contaminating proteins were taken into consideration for the preparation of PcMSP4/5 
in the vaccine trial. Processed PcMSP4/5 was stored at −20ºC for nanocapsule synthesis. The 
concentration of protein was determined for pre- and post-storage of up to 6 months. There 
was no loss in the protein amount and no breakdown. 
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Figure 4.10. Samples from buffer exchange visualised on an instant stained SDS-PAGE 
gel. Lane 1: protein molecular marker, Lane 2: flow through from the filtration, Lane 3: 
filtered PcMSP4/5 with 23 and 27 kDa proteins. 
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4.3.3 PcMSP4/5 nanocapsule synthesis 
4.3.3.1 Recombinant PcMSP4/5 for nanocapsule synthesis  
The surface of SC/MS nanoparticle templates was modified by amine functionalisation to 
gain positive charges. This step was necessary to allow the negatively charged protein to 
infiltrate into the mesoporous layer of the SC/MS nanoparticle template. The net charge of 
recombinant PcMSP4/5 was estimated to be negative by the number of charged amino acids it 
possesses. The total number of negatively charged residues (aspartic acid and glutamic acid) 
were calculated to be 35, while the total number of positively charged residues (arginine and 
lysine), was 9.  
 
An infiltration load efficiency of PcMSP4/5 in PBS pH 7.4 was mostly above 25%, and as 
high as 40.6%. This was greatly higher than ovalbumin, however, the loading capacity 
translated to 32.96 mg/g SC/MS template. This is equivalent to the ovalbumin loading 
capacity in PBS at pH 7.4. This was expected as ovalbumin and the recombinant PcMSP4/5 
had very close pI value of 4.6 and 4.19 (discussed in Section 3.4.1.2), respectively. The 
attraction between the positively charged silica template and the negatively charged protein 
increases when the pI of the infiltrating molecule is lower than the physiological pH of the 
buffer where the reaction takes place. An increase in the filtration load was evident in Chapter 
3, where the ovalbumin infiltration load into SC/MS template was tested against different pH 
of PBS (Section 3.3.2.1). 
 
To increase the integrity of the nanocapsule in order to avoid in vivo degradation before 
reaching immune cells, GA was selected as a cross-linking agent for PcMSP4/5 nanocapsule 
synthesis. GA was favoured based on the stronger covalent bonds it can provide as each 
molecular possess two aldehyde groups compared to those of formalin, made from PFA with 
only one aldehyde group (Hopwood & Path, 1976). GA is often used to cross-link 
nanoparticles of different formulas (Langer et al., 2003; Coester et al., 2006; Wang et al., 
2010; Altintas et al., 2013), as it provides strong bonding. GA cross-linked nanoparticles can 
be degraded by a simple enzymatic digestion by proteases, such as α-chrymotrypsin and 
trypsin (Leo et al., 1997; Lin et al., 2001). This was particularly important, as a nanocapsule 
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must be easily degraded in vivo to enable antigen presentation.   
 
4.3.3.2 Quantification of synthesised recombinant PcMSP4/5 nanocapsules 
Although it is the preferred choice of cross-linking agent, using GA compromised the 
accurate quantification of synthesised nanocapsules. During cross-linking of specific amine 
residues, Schiff bases are formed between the aldehyde groups, causing autofluorescence of 
the nanocapsule (Collins & Goldsmith, 1981; Lee et al., 2013). Although attempted, it was 
suspected to have interfered with quantifying an accurate concentration of nanocapsules when 
measured by UV absorbance reading at 280 nm. Autofluorescence of synthesised ovalbumin 
nanocapsule was also observed (Section 3.3.2.2) but a broad estimation was made by UV-vis 
spectroscopy and SDS-PAGE as such estimation was suitable for the purpose of in vitro 
studies. However, more accurate quantification of PcMSP4/5 nanocapsules was necessary in 
order to use the material for a vaccine trial.  
 
Bradford assay was used next to measure the concentration of PcMSP4/5 nanocapsules 
however; it too was unsuccessful due to false readings given by the insoluble nanocapsules in 
solution. Synthesised nanocapsules were sonicated extensively before assays were carried out 
in an attempt to dissociate and solubilise the aggregated capsules, but strongly cross-linked 
structure hindered solublisation of the cross-linked material. Bradford reagent binds to amino 
acids in protein to give a colorimetric reaction (Bradford, 1976), and some blue-stained 
particulates were seen in the solution, however this was not detectable at 595 nm. 
Microscopic observations confirmed that these particulates were in fact the stained 
nanocapsules remained intact, which suggested that solublisation was not achievable by 
sonication. The concentration determined for nanocapsules by the Bradford assay was as low 
as 50 µg/mL, despite the values obtained by an infiltration load estimation of up to             
330 µg/mL. 
 
Formalin cross-links made by PFA are reversible by boiling at 99°C for 15 min in 
SDS-PAGE sample buffer (Klockenbusch & Kast, 2010). Therefore, the same treatment with 
a longer incubation time of 30 min was applied to nanocapsules to estimate concentration on a 
SDS-PAGE. To confirm protein was changed to a reduced state, a batch of PFA cross-linked 
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nanocapsules were also treated. As expected, reduced PFA cross-linked PcMSP4/5 
nanocapsules and also PFA cross-linked ovalbumin nanocapsules were able to enter the 
SDS-PAGE gel (Figure 4.11A, Lane 2), however GA cross-linked PcMSP4/5 remained intact 
in the well (Figure 4.11B, lane 2-4).  
 
Protein concentration was finally estimated by a simple dot-blot method by marking spots of 
nanocapsule solution onto a nitrocellulose membrane. A serially diluted BSA of known 
concentration was also applied onto the membrane as concentration standards. The estimated 
concentration of PcMSP4/5 nanocapsules was then compared to the values obtained from 
UV-vis spectrophotometry. With considerations of the affect of autofluorescence possibly 
increasing the spectrophotometric measurement, the concentration of PcMSP4/5 in 
synthesised nanocapsule was finally estimated to be 0.7 mg/mL. 
 
4.3.3.3 Protein stability for repeated use for nanocapsule synthesis 
In order to maximise the use of purified recombinant PcMSP4/5, protein samples were 
recycled for consecutive synthesis reactions. It was evident from the infiltration load 
optimisation study in Chapter 3 that a large amount of protein did not infiltrate into SC/MS 
templates. There were large amounts of unbound protein that could be reused for subsequent 
infiltration experiments. The washes obtained by the initial centrifugation step were collected 
from each infiltration reaction. To prevent the nanocapsules being synthesised with degraded 
protein, each batch of washes were visually audited on SDS-PAGE gels for its integrity 
before applying them to an infiltration experiment for the next synthesis batch.  
 
No obvious degradation was seen up to four uses of the same protein sample (Figure 4.12). 
This was probably aided by maintaining the storage and protein infiltration condition at 4°C. 
The computed protein instability index showed that the recombinant PcMSP4/5 is stable. This 
also supported the stability of recombinant PcMSP4/5 for multiple uses in consecutive 
experiments over a week. A protein of approximately 32 kDa was seen in the wash after the 
fourth synthesis reaction indicating possible protein degradation, therefore the protein was 
recycled for no more than four uses.   
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A)              B)  
 
 
Figure 4.11: PcMSP4/5 nanocapsules after boiling treatment at 99°C for 15 min. A) 
PcMSP4/5 nanoparticles cross-linked with PFA were able to enter the gel, while B) 
cross-linked GA remained intact in the wells. A) Lane 1: protein molecular marker, Lane 2: 1 
µg PFA cross-linked PcMSP4/5 nanocapsules. B) Lane 1: protein molecular marker, Lane 2: 
1 µL, Lane 3: 5 µL, Lane 4: 10 µL of GA cross-linked PcMSP4/5 nanocapsules. The red box 
indicates the presumed intact nanocapsules remaining in the well.  
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Figure 4.12: PcMSP4/5 collected after the initial washes from nanocapsule synthesis. 
Lane number corresponds to the number of synthesis reactions taken. Lane 1: wash 
collected after the 1st synthesis reaction, Lane 2: wash collected after the 2nd synthesis 
reaction, Lane 3: wash collected after the 3rd synthesis reaction, Lane 4: wash collected after 
the 4th synthesis reaction, and Lane 5: Molecular weight marker. 5 µL of proteins at different 
concentrations were separated.  
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4.3.3.4 Cytotoxicity of PcMSP4/5 Nanocapsules 
The cytotoxic effect of recombinant PcMSP4/5 nanocapsules was evaluated using DC2.4 
murine DCs. Different concentrations of PcMSP4/5 nanocapsules were applied to 5 x 104 cells 
and exposed for up to 96 h. Cell viability of 100% was represented by those of which were 
incubated with culture medium alone and complete cell death was achieved by inhibition with 
0.1% Triton X-100. An internal PBS control was also included to exclude the effect caused by 
the solvent which maintained nanocapsules. The relationship between the nanocapsule 
concentration (µg/mL) and cell viability (% of control) of up to 96 h of exposure time is 
presented in Figure 4.13A. The same conditions were applied to cells with the purified 
PcMSP4/5 used to synthesise nanocapsules and the results are shown in Figure 4.13B. Each 
experimental curve represents the mean of three experiments.  
 
The cell viability of PcMSP4/5 nanocapsule applied cells was maintained at 100% for even 
the highest concentration tested across different time points measured. Differences in 
nanocapsule concentration did not change the level of viability and also showed a slight 
increase after 96 h. Purified PcMSP4/5 had a reverse effect on cell viability. An immediate 
response indicated after 24 h was especially noticeable by a significant decrease in the 
viability to 75% in the lowest concentration of 3.13 µg/mL (p≤0.001). Cell viability was 
significantly lowered in all time points at 12.5 µg/mL (p≤0.0001). Although it was slightly 
less effective at lower concentrations with longer incubations, cell viability reached below 
50% with 25 µg/mL of PcMSP4/5 (Figure 4.14).  
 
The trend seen in the effect of soluble or nanocapsule proteins on DC2.4 cells was completely 
contradictory to the finding in the ovalbumin study. The soluble ovalbumin had minimal 
toxicity effect across all the concentration tested while ovalbumin nanocapsules showed also 
minimal, but increasing toxicity after 25 µg/mL (Section 3.3.3.1). On the contrary, the soluble 
PcMSP4/5 showed nearly dose-dependent cytotoxic effects, while the nanocapsule showed no 
effects.  
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A)  
 
 
B)  
 
Figure 4.13: Cell viability curve of DC2.4 cells against protein concentration of A) 
PcMSP4/5 nanocapsules, and B) purified PcMSP4/5 over 96 h.  
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Figure 4.14: Cell viability of DC2.4 cells over different time points against different 
concentration of PcMSP4/5 materials. (Statistical significance against 100% viable control 
group is represented in asterisks. ✻ is p≤0.05, ✻✻ is p≤0.01, ✻✻✻ is p≤0.001 and ✻✻✻✻ is 
p≤0.0001) 
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4.4 Discussion 
4.4.1 Endonuclease digestion and sequencing analysis of 
pT.MSP4/5 construct 
The purpose of this study was to confirm the integrity of the PcMSP4/5 gene in pT.MSP4/5 
including no mutation has been caused before receipt of the plasmid. Nucleotide sequencing 
of pT.MSP4/5 produced a sequence that aligned with a predicted PcMSP4/5 sequence. 
Alignments of these two sequences showed 100% match in the gene and showed no 
introduction of mutations. It also showed a sequence encoding for six cysteines was preserved 
in the C-terminal region, which encodes an EGF-like domain. 
 
The second exon in the full length PcMSP4/5 gene contains a region that is highly similar to 
the EGF-like domains present in the P. falciparum MSP4 and MSP5 genes (Marshall et al., 
1997; Black et al., 1999). The EGF-like domain on the C-terminal end of the protein is also 
present in MSP4/5 from other murine malaria species including P. berghei ANKA, P. yoelii. 
yoelii YM (Kedzierski et al., 2000a), P. yoelii. killicki 193L, P. yoelii. nigeriensis N63 
(Goschnick et al., 2004) and in many P. falciparum MSP’s (Kaslow et al., 1988; Black et al., 
2001; 2003; Wu et al., 1999). This conservation indicates that the EGF-like domain may have 
potential as vaccine candidate in preventing malaria infections. Immunisation with MSP with 
the EGF-like domain or the domain alone is capable of eliciting antibodies to induce 
protective immunity (Calvo et al., 1996; Kedzierski et al., 2000b; James et al., 2006), and 
inhibits the parasite invasion of host erythrocytes (Blackman, 1990; Woehlbier et al., 2010). 
 
The conformation of the epitope is crucial as the antigenicity of MSP is possibly dependent 
on the correct folding of the EGF-like domain (Wang et al., 1999). The conformation of the 
protein may influence vaccine efficacy, as either reduced or alkylated MSP protein and the 
parasite lysate decreased the reactivity of anti-MSP4/5 antibody binding (de Silva et al., 2011; 
Wang et al., 1999). However, if the level of antibody production is very high, the recognition 
of native MSP4/5 may not be abolished (Kedzierski et al., 2000b). This needs to be taken into 
consideration when the PcMSP4/5 nanocapsules are synthesised for the vaccine trial. As the 
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covalent cross-linking of proteins may hinder the exposure of EGF-like domain in PcMSP4/5, 
it may possibly decrease the efficacy of the vaccine by reducing conformation-specific 
antibody production, if protective humoral immunity is desired.  
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4.4.2 Recombinant PcMSP4/5 protein expression in E. coli 
BL2(DE3)pLysS and purification by IMAC 
4.4.2.1 Expression of recombinant PcMSP4/5 in E. coli BL2(DE3)pLysS  
It was previously demonstrated that the expression of recombinant PcMSP4/5 was successful 
in E. coli BL21(DE3) and purified by IMAC for the purpose of raising antisera in animals 
(Black et al., 1999). The same plasmid construct with the PcMSP4/5 gene was used in this 
study. pLysS is a non-cloning vector that encodes a T7 phage lysozyme to inhibit 
transcription initiation from T7 promoter (Duberndorff & Studier, 1991). It has benefits by 
providing tight regulation of basal expression by the T7 promoter, however it was thought 
that pLysS had no effect on the expression of PcMSP4/5 as the introduced pTrcHis-A vector 
did not have a T7 promoter region.  
 
Regulation of PcMSP4/5 expression was still met by the repression gene in the pTrcHis-A 
vector. The pTrcHis-A vector is capable of expressing proteins through the trc (trp-lac) 
promoter (Amann et al., 1983). The trc promoter contains regions of the trp and lac promoter 
(Brosius et al., 1985; Mulligan et al., 1985), and higher transcriptional regulation of the 
inserted gene in any E. coli strain is achievable with the repression protein produced by the 
lacIq gene. The expression of gene can be induced by the addition of a synthetic lactose 
analogue, such as IPTG to inhibit repression of the trc promoter.  
 
Difficulties were encountered when expressing PcMSP4/5 in E. coli BL21(DE3) grown in LB 
broth, and no expression was detected for up to 5 h after an induction with 1 mM IPTG. There 
was no obvious reduction in the amount of E. coli cells between 0 and 5 h post-induction, 
however it could possibly be due to a toxic effect of expressed recombinant PcMSP4/5 
inducing E. coli cell death. The EnPresso™ cultivation system was therefore used instead of 
LB broth as this system supports more difficult protein expression with slow protein synthesis 
by controlled cell growth. With the use of the EnPresso™ system, recombinant PcMSP4/5 
was successfully expressed in E. coli BL21(DE3)pLyS.  
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4.4.2.2 Purification of recombinant PcMSP4/5 by IMAC  
Successfully expressed recombinant PcMSP4/5 was purified using a nickel charged IMAC 
column. A series of wash buffers with an increasing concentration of imidazole were applied 
to the column of which the clarified E. coli cells have been passed through. Fractions of wash 
buffers from each imidazole concentration were collected and the proteins were separated and 
visualised on a SDS-PAGE gel. Several proteins were detected to have a high affinity to the 
nickel column but none of them match the predicted molecular weight of recombinant 
PcMSP4/5. It was revealed from the immunoblotting with anti-6xHis antibody that the protein 
of 37 kDa on SDS-PAGE gel was in fact the recombinant PcMSP4/5, despite its predicted 
molecular weight of 16.8 kDa. 
 
Slow mobility of other murine malarial recombinant MSP4/5s on SDS-PAGE has been 
observed previously (Black et al., 1999; Goschnick et al., 2004; Kedzierski et al., 2000a; 
2000b). These recombinant MSP4/5s were also expressed without N-terminal signal and 
C-terminal GPI anchor sequences, yet all migrated as approximately 36 kDa protein on 
SDS-PAGE under reducing conditions despite their predicted molecular weight being much 
lower. Furthermore, a full-length PcMSP4/5 from a P. chabaudi adami DS parasite lysate also 
had slow mobility of approximately 36 kDa under reducing condition (Black et al., 1999) 
while the molecular weight for a full-length PcMSP4/5 is only 22.3 kDa. This apparent slow 
mobility is also typical for many P. falciparum asexual-stage proteins, including MSP4 
(Wang et al., 1999; Anders et al., 1988).  
 
It was difficult to obtain PcMSP4/5 at higher purity due to two unknown proteins co-eluting, 
even in stringent imidazole washes. Several optimisation studies were performed by changing 
the imidazole concentrations, however the protein of approximately 23 and 27 kDa could not 
be eliminated. Neither of these proteins nor PcMSP4/5 filtered through the 30 kDa cut-off 
membrane when concentrating the sample, it was speculated that all three proteins were 
somehow bound together in the non-reduced state. Interestingly, a similar purification profile 
was seen in a study where the same expression vector was used to express murine malarial 
MSP4/5s (Goschnick et al., 2004; Kedzierski et al., 2000a; Black et al., 1999) and P. 
falciparum MSP4 (Wang et al., 1999) in E. coli. These proteins did not react with the 
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anti-6xHis antibody, indicating that they are either C-terminally truncated products which 
have lost 6xHis tag, or E. coli contaminants. As these were always co-purified through a 
cobalt-charged IMAC, but not present in lysates purified through amylose resin or glutathione 
agarose resin (Kedzierski et al., 2000a; Wang et al., 1999), or when the protein was expressed 
in yeast system (Kedzierski et al., 2000a), it was suggested that these unknown proteins of 23 
and 27 kDa were in fact co-purified E. coli contaminants.  
 
Since these contaminants were E. coli proteins, a yeast expression system was considered. It 
was thought that the six cysteine residues in the EGF-like domain of PcMSP4/5 was binding 
to these E. coli proteins, therefore expression in a yeast system may eliminate these E. coli 
proteins by producing recombinant protein in a form closer to the native conformation of 
PcMSP4/5. Upon reduction by β-mercaptoethanol, these proteins separate from PcMSP4/5 as 
the reducing agent breaks the disulphide bonds within the protein. However, the E. coli 
derived MSP4/5 can provoke better protection than yeast derived MSP4/5 in mice (Kedzierski 
et al., 2001), therefore expression of PcMSP4/5 in E. coli expression was preferred for the 
purpose of the in vivo trial performed in study.  
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4.4.3 PcMSP4/5 nanocapsule synthesis 
4.4.3.1 Recombinant PcMSP4/5 for nanocapsule synthesis  
This section describes the synthesis of recombinant PcMSP4/5 nanocapsule. Successfully 
expressed and purified recombinant PcMSP4/5 from the previous section was used to 
infiltrate the SC/MS templates. Recombinant PcMSP4/5 has a relatively low pI, allowing 
better electrostatic attraction to the positively charged SC/MS templates than proteins of 
higher pI. Ovalbumin and recombinant PcMSP4/5 share a similar pI, therefore a high loading 
efficiency of PcMSP4/5 PBS was expected.  
 
The theoretical molecular weight of recombinant PcMSP4/5 was predicted to be 16.8 kDa, 
which is less than half of what was detected on SDS-PAGE when purified protein was 
separated. Although it was due to its slow mobility on the SDS-PAGE gel, PcMSP4/5 was 
most likely bound to two E. coli proteins in their native form; therefore the total molecular 
mass was expected to be much higher than 16.8 kDa. This made the PcMSP4/5-complex 
sizing close to that of ovalbumin (44 kDa), which might have also aided in increasing the 
infiltration efficiency. It was shown in Chapter 3, that the ovalbumin formed a complete 
capsulated structure when observed under TEM, therefore a capsule structure with similar 
wall thickness was expected for PcMSP4/5 nanocapsules.   
 
4.4.3.2 Quantification of synthesised recombinant PcMSP4/5 nanocapsules 
Difficulties were encountered with the quantification of synthesised nanocapsules. The 
concentration was unable to be determined using commonly used protein determination 
methods such as UV-vis spectrophotometry or Bradford assay. Estimation by SDS-PAGE was 
also not possible due to the large molecular mass of the nanocapsules. GA cross-linked 
nanocapsules retained their structural integrity despite treatment with reducing agents. 
Nanocapsules were unable to enter the SDS-PAGE gel and remained intact in the well. GA 
cross-linked nanoparticles can be digested with simple enzymes (Leo et al., 1997; Lin et al., 
2001), with the exception of cross-linked nanoparticles which may be too rigid (Babin et al., 
2013). This may reduce the level of the peptide’s availability by cellular proteases for 
presentation in antigen presenting cells. Therefore, a balance between nanocapsule integrity 
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and ease of digestion by an optimal GA concentration needs to be made.  
 
4.4.3.3 Cytotoxicity of MSP4/5 nanocapsules 
The cytotoxicity of synthesised PcMSP4/5 nanocapsules was evaluated using DC2.4, a 
murine dendritic cell. Surprisingly, the soluble PcMSP4/5 had a significantly higher toxicity 
level compared to the PcMSP4/5 nanocapsules. This was totally opposite to the effects 
observed with ovalbumin nanocapsules, which displayed more toxic effect on cells while the 
soluble ovalbumin had none. A higher toxicity level of soluble PcMSP4/5 may be due to the 
presence of E. coli endotoxin in the purified product. Lipid A is the hydrophobic lipid region 
of bacterial LPS and is responsible for its toxicity (Rietschel et al., 1994). Lipid A may be 
infiltrated and cross-linked within the protein layer of nanocapsule, causing it to have less 
exposure to the cells compared to the level in soluble state. However, this is highly unlikely 
due to the extensive washes given during the purification process.  
 
To eliminate any possible cytotoxic effects of endotoxin in the synthesised protein 
nanocapsules to use as an antigen delivery system, the removal of endotoxin from the final 
product purified from E. coli must be considered.  
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4.5 Conclusion  
Findings from this work determined that the SC/MS nanoparticle templating system is 
suitable for proteins, therefore an antigenic protein was used to synthesise nanocapsules in 
this section of study, in order to prepare for in vivo immunisation study. Firstly, P. chabaudi 
adami MSP4/5 (PcMSP4/5) was successfully expressed as a soluble protein in E. coli 
BL21(DE3)pLysS and purified using IMAC.  
 
The purified recombinant PcMSP4/5 co-eluted with two E. coli proteins, resulting >70% 
purity. However, the purpose of the next phase of study is to make a comparison between two 
different delivery systems, rather than determining the efficacy of the antigen. Therefore, it 
was decided that PcMSP4/5 with this level of purity was sufficient to continue.  
 
Secondly, PcMSP4/5 was applied to the templating system, and subsequently synthesised 
PcMSP4/5 nanocapsules showed minimal toxicity effects on DCs. Therefore PcMSP4/5 
nanocapsules were deemed suitable for the use in an animal model in the next phase of study.   
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Evaluation of protein-based 
nanocapsules as a delivery system 
in an animal model  
 
 
This chapter reports the comparative study of the in vivo effect of the subunit  
and nanocapsule vaccines in immunised mice.  
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5.1  Introduction  
Following the in vitro characterisation of cellular uptake and presentation of the 
ovalbumin-based nanoparticles using murine dendritic cells (DCs) as described in Chapter 3, 
this study outlines the final experiments performed to investigate the potential of 
protein-based nanocapsules as a new antigen delivery system. 
 
As shown in Chapter 3, the ovalbumin-based nanocapsule synthesised using the SC/MS silica 
template successfully localised intracellularly in less than 30 min of incubation with DCs. 
Accordingly, these endocytosed ovalbumin-based nanocapsules were processed and the 
ovalbumin peptides were presented in context with the MHC I molecule on DCs via the 
cross-presentation pathway. This indicated that the protein-based nanocapsules are possibly 
capable of activating CD8+ T cells (Segura et al., 2009). Primed CD4+ T cells can divide into 
two different subsets, known as T helper 1 (Th1) and T helper 2 (Th2) cells (Mosmann et al., 
1986; Constant & Bottomly, 1997). Each subset can effectively influence immune responses 
by secreting the cytokines associated with cellular and humoral responses, respectively. 
Up-regulation in Th1 cells can indicate induction of the cellular responses. In order to surpass 
the subunit vaccine, which primarily induces a humoral response, the induction of such 
cellular responses from the protein-based nanocapsule vaccine may be observed.   
 
The activation of cellular responses by different types of nanoparticles either used as a 
vaccine or adjuvant has been previously documented in many reports (Emeny et al., 2002; 
Uto et al., 2009; Keller et al., 2014; Chong et al., 2005), and increased secretion of IFNγ was 
evident. While various nanoparticles were shown to be phagocytosed by DCs and 
macrophages (Lutsiak et al., 2002; Choi et al., 2010; Carney et al., 2012; Akagi et al., 2007; 
Uto et al., 2013), the influence of particle size on the type of induced immune response is 
debatable (Gutierro et al., 2002; Reddy et al., 2006; Kanchan & Panda, 2007).  
 
The study described in this chapter compared the immunogenicity of two different delivery 
systems using the recombinant PcMSP4/5 and the recombinant PcMSP4/5 nanocapsules, 
obtained as described in Chapter 4. It also determined the efficacy of two differently 
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formulated nanocapsule vaccines, by using the recombinant PcMSP4/5 nanocapsules 
formulated with the presence or absence of complete Freund’s adjuvant, as vaccines. The 
magnitude of humoral and cellular response was measured by detecting the level of 
antigen-specific antibodies and cytokines, as well as the population of induced memory cells. 
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The aim of the experiments outlined in this chapter were: 
 
• To use the recombinant PcMSP4/5 and the recombinant PcMSP4/5 nanocapsules as 
vaccines in the C57BL/6 mouse strain. 
• To determine the level of serum antigen-specific antibodies, more specifically IgG and 
IgG1, by indirect enzyme-linked immunosorbent assay (ELISA). 
• To determine the concentration of antigen-specific cytokines, more specifically IFNγ, 
IL-2, IL-4 and IL-10 from the restimulated mouse splenocytes, by sandwich ELISA. 
• To determine the number of proliferated antigen-specific memory cells within the 
restimulated mouse splenocytes using flow cytometry.  
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5.2 Materials and Methods 
All experiments involving animals were carried out with the approval of the RMIT Animal 
Ethics Committee (AEC permit number 1319). 
 
5.2.1 Immunisation protocols 
This section details the immunisation studies in mice to evaluate the efficacy of different 
types of vaccine delivery systems.  
 
5.2.1.1 Animal model 
Six week old female C57BL/6 mice were used. Four mice per group were maintained in a 
single housing unit. In total, 16 mice were immunised. Mice were bred and sourced from the 
Animal Resource Centre, Canningvale, Western Australia.  
 
5.2.1.2 Immunisation groups 
Four mice were randomly allocated per immunisation group. The detail of vaccine 
formulation is listed in Table 5.1. 
 
5.2.1.3 Protein preparation 
The antigenic protein, recombinant PcMSP4/5 was purified as described in Section 4.2.2.2.  
 
5.2.1.4 Nanocapsule preparation 
The recombinant PcMSP4/5 nanocapsule was synthesised as described in Section 4.2.2.3.  
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Table 5.1: Immunisation groups and the vaccine formulation used.  
 
Group  Vaccine formulation Adjuvant Number of mice 
1 PBS ✓ 4 
2 Soluble recombinant PcMSP4/5 ✓ 4 
3 PcMSP4/5 nanocapsules ✓ 4 
4 PcMSP4/5 nanocapsules ✗ 4 
*✓ = added, ✗ = not added. 
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5.2.1.5 Preparation of vaccines  
Sterile PBS (negative control), and the PcMSP4/5 or the PcMSP4/5 nanocapsules in PBS 
were used. PBS, PcMSP4/5 or PcMSP4/5 nanocapsules for three separate groups were 
combined with an equal volume of Freund’s adjuvant. PcMSP4/5 nanocapsules for one group 
was maintained in PBS without adjuvant. Each vaccine was made up to a total volume of   
100 µL per mouse. To minimise the loss of prepared vaccine, a volume equivalent to double 
the number of doses required was prepared, eg if 4x100 µL doses were needed, 800 µL of 
vaccine was prepared. Vaccines were prepared in a biosafety cabinet class II using sterile 
materials. An emulsion was made by mixing the adjuvant and protein/PBS using two glass 
syringes connected with a sterile plastic stopcock, using around 300 mixing repetitions. The 
emulsion was tested by injecting a single drop of the mixture into a beaker of tap water for the 
formation of a stable ball.  
 
Mice were immunised twice, the first immunisation was emulsified in complete Freund’s 
adjuvant and the subsequent immunisation was emulsified in incomplete Freund’s adjuvant. 
 
5.2.1.6 Vaccination  
Mice were given an intraperitoneal injection of a total vaccine volume of 100 µL containing 
15 µg of protein, using a 25-gauge needle. The animals were monitored following the 
injection for at least 4 h. Two vaccinations were timed two weeks apart.  
 
5.2.1.7 Termination of experiment 
Mice were killed by cervical dislocation and organs were collected immediately for 
immunological assays.  
 
5.2.1.8 Serum collection  
Once mice were killed, an incision was made in the abdomen and diaphragm to visualise the 
heart, and blood was collected from the left ventricle using a 19-gauge needle. Blood was 
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centrifuged at maximum speed for 3 min and the sera supernatants were transferred to a clean 
tube. Serum was stored at 4°C for immediate use, otherwise at −20°C for longer storage.  
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5.2.2 Immunoassay protocols 
This section describes the post-trial analysis. Collected serum samples were subjected to 
ELISA assays to measure humoral antibody responses. Spleens were removed and the cellular 
cytokine response from the isolated lymphocytes was quantitatively analysed. Proliferation of 
splenocytes in response to PcMSP4/5 was also assessed.  
 
5.2.2.1 Measurement of humoral responses by serum antibody detection 
5.2.2.1.1 Indirect ELISA 
Indirect ELISA was performed to measure antibody production. This protocol was used to 
measure the level of IgG and IgG subtype - IgG1. 
 
Ninety-six-well flat-bottomed sterile plates were coated with 100 µL of 2 µg/mL purified 
PcMSP4/5 in ELISA Coating buffer and incubated at 4ºC overnight. Coating buffer alone was 
added to two wells to serve as a blank. Two wells of the first row of the plate were used for 
each of the following controls: no antigen (coating buffer only), no blocking, no antisera, and 
no secondary antibody. All other ELISA steps were performed on each of the control wells. 
All samples were tested in duplicate. Coating buffer and unbound protein were removed by 
inverting the plate with three washes in PBS/Tween and patted dry on absorbent paper 
towelling, then blocked with 200 µL blocking buffer for 1 h at 37ºC. After incubation, the 
plate was washed and patted dry as above, and 100 µL of two-fold serially diluted antisera 
was added to the blocked wells. Vaccine trial antisera were diluted in PBS/Tween with skim 
milk (1% w/v) in doubling dilutions performed in a separate 96-well plate. The plate was 
incubated at 37ºC on an ELISA shaker platform for 2 h. Unbound serum was removed and the 
plate was washed as above and patted dry. Detection antibody conjugated to enzyme was 
diluted in PBS/Tween with skim milk (1% w/v) and 100 µL was added to each well. 
Following 1 h incubation at 37ºC on a shaking platform, the plate was washed four times with 
PBS/Tween followed by two washes with PBS, then patted dry. Substrate was added in   
100 µL to each well and the colour development was allowed to proceed for up to 30 min and 
the reaction was stopped by the addition of 50 µL of substrate-specific reagent. Absorbance 
was recorded at the wavelength appropriate for each assay using the POLARstar Omega 
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microplate reader.  
 
5.2.2.1.2 IgG indirect ELISA 
Alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG polyclonal antibody was used to 
detect the level of IgG in the collected serum. Working dilution used for detection was 
1:5000. p-nitrophenyl phosphate (pNPP) was used as a substrate and the reaction was stopped 
with the addition of 3M NaOH. Absorbance at 405 nm was recorded. 
 
5.2.2.1.3 IgG1 indirect ELISA 
Horseradish peroxidase (HRP)-conjugated rat anti-mouse IgG1 monoclonal antibody was 
used to detect IgG subtype level in the collected serum. The working dilution used for 
detection was 1:750. 3,3′,5,5′-tetramethylbenzidine (TMB) was used as a substrate and the 
reaction was stopped with the addition of 1M HCl. Absorbance at 450 nm was recorded.  
 
5.2.2.2 Measurement of cellular responses by ex vivo restimulation 
5.2.2.2.1 Counting cell number using an automated machine 
The number of cells was counted using a Countess® Automated Cell Counter. Ten microlitres 
of either neat, or diluted cell sample was mixed with 10 µL of 0.4% Trypan Blue Dye in a 
sterile tube, then 10 µL of mixture was transferred into a Countess® chamber slide. All 
samples were processed and read within 2 min. The actual volume counted was 0.4 µL, the 
same as counting four (1 mm x 1 mm) squares in a standard haemocytometer.  
 
5.2.2.2.2 Collection of spleen cells 
Mice were sacrificed and their spleens collected in sterile RPMI GlutaMAX™ 1640 with 10% 
heat inactivated FBS, 100 U/mL of penicillin and 100 µg/mL streptomycin. Spleens were 
placed in petri dishes, crushed with the end of a 3 mL syringe and resuspended in a final 
volume of 3 mL of the same media, and filtered through a 100 µm cell strainer.  
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5.2.2.2.3 Isolation of splenocytes from buffy coats by Ficoll density centrifugation 
Splenocytes were isolated from the spleen cell suspension by a standard Ficoll density 
separation method, as per the manufacturer’s instructions. The filtered cell suspension was 
slowly added to a tube containing 3 mL of Histopaque-1077 with minimal disturbance. 
Following centrifugation at 400 x g for 20 min at room temperature without the break stop, 
the upper layer was carefully removed with a sterile Pasteur pipette to within 0.5 cm of the 
opaque interface containing splenocytes. The opaque interface was transferred to a clean tube 
with a fresh Pasteur pipette and washed in 10 mL of sterile DPBS solution by centrifugation 
at 250 x g for 10 min at 4°C. This process was repeated once more under the same conditions 
and resuspended in a final volume of 1 mL of DPBS. Recovered cells were counted using a 
Countess® Automated Cell Counter. 
 
5.2.2.2.4 Labelling of lymphocytes with carboxyfluorescein diacetate succininmidyl ester 
(CFSE)  
The number of splenocytes were counted and adjusted to 1.2 x 107 cells/mL in a final volume 
of 3 mL and warmed briefly in a 37°C water bath. Three millilitres of freshly prepared 5 µM 
CFSE staining solution in DPBS was also warmed and combined with the 3 mL of warm cell 
suspension, immediately followed by gentle mixing by inverting the tube. The mixture was 
incubated in a CO2 incubator at 37°C for 15 min with occasional mixing to ensure proper 
staining. The staining mixture was washed twice in 10 mL DPBS by centrifugation at 400 x g 
for 5 min at room temperature and resuspended in 3 mL of media. 
 
5.2.2.2.5 Restimulation of splenocytes 
CFSE-stained splenocytes were re-counted and seeded in 24 well plates at the final cell 
density of 1 x 106 cell per well. Cells from each mouse were seeded in quadruplicate in a final 
volume of 1 mL and restimulated in vitro in the presence or absence of recombinant 
PcMSP4/5. The first well was restimulated with 2 µg/mL Concanavalin A (Con A) to elicit a 
positive response. The second and third wells were restimulated with 10 µg/mL of the 
purified recombinant PcMSP4/5 prepared as described in Section 4.2.2.2, and the fourth well 
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was unstimulated and served as an internal control. Splenocytes were incubated for 3 days at 
37°C in a 5% CO2 humidified atmosphere. Following 65 h incubation, culture supernatants 
were collected for cytokine level measurement. Freshly prepared media with 20 IU/mL 
recombinant mouse IL-2 was added and incubated for a further 2 days.  
 
5.2.2.2.6 Cytokine profiling - ELISA 
Collected culture supernatants were subjected to ELISA to quantify the level of IFNγ, IL-2, 
IL-4 and IL-10 using the Affymetrix eBioscience Mouse Th1/Th2 ELISA Ready-SET-Go® 
kit, as per the manufacturer’s instructions. Mean values were expressed in pg/mL derived 
from standard curves performed with the corresponding murine recombinant cytokine 
standards.  
 
5.2.2.2.7 Splenocyte proliferation assay 
The ability of memory cells to induce cell proliferation was assessed in response to in vitro 
restimulation. CFSE-stained splenocytes were restimulated in presence or absence of 
recombinant PcMSP4/5 as described in Section 5.2.2.2.5. After 5 days of culture (3 days with 
mitogens and 2 days with IL-2 supplement), cells were harvested by centrifugation at 300 x g 
for 5 min at room temperature. Cells were washed once in a 96 well plate with 200 µL of 
chilled FACS wash buffer. Resuspended cells were fixed with 1% PFA and analysed for 
proliferation using the FACS Canto II cytometer. The level of relative fluorescence intensity 
of CFSE was measured at 490 nm. The cytometer setting for detection of the FITC label was 
used for the wavelength settings. 
 
5.2.2.2.8 Statistical analysis 
Statistical variables (mean, standard deviation, and standard error), were calculated for all 
data and presented graphically. Comparisons between groups were accessed by one-way 
ANOVA followed by a Tukey’s multiple comparison test to determine significant differences 
between groups. GraphPad Prism 6 software was used to perform the statistical analysis.  
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For cytokine levels, a Dunnett’s multiple comparison test was used to determined the 
significant differences between the immunised groups against the control (PBS with adjuvant) 
group. A P value of 0.05 was used to determine the significance.  
 
Chapter 5 
181 
5.3 Results 
5.3.1 Humoral responses against the PcMSP4/5 vaccines 
5.3.1.1 Levels of antigen-specific IgG responses   
Mice were immunised by i.p. injection with 15 µg of PcMSP4/5 in different formulations as 
listed in Table 5.1. One group was given subunit PcMSP4/5 adjuvated with Freund’s 
adjuvant, while two other groups were given PcMSP4/5 nanocapsules in the presence or 
absence of Freund’s adjuvant. Serum samples were collected three weeks after the final 
vaccination and tested for humoral immune responses by detecting the levels of 
MSP4/5-specific IgG antibodies.  
 
Antigen-specific IgG titres for individual mice were determined by indirect ELISA. Sera 
obtained from immunised mice were used as the primary antibody, which bound to PcMSP4/5 
pre-coated plates. Enzyme-conjugated detection antibodies were used to give a colorimetric 
reaction to obtain absorbance readings in order to interpolate the titre. The titre cut-off point 
was determined based on the mean and 3 standard deviations from the negative control 
readings. IgG levels were expressed as a logarithm of the titre. 
 
Serum analysis from individual mice is shown in Figure 5.1. It revealed that immunisation 
with the subunit vaccine induced very high levels of PcMSP4/5-specific IgG in 75% of the 
group, exceeding a titre of 60,000, with the highest titre measured at 128,000. 
PcMSP4/5-specific IgG production was also detected in groups immunised with PcMSP4/5 
nanocapsules. It was detected in 100% of the group vaccinated without adjuvant with the 
highest titre being 3,200, however only 25% produced IgG in the group vaccinated with 
adjuvant, with a titre of 400. The result depicted in Figure 5.1 indicates that humoral 
responses were preferably induced by adjuvated subunit vaccine or nanocapsules alone.  
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Figure 5.1: Titre of IgG in individual immunised mice. PcMSP4/5 specific-IgG level from 
individual mice was tested from collected serum. Measurable responses were observed in the 
groups in which PcMSP4/5 was delivered. No response was observed in the PBS control 
group.   
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The mean titre for each group was calculated and presented in Figure 5.2. While there was no 
significant difference between the two nanocapsule groups, IgG levels in both groups were 
significantly lower when compared to those of the subunit vaccine group (p<0.05). The mean 
titre of the subunit vaccine group was 64,250, 640-fold higher than the adjuvated nanocapsule 
group (titre = 100), and 45-fold higher than non-adjuvated nanocapsule group (titre = 1,400).  
 
5.3.1.2 Levels of antigen-specific IgG subtype composition 
To determine whether the production of IgG was influenced by Th2 response, the level of 
specific IgG1 in individual mice sera was determined and the mean titre was correlated as 
shown in Figure 5.3. High levels of IgG1 were detected in mice immunised with the subunit 
vaccine, and some level of IgG1 detected in mice immunised with nanocapsules without 
adjuvant. Subunit vaccine and the non-adjuvated nanocapsule groups had an average titre of 
25,600 and 1700, respectively. A significantly high level of IgG1 from the subunit vaccine 
group, compared to the PBS control, was expected from the result observed for IgG 
(p≤0.0001). Statistical differences were also observed in the levels of IgG1 between the 
non-adjuvated nanocapsule groups and the PBS control group (p≤0.001).  
 
Low level of IgG1 was also detected in the adjuvated nanocapsules group, however this may 
be due to the non-specific binding of anti-IgG1 antibodies to the saturated serum, tested at a 
1:20 dilution. Similar titre was also observed in the PBS control group. As the mice in PBS 
control group never received PcMSP4/5, non-specific binding of anti-IgG1 antibodies was 
suspected. 
 
IgG2a level was also determined, however no detectable levels were measured by ELISA 
analysis (data not shown).  
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Figure 5.2: Titre of IgG in immunised groups. Mean titre for PcMSP4/5-specific IgG in 
each group was determined. Statistical differences were analysed by a Tukey’s test. 
(Statistical significance against 100% viable control group is represented in asterisks. ✻ is 
p≤0.05, ns = no significant difference). 
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Figure 5.3: Mean titre of IgG1 in immunised groups. Mean titre for PcMSP4/5 
specific-IgG1 in each group was determined. Statistical differences were analysed by a 
Tukey’s test. (Statistical significance against PBS group is represented in asterisks.  ✻✻ is 
p≤0.01, ✻✻✻ is p≤0.001 and ✻✻✻✻ is p≤0.0001). 
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5.3.2 Cellular responses against the PcMSP4/5 vaccines 
5.3.2.1 Levels of antigen-specific cytokine production 
The production of four different cytokines by restimulated splenocytes was measured in the 
culture supernatant by sandwich ELISA. The concentrations of IFNγ, IL-2, IL-4 and IL-10 in 
each immunised group were assessed, and the mean values were expressed in pg/100 µL, 
derived from standard curves performed with the corresponding mice recombinant cytokine 
standards. The concentrations depicted in the figures were expressed per 100 µL, as this was 
the volume of culture supernatant subjected to ELISA.  
 
An elevated IFNγ level was observed in all groups given PcMSP4/5 (Figure 5.4). Although 
the mean value for the non-adjuvated nanocapsule group was lower and the distribution of 
detected concentration was very wide, one mouse actually produced the highest amount of 
IFNγ in the whole experiment (1120 pg/100 µL). The statistically significant difference to the 
PBS control group was found with the subunit and adjuvated nanocapsule groups (p≤0.05), 
with a mean concentration of 878 pg/100 µL and 843 pg/100 µL, respectively.  
 
The levels of IL-2 between all four immunised groups were significantly different (p=0.0002). 
The production of IL-2 in the groups immunised with any form of PcMSP4/5 was elevated in 
a way similar to that of IFNγ. As such, a significantly higher level of IL-2 compared to the 
PBS control group was detected in both subunit and adjuvated nanocapsule groups (p≤0.01 
and p≤0.001, respectively), and an increase was also observed in the non-adjuvated 
nanocapsule group (Figure 5.5). The mean concentration of IL-2 detected in the adjuvated 
nanocapsule group was 80.8 pg/100 µL, a somewhat higher level than in the subunit group at 
62.5 pg/100 µL. The level of IL-2 was significantly lower when nanocapsules were given 
without the use of adjuvant (p≤0.01).  
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Figure 5.4: IFNγ production by immunised groups. Supernatant concentrations of IFNγ, 
produced by splenocytes restimulated in vitro in the presence or absence of recombinant 
PcMSP4/5. Statistical differences were analysed by a Dunnett’s test. (Statistical significance 
against PBS group is represented in asterisks. ✻ is p≤0.05). 
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Figure 5.5: IL-2 production by immunised groups. Supernatant concentrations of IL-2, 
produced by splenocytes restimulated in vitro in presence or absence of recombinant 
PcMSP4/5. Statistical differences were analysed by a Dunnett’s test. (Statistical significance 
against PBS group is represented in asterisks. ✻ is p≤0.05, ✻✻ is p≤0.01 and ✻✻✻ is 
p≤0.001). 
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Despite the strong responses observed in the other cytokines, no measurable level of IL-4 was 
detected in any group (Figure 5.6). A high concentration of IL-4 was measured from the Con 
A positive group; therefore it showed that the assay system was valid to use.  
 
While the level of the Con A positive control was very low, the PBS negative control group 
indicated an increased level of IL-10 concentration (Figure 5.7). The mean concentration of 
PBS, subunit and the adjuvated nanocapsule groups were very similar, and were              
1,989 pg/100 µL, 2,559 pg/100 µL and 2,339 pg/100 µL, respectively. In comparison to the 
level of IL-10 detected in the subunit group, which was the highest amongst all groups, the 
non-adjuvated nanocapsule group produced IL-10 at a significantly lower level (p≤0.05). 
However the mean concentration of IL-10 in this group was 1,059 pg/100 µL, which was 
almost double that produced in the Con A-stimulated cells (564.3 pg/100 µL). 
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Figure 5.6: IL-4 production by immunised groups. Supernatant concentrations of IL-4, 
produced by splenocytes restimulated in vitro in presence or absence of recombinant 
PcMSP4/5.   
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Figure 5.7: IL-10 production by immunised groups. Supernatant concentrations of IL-10, 
produced by splenocytes restimulated in vitro in presence or absence of recombinant 
PcMSP4/5. Statistical differences were analysed by a Dunnett’s test. (Statistical significance 
against PBS group is represented in asterisks. ✻ is p≤0.05). 
Co
nA
 co
ntr
ol
Un
sti
mu
lat
ed
PB
S+
Ad
j
Fr
ee
 M
SP
4/5
+A
dj
MS
P4
/5 
NP
+A
dj
MS
P4
/5 
NP
0
1000
2000
3000
4000
IL-10
pg
/1
00
 µ
L
*
Chapter 5 
192 
5.3.2.2 Levels of antigen-specific cell proliferation 
The induction of memory T cells was assessed in vitro by measuring the proliferation of 
splenocytes in response to recombinant PcMSP4/5. Isolated splenocytes were stained with 
CFSE, which was retained within the cells to monitor cell division by measuring the 
progressive halving of the CFSE fluorescence within daughter cells. The stained cells were 
restimulated in vitro for 3 days, with or without the presence of the recombinant PcMSP4/5, 
and incubated in fresh media containing the recombinant mouse IL-2 for a further 2 days to 
allow continuous cell division.  
 
Firstly, a population of splenocytes with forward scatter ranging from 30,000 to 240,000 was 
gated (Figure 5.8A). Secondly, the level of relative fluorescence intensity of CSFE was 
measured at 490 nm. The cytometer setting for the detection of the FITC label was used for 
the wavelength settings, as CFSE fluoresced at the same wavelength. The number of cells at 
different fluorescence intensity was displayed in a histogram. The unstimulated cells were set 
as a baseline (red), to make comparisons to the stimulated cells (blue) (Figure 5.8B-F). The 
percentage of the proliferated cell population was evaluated and is shown in Figure 5.9. 
 
Proliferation was observed when splenocytes were restimulated in vitro with the recombinant 
PcMSP4/5, while unstimulated cells produced no proliferating cells as expected. While Con 
A-stimulated cells produced a large number of proliferated cells (Figure 5.8B), the 
splenocytes isolated from the subunit vaccine group also had a notably large population 
(Figure 5.8D). The percentage population of proliferated cells within the subunit group was 
8.8%, which was very close to that of Con A-stimulated cells, with 11.1% (Figure 5.9). The 
group immunised with nanocapsule with adjuvant showed increased proliferated population 
of 7.6% (Figure 5.8E, and Figure 5.9), however, the same population was also observed in the 
PBS control group (Figure 5.8C). The PBS control group never received the recombinant 
PcMSP4/5, yet 6.3% of splenocytes were observed to have proliferated (Figure 5.9). In 
contrast, the group immunised with nanocapsule without adjuvant, had the smallest 
population of proliferated cells at 3.7% (Figure 5.8F), while cells from the PBS control group 
induced higher levels of proliferation. This was unexpected, as PcMSP4/5 was never 
introduced to mice in the PBS control group.  
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A) B)  
C) D)  
E) F)  
 
Figure 5.8: Proliferation of mouse splenocytes, restimulated in vitro with PcMSP4/5.  
A) Lymphocyte population was gated. The percentages of proliferated lymphocytes in each 
vaccination groups (B-F) are represented in the blue open histogram, while the red open 
histogram represents unstimulated cells. The Y-axis represents the number of cells detected 
for each group. The X-axis represents the level of relative fluorescence intensity of CFSE 
measured at 490 nm. The cytometer setting for detection of FITC label was used for the 
wavelength settings.  
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Figure 5.9: Percentage of proliferated mouse splenocytes, restimulated in vitro with 
PcMSP4/5. Percentage of population calculated based on the unstimulated cells.  
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5.4 Discussion 
Significantly high levels of IgG were detected in mice immunised with the subunit PcMSP4/5 
emulsified with Freund’s adjuvant, or when immunised with the PcMSP4/5 nanocapsules 
with no adjuvant. The ability of recombinant PcMSP4/5 to elevate antibody production was 
expected, since in previous studies the recombinant P. yoelii MSP4/5 expressed in E. coli 
showed a significant increase in the level of antibodies in mice (Kedzierski et al., 2000b; 
2001). High level of IgG1 was detected in these two groups, while no measurable level of 
IgG2a was detected in either group (data not shown).  
 
It has been found that IgG2a cannot be detected in C57BL/6 mouse sera, as C57BL/6 mice 
expresse a different IgG subtype due to deletion of the allele for IgG2a gene (Martin & Lew, 
1998; Martin et al., 1998). The corresponding antibody for IgG2a in C57BL/6 mice is IgG2c, 
however ELISA analysis was still attempted using anti-IgG2a. The detection of IgG2c was 
unsuccessful, as might have been expected. The differences in amino acid sequence between 
IgG2a and IgG2c is 16%, therefore the commonly available anti-IgG2a sera probably could 
not cross-react with IgG2c. 
 
Previously reported BALB/c mouse immunisation trial showed that P. yoelli MSP4/5 induced 
higher level of IgG2a production compared to IgG1, when MSP4/5 was given i.p. vaccine 
with Freund’s adjuvant (Kedzierski et al., 2001). Given that a similar protein was used for 
immunisation in the same formula and vaccination method, IgG2c may have been increased 
in mice from the subunit group. Contradictory to their result, higher level of IgG1 production 
than IgG2a was recorded in another study, when P. falciparum MSP4 and MSP5 were given 
subcutaneously in the same vaccine formulation (Bracho et al., 2009). However, the site of 
vaccine administration may have influenced the immune response (Yip et al., 1999).  
 
Antibody class switches from the initially produced IgM to different Ig and IgG subtypes 
upon maturation of B cells (Coffman et al., 1993), and this can be influenced by the cytokines 
secreted from CD4+ T cells (Stavnezer & Amemiya, 2004). Th1 cells secreting IFNγ can 
induce an immunoglobulin class switch to IgG2a, while IL-4 secreted from Th2 cells induces 
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an IgG1 class switch (Snapper & Paul, 1987; Sideras & Lindqvist, 1985). More recently, it 
was documented that IFNγ secreted by the activated CD8+ T cells can also induce Ig class 
switching to IgG2a (Mohr et al., 2010). Therefore, the secretion of IFNγ and IL-4 is an 
indication of either Th1 or Th2 responses elicited in mice, respectively (Constant & Bottomly, 
1997; Mosmann et al., 1986).  
 
Although the production of IgG2c could not be determined, a high level of IgG1 was detected 
in mice from the subunit group and the adjuvated nanocapsule group. This suggested that 
there were some degree of Th2 bias in the immune response, therefore an elevated level of  
IL-4 was anticipated for the cytokine ELISA analysis in these groups. However, no 
production of IL-4 was found in any of the immunised groups. The animal used for this trial 
was mouse C57B/6 strain, which is known to preferentially produce Th1 cytokines with high 
IFNγ and low IL-4 (Mills et al., 2000). The use of this Th1-biased mouse could possibly be 
the reason that no detectable level of IL-4 was produced (Diwan et al., 2002). IL-10 is another 
cytokine secreted by Th2 cells, which can also induce IgG class switching to IgG1 (Malisan et 
al., 1996). Increased level of IL-10 in subunit group and nanocapsule group without adjuvant 
was in line with the high IgG1 level detected, however no conclusion could be made to 
indicate the influenced of Th2 cells, due to the high amount of IL-10 observed in PBS control 
group.  
 
In contrast, the nanocapsules emulsified with Freund’s adjuvant did not produce any IgG or 
IgG subtype, but produced significantly higher levels of IFNγ and IL-2. Furthermore, the IL-2 
production was elevated at much higher level than that of the subunit group, and also 
significantly higher than the non-adjuvated nanocapsules (p≤0.01). In consideration with the 
IgG level found and the elevation in IFNγ and IL-2 levels, it was suggested that the immune 
response induced in mice from the adjuvated nanocapsule group was most likely mediated by 
the cellular response involving Th1 cells.  
 
The differences in the use of adjuvant with nanocapsules were contrary. The complete 
Freund’s adjuvant used for this experiment was composed of inactivated mycobacteria, which 
is known to promote the proliferation of CD4+ T cells and skew to Th1 responses by various 
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mechanisms (Reviewed in Billiau & Matthys, 2001). The mycobacteria in the adjuvant 
contains several active components including LPS and the unmethylated CpG 
oligodeoxynucleotides, which are pathogen-associated molecular patterns (PAMPs). PAMPs 
are found on non-mammalian cells and recognition by TLRs can provoke innate immunity to 
mediate against the invasion of a microbial pathogen (Underhill & Ozinsky, 2002; Kopp & 
Medzhitov, 2003). The ligation of PAMPs to TLR can stimulate cells to increase the 
phagocytosis of exogeneous antigens (Redlich et al., 2013), in this case the nanocapsules, 
thereby the phagocytosis of nanocapsules enhanced and leads to T cell differentiation to Th1 
cells. Therefore, the elevated level of IFNγ and IL-2 in the adjuvated nanocapsule group may 
be explained by the functionality of the complete Freund’s adjuvant. However, the elevation 
in IFNγ was probably not due to the adjuvant components alone, but rather a combination of 
adjuvant effect with the nanocapsules, resulting in the enhancement of the cellular response. 
This was supported by the significantly low level of IFNγ detected in the PBS control group.  
 
The observation of IL-10 production between the immunised groups was very interesting. 
High level of IL-10 was detected in all groups, including the PBS negative control group, 
which was not expected, as this group did not receive any form of PcMSP4/5. The mean 
concentration of IL-10 from the PBS control group was as high as the other groups given the 
adjuvant. It was also higher than the concentration measured in the non-adjuvated 
nanocapsule group. PBS was given to mice with the addition of Freund’s adjuvant; therefore 
this could possibly be the reason for such a response. IL-10 is anti-inflammatory cytokine 
(Berger, 2000), therefore IL-10 may have been produced to counteract the inflammation 
possibly caused by the adjuvant. On the contrary, this hypothesis did not explain the low level 
of IL-10 indicated in the unstimulated control. The cells used for this control type were 
isolated from mice in the PBS control group, however no such elevation was observed. This 
also applied to the Con A control, which also exhibited low levels of IL-10. IL-10 functions to 
suppress inflammation caused by the Th1 response, by blocking IFNγ secretion. If high levels 
of IL-10 were secreted in response to the adjuvant, the level of IFNγ would also be expected 
to rise. However, a very low level of IFNγ was detected in the PBS control group. 
Furthermore, the production of cytokines in this assay was induced by the specific antigen 
used for immunisation. Therefore, any increase in the level of these cytokines should be 
PcMSP4/5-specific, and not due to the adjuvant.  
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A similar observation was made for cell proliferation, where the PBS control group had a high 
population of proliferated cells. Memory cells produced from immunisation were restimulated 
to proliferate specifically against the recombinant PcMSP4/5 in this assay. All groups given 
the adjuvant achieved a larger proliferated population, while the non-adjuvated nanocapsule 
group had half that detected in the PBS group. However, the unstimulated cells isolated from 
the PBS group mice showed differences in the proliferated cell population to the PBS group. 
It is unlikely that the increase of IL-10 and the proliferation of memory cells was solely 
attributed to the effect of the adjuvant. The mechanism behinds these results are not fully 
understood.  
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5.5 Conclusion 
Immune response can be elicited by the antigen-based nanocapsules given by i.p. vaccine, 
while the humoral or cellular response is induced with or without the use of adjuvant. 
Significantly high level of IgG, possibly influenced by Th2 cells is achievable by 
immunisation with the antigen-based nanocapsules alone. While the strong cellular response 
with significantly high levels of IFNγ and IL-2 can be elicited by the antigen-based 
nanocapsules, in combination with adjuvant.  
 
These findings suggest that the antigen-based nanocapsules may also be capable of promoting 
a stronger cellular response than the subunit vaccine when formulated with the adjuvant, by 
inducing a higher level of Th1-biased cytokine secretion.  
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An ideal vaccine should be able to elicit strong humoral and cellular responses with a single 
dose without posing any risks associated with the attenuated vaccines reverting to being 
virulent (World Health Organization, 2014; Youngner et al., 1994). For this reason, subunit 
protein or peptide vaccines are a safer alternative to attenuated vaccines and many are 
considered to have potential as vaccine candidates (Rueckinger et al., 2011; Peltola et al., 
1992; Georges et al., 2013; Purcell et al., 2007), however the immunogenicity is often 
suboptimal (Aguilar & Rodriguez, 2007). Therefore, novel antigen delivery methods are 
being investigated.  
 
It has been demonstrated that the nanocapsule is a promising antigen delivery system to 
increase the efficacy of subunit vaccines, as they can stabilise the antigens and ensure 
delivery to intracellular compartments. Antigen delivered in a particulate form has been 
shown to facilitate more efficient cellular uptake by the APCs, and induced potent 
antigen-specific humoral response, in particular cellular responses by promoting a higher 
level of cross-presentation (Shen et al., 1997; Sexton et al., 2009; Kaba et al., 2012; Hirosue 
et al., 2010; Sneh-Edri et al., 2011; Yang & Hsu, 2008; Plebanski et al., 1998; Akagi et al., 
2007).  
 
A sacrificial template can provide greater mechanical stability to capsule formation during the 
preparation process (Cui et al., 2014). Highly monodispersed SC/MS silica nanoparticles are 
suitable as a nanocapsule template because of the unique properties of the MS. The structure 
of resulting nanocapsules can be tailored with minimal alteration to the structure of the MS, 
such as porosity and size (Goethals et al., 2013), and the fabrication of mesoporous silica 
nanoparticles is very simple, scalable and cost-effective (Tang et al., 2012). Well-define 
surface chemistry can also functionalise the silica template to accommodate almost any 
antigen to be infiltrated to form the antigen nanocapsule. Most importantly, this templating 
approach eliminates the need of polymeric or lipid materials often used in the other 
nanoparticle system. The particles consisting of a single component (antigenic protein) is an 
attractive feature as a delivery system. 
 
In this study, a templating method was utilised to synthesise antigen-based nanocapsules. This 
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method enabled the synthesis of nanocapsules with high homogeneity and stability by 
employing highly monodispersed SC/MS silica nanoparticles with an average diameter of 410 
nm as a template (Stöber et al., 1968; Büchel et al., 1998). Ovalbumin, C27 H1N1 protein,    
P. chabaudi adami MSP4/5-based nanocapsules were synthesised using minimal chemical 
complexity, with final particles consisting of only the cross-linked protein (Wang et al., 
2008a). Negatively charged protein nanocapsules induced minimal toxicity to cells, 
alleviating the cytotoxic effects often associated with the cationic polymer particles. This 
method allowed a larger capacity of antigen to be loaded per nanoparticle in a single step 
compared to the currently existing nanocapsule preparation techniques, resulting with a 
thicker capsule wall fabricated using the large specific surface area of SC/MS nanoparticle 
(Yang & Hsu, 2008; Goethals et al., 2013). 
 
DCs are the most potent professional APCs for the initiation of immune responses, and their 
ability to prime naïve T cells has been well studied (Steinman, 2007b; Villadangos & 
Schnorrer, 2007). It was shown that the synthesised ovalbumin nanocapsules were efficiently 
internalised by immature DCs in less than 30 min, and induced a significantly higher level of 
ovalbumin peptide to be processed via the cross-presentation pathway than incubation with 
soluble ovalbumin. This is a crucial finding, as targeting the cross-presentation pathway is the 
key to develop effective vaccines against tumors, intracellular parasites, intracellular bacteria 
and viruses (Rock et al., 1990; Moron et al., 2004). Increased levels of peptide presentation 
with MHC class I leads to the efficient induction of a cellular response by activating CD8+ T 
cells (Sneh-Edri et al., 2011; Shen et al., 2006). In addition, internalised antigen may be also 
presented by MHC class II molecules to prime CD4+ T cells to promote Th1 and Th2 biased 
cytokine secretion (Paul & Seder, 1994; Swain et al., 1990; Berger, 2000; Uto et al., 2013; 
2009; Mohr et al., 2010). 
 
The application of antigen-based nanocapsules as delivery system was further investigated in 
the immunization trial using a mouse model. Synthesised PcMSP4/5 nanocapsules were 
administered by i.p. injection twice with a two week interval. The PcMSP4/5 nanocapsule 
was able to produce significantly high levels of IgG without being formulated with adjuvant. 
The Ig class switch to IgG1 indicated that there was a Th2 influence in the immune response. 
A strong cellular response was also achievable with the PcMSP4/5 nanocapsules in 
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combination with adjuvant, promoting significantly high levels of IFNγ and IL-2 compared to 
vaccination with soluble antigen formulated with adjuvant. This latter result suggests that the 
antigen-based nanocapsules may be capable of promoting a stronger cellular response than the 
subunit vaccine when formulated with the adjuvant, by inducing a higher level of Th1-biased 
cytokine secretion.  
 
Conventional adjuvants such as Alum have been approved for human use however it is 
historically shown to elicit strong humoral responses with weaker cellular responses. More 
potent adjuvants that can induce stronger cellular responses are available, however their use in 
human is limited due to their high toxicity. This study showed that the antigen in a particulate 
form could potentially elicit strong cellular responses, possibly mediated by primed Th1 cells. 
Therefore, the inability of Alum to induce cellular responses may be overcome when 
co-delivered with antigen-based nanocapsules. The conjugation of various 
immunostimulating molecules such as PAMPs to the surface of antigen-based nanoparticle 
can be achieved by adsorption, chemical cross-linking or encapsulation (Diwan et al., 2002; 
Hermanson, 2013; Di Marco et al., 2010), to induce more efficient uptake and APC activation 
(Demento et al., 2011; Redlich et al., 2013). Particular subsets of DCs can be targeted by 
surface modification of nanocapsule to immobilise monoclonal antibodies (Mintern et al., 
2013). The mechanical stability of the particles allows the conjugation of almost any materials 
to be co-delivered, and the possibility is broad.  
 
Some pathogens such as malaria are difficult to vaccinate against due to antigenic variability 
during their complex life cycle (Su et al., 1995). This enables the pathogen to evade the host 
antigen-specific immune response. One approach to overcome this is to formulate vaccines 
with multiple antigens expressed by the pathogen. Multivalent vaccines are shown to be 
effective across different serotypes of Streptococcus pneumoniae and several viruses 
(Rueckinger et al., 2011; Atkinson et al., 2011). Employing this templating method can most 
likely cater the formation of multivalent nanocapsules by multiple antigens infiltration into 
the MS of nanoparticle template. This should be an area of future research.   
 
The work conducted in this study demonstrated that the templating approach using the 
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monodispersed SC/MS silica nanoparticle is suitable to synthesise various types of 
antigen-based nanocapsules. The antigen-based nanocapsules were also able to be internalised 
and cross-presented on DCs with minimal toxicity, and induce both humoral and cellular 
responses in an animal model. Therefore this study highlighted the potential of the templating 
approach for the nanocapsule preparation technique to be used for the antigen delivery.  
 
The factors that determine the type of immune response and the level of cross-presentation 
remain unclear in the field of particulate delivery system. Therefore, further studies need to be 
conducted to assess the effect of nanoparticle size on antigen presentation and the protective 
efficacy of the vaccines in vitro and in vivo, by fabricating various sizes of SC/MS templates. 
More precisely, ovalbumin nanocapsules at 50 nm (viral size range) and 500 nm (bacterial 
size range) should be tested in a mouse study, and pathogenic antigen-based nanocapsules to 
be used in studies where the immunised mice are challenged with an infectious agent.  
 
The future work should also comprise further characterisation of protein-based nanocapsules. 
Nanocapsule stability at various temperatures is crucial to use as a vaccine. The degradation 
of protein-based nanocapsules incubated at different temperatures (i.e. -20°C, 4°C and room 
temperature) should be monitored over time (hours to days). Aggregation behaviour of 
nanocapsules should also be observed. In this way the potential of these particles as stable, 
efficacious vaccines can be assessed. 
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8.1 Appendix 1 
 
 
 
Figure A1: PstI-digested lambda DNA ladder. PstI digested-DNA separated by agarose gel 
electrophoresis with size and quantity of individual DNA fragments specified. Reproduced 
from Lambda DNA/PstI marker certificate of analysis (Fermentas).  
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8.2 Appendix 2 
 
 
 
A) B)  
 
 
Figure A2: Protein molecular markers. A) Precision Plus ProteinTM standard (unstained). 
Reproduced from Precision Plus ProteinTM standard product specifications sheet (BioRad). B) 
Precision Plus ProteinTM Dual Colour Standard. Reproduced from Precision Plus ProteinTM 
Dual Color standard product specifications sheet (BioRad).  
 
 
 
